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1. THE LIVER 
1.1 Function and structure: generalities 
The liver, the largest internal organ in the body, is situated under the diaphragm. It is 
divided into two portions: a right lobe and a left lobe. The right lobe is much larger and 
it is further separated in two smaller lobes: the caudate and quadrate lobes. Liver has a 
central role in metabolic homeostasis, being responsible for the metabolism, synthesis, 
storage and redistribution of nutrients, carbohydrates, fats and vitamins. Its “strategic” 
location in relation to the food supply via the portal vein, and the unique gene-and 
protein-expression patterns of hepatocytes (the main functional cells of the liver) allow 
it to function as a biochemical defense against toxic chemicals entering through the 
food and as a processor of absorbed food ingredients (Michalopoulos 2007). 
Importantly, it is the main detoxifying organ of the body, which removes wastes and 
xenobiotics by metabolic conversion and biliary excretion (Hata et al. 2007). 
In its simplest formulation, the histological units of the liver are the lobules (FIGURE 1A 
and B), randomly oriented structures that contain rows of hepatocytes (hepatocyte 
plates or cords). The lobules are demarcated by peripheral spaces (portal spaces or 
portal triads) that contain small branches of the portal vein, hepatic artery and bile 
ducts. In the portal spaces, the terminal segments of the biliary system connect with 
hepatocytes in the liver parenchyma through a terminal bile ductule known as the canal 
of Hering (Fausto and Campbell 2003). The hepatocytes plates extend from the 
periphery of the portal tracts to the central vein. Blood flows in sinusoids between one-
cell thick hepatocyte plates from portal spaces to central vein; bile flows in the opposite 
direction.  
 
 
 
 
FIGURE 1. Lobular structure of the liver 
A. Portal tracts contain branches of the portal vein and hepatic artery, as well as bile 
ducts. Hering canals and bile canaliculi are also indicated. B. Three lobules are shown 
as hexagonal structures demarcated by portal tracts or triads in the periphery and 
containing a central vein at the center. 
(Modified from Fausto and Campbell, 2003) 
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1.2 Hepatic cell types 
At least 15 different cell types can be found in normal liver (Kmiec 2001; Malik et al. 
2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatocytes are the most abundant liver cell type and comprise 60% of the total cells 
and 80% of the volume of liver. In the liver plate, hepatocytes are referred to as 
periportal or centrolobular depending on their distance from the portal spaces 
(Malarkey et al. 2005). Hepatocytes carry out all the essential functions of the organ 
and are the cells responsible for bile production that is secreted from the apical 
membrane into the bile canaliculi that run between hepatocytes and merge to form bile 
ducts, which are lined by cholangiocytes. Cholangiocytes and hepatocytes, the 
epithelial cells of the liver, share a common precursor cell, the hepatoblast (Kang et al. 
2012).  
The remaining 40% of cells (the rest 20% of the total liver cell mass) comprises 
other cell types, collectively termed as non-parenchymal cells (NPCs), which include 
sinusoidal endothelial cells (SECs), Kupffer cells (KCs) (functioning as in situ 
macrophages), hepatic stellate cells (HSCs) and cholangiocytes as the prevalent 
populations of NPCs (Racanelli and Rehermann 2006; Godoy et al. 2013). 
Lymphocytes are also part of the innate immune system that resides within the liver to 
help resist infection and are included into the NPCs. NPCs play important roles in 
nutrients transport, metabolism, inflammatory response, growth functions and therefore 
they are involved in several pathophysiological processes in the liver, which makes 
them interesting for pharmaceutical research. 
TABLE 1. Cells types found in the liver 
Hepatocytes  
Biliary epithelial cells (also known as cholangiocytes) 
Endothelial cells 
 Sinusoidal endothelial cells 
 Arterial and venous endothelial cells 
 Lymphatic endothelial cells 
Kupffer cells 
Hepatic stellate cells 
(also known as Ito or fat-storing cells) 
Lymphocytes (Pit cells) 
Progenitor cells  
(fetal, also known as hepatoblasts, and adult, known as 
oval cells in rodent models) 
Fibroblasts 
Smooth muscle cells (blood vessels) 
Mesothelial cells 
Nerve cells (unmyelinated) 
Neuroendocrine cells 
Hematopoietic cells 
Blood (erythrocytes, leukocytes, etc.) 
(Modified from Malarkey et al., 2005) 
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Different evidences based primarily on experimental models of liver injury and 
carcinogenesis have led to the concept that in the adult liver there are cells that 
function as stem cells or stem-like cells. Upon severe liver injury these cells, which are 
believed to be located in the canals of Hering, expand and give rise to a heterogeneous 
multipotent transient amplifying cell population known as hepatic progenitor cells 
(HPCs), known as “oval cells” in mouse and “intermediate hepatobiliary cells” in 
humans  (Fausto and Campbell 2003; Esrefoglu 2013). We will study thoroughly this 
population in next chapters of this thesis. 
1.3 Hepatic Extracellular Matrix (ECM) 
The hepatic ECM is a complex macromolecular structural network surrounding stromal 
cells and underlying the majority of endothelial and epithelial cells. It is not only a 
physical scaffold that supports the parenchyma and maintains hepatic integrity but also 
a crucial modulator of biological processes including cell attachment, migration, 
differentiation and survival (Schuppan 1990; Martinez-Hernandez and Amenta 1995; 
Frantz et al. 2010). Recent studies indicate that the ECM modulates hepatic 
development, regeneration, and even the maintenance of the normal architecture and 
differentiated state in a variety of ways: by acting as a solid phase agonist, as 
polypeptides interacting with cell surface receptors, or by facilitating the maximal 
exchange of nutrients or cytokines between circulating blood and hepatocytes during 
liver regeneration (Kim et al. 1997; Michalopoulos 2010). Thus, the ECM creates a 
complex and naturally dynamic microenvironment that undergoes continuous 
remodeling. 
In normal liver, ECM proteins are distributed mainly in the liver capsule, in the portal 
tracts and in the ducts and ductules of the biliary tree, whereas a basement-like matrix 
is located in the sinusoidal space or space of Disse (the small space between 
hepatocytes and sinusoidal endothelial cells), where the most prevalent ECM 
components are the collagens, elastin, structural glycoproteins and proteoglycans 
(FIGURE 2).  
 
 
 
  
 
FIGURE 2. The hepatic ECM remodeling during the development of fibrosis 
The main ECM structural components are shown in healthy and fibrotic tissue. ECM remodeling is 
tightly controlled to ensure homeostasis; during fibrogenesis, however, this process is disturbed. 
(Modified from Morten A. Karsdal, 2014)  
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Interestingly, the structure of the sinusoidal space of Disse is different from other 
organs because it lacks a true basement membrane (Friedman 2003).  
The ECM remodeling is a complex and highly coordinated process resulting from the 
balance between synthesis, degradation and reorganization of its components, in 
response to signals conveyed by cell surface receptors, among which integrins seem to 
play a major role (Arriazu et al. 2014). Matrix endopeptidases play a crucial role in this 
process and, not surprisingly, also in the liver regeneration process. Matrix 
metalloproteinases (MMPs) are the most relevant ECM-modifying enzymes. MMPs are 
a family of over 24 zinc-dependent endopeptidases capable of degrading virtually any 
component of the ECM (Kessenbrock et al. 2010). MMP-1 (collagenase-1), MMP-2 
(gelatinase-A), MMP-3 (stromelysin-1), MMP-11 (stromelysin-3) and MMP-13 
(collagenase-3) are among the MMPs constitutively expressed in normal liver, although 
other different MMPs can be secreted in several acute or chronic liver injury states 
contributing to the changes in the ECM (Duarte et al. 2015). 
Significant ECM alterations are observed in liver cirrhosis and fibrosis (Schuppan et al. 
2001; Wells 2008; Morten A. Karsdal 2014), in particular the balance between matrix 
formation and degradation in these pathological disorders is shifted leading to an 
abnormal and progressive deposition of ECM in the liver. 
In spite of the fact that the mechanisms of ECM remodelling in development and 
disease have been thoroughly studied, the role of ECM in liver regeneration is still 
poorly understood; in particular the study of the potential mechanisms by which these 
changes regulate the proliferative properties of liver cells during the regenerative 
process would be very relevant. Recently, a very interesting work has demonstrated 
selective growth stimulation properties for ECM components; thus, collagen type IV 
(Col4) was shown to efficiently support  hepatocyte proliferation in vitro, and high Col4 
expression coincided with proliferating hepatocytes also in regenerating liver (Klaas et 
al. 2016). Moreover, it has been demonstrated that matrix components have also 
important effects in hepatic progenitor cells. For example, collagen I favours the 
differentiation of hepatic progenitor cells, while laminin maintains their stemness 
properties (McClelland et al. 2008); in addition, it has been shown that fibronectin 
promotes the differentiation of liver progenitor cells towards the hepatocyte phenotype 
(Lorenzini et al. 2010). 
1.4 Liver regeneration 
The liver has a remarkable regenerative capacity. In adult human, the liver is a 
mitotically quiescent organ with most hepatocytes in the G0 phase of the cell cycle and 
mitotically inactive (Thorgeirsson 1996). Under physiological conditions, mature 
hepatocytes and biliary epithelial cells maintain the balance between cell loss and cell 
gain by dividing themselves (Knight et al. 2005). Additionally, following partial removal 
of tissue, the remaining population of hepatocytes and cholangiocytes have a 
remarkable capacity to meet replacement demands of cellular loss accounting for the 
extraordinary regenerative capacity of the liver. Specifically, the regeneration of the 
liver can be more correctly defined as compensatory hyperplasia as the remaining liver 
tissue expands to meet the metabolic needs of the organism although the expanding 
liver does not regain its original gross anatomical structure (Mao et al. 2014). 
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A number of models have been used for the study of liver regeneration, but the best 
studied model is the partial hepatectomy (PH) in which two-thirds of the rodent liver are 
removed (Michalopoulos 2010; Gilgenkrantz and Collin de l'Hortet 2011; Michalopoulos 
2014). This loss of liver mass leads to a rapid cellular proliferation and restoration of 
functional liver tissue. 24 hours after PH in the rat, more than 90% of the hepatocytes 
in the remnant 30% liver tissue are in the process of dividing and the liver mass is fully 
restored 7 to 10 days later (Higgins GM 1931). This process also occurs in human, 
although the precise timing of events is currently less clear: the available evidence 
suggests there is rapid regeneration during the first two weeks after major hepatectomy 
or transplantation in both donors and recipients, followed by a more gradual increase in 
size which ceases about 6 to 12 months later (Marcos et al. 2000). 
Despite the high regenerative capacity of the liver, there are several situations where 
the hepatocyte proliferation is blocked or cannot be sufficient to prevent the damage, 
as it is the case in chronic liver disease or in conditions of replicative senescence of the 
majority of hepatocytes. In these situations an alternative regenerative pathway is 
activated in which the main mediators are the HPCs (Tanaka et al. 2011), process that 
will be discussed in detail in next sections. 
2. CHRONIC LIVER DISEASES (CLDs) 
Chronic liver diseases (CLDs) constitute a major medical and public health problem 
worldwide. Currently, liver diseases are the tenth most common cause of death in the 
USA and, in Europe, are at least comparable with other diseases that are considered to 
be of major public health concern (Blachier et al. 2013). This situation is unlikely to 
change in the next decade since recent World Health Organization (WHO) projections 
have demonstrated that cirrhosis is one of the top 10 causes of death in the western 
world. Moreover, if we take a look at data from Asian and African countries where liver 
diseases are more prevalent, there is no doubt that liver disease is becoming a global 
problem. While the mortality rates for most other leading causes of death declined 
significantly over the last 40 years, the age-adjusted mortality rate for CLD has 
changed little. The large number of people affected worldwide and the lack of effective 
anti-fibrotic treatment make a deeper understanding of mechanism driving CLD an 
absolute requirement in order to deliver novel and more effective therapies. 
2.1 The natural history of CLDs 
CLD refers to a disease process that involves progressive destruction and regeneration 
of liver parenchyma leading to fibrosis and cirrhosis. Liver fibrosis is the first stage of 
CLDs; if the cause of fibrosis is eliminated, resolution (that is, complete reversal to 
near-normal liver architecture) of early hepatic fibrosis can occur. In general, in the 
early stages of fibrosis, the liver functions relatively well and few people experience 
symptoms. But as the inflammation and liver injury continue, scar tissue builds up and 
connects with existing scar tissue, which can eventually disrupt the metabolic functions 
of the liver. If the disease progresses, it can lead to cirrhosis, a condition in which 
tissue architecture is disrupted, and the liver is severely scarred with fibrotic bands, 
parenchymal nodules, and vascular distortion. Pathophysiologically, this often leads to 
portal hypertension and hepatic failure. Therefore, cirrhosis represents the final stage 
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of liver fibrosis and the final histological pathway for a wide variety of liver diseases 
(FIGURE 3).  
 
 
 
 
 
 
The progression to cirrhosis is very variable and may occur over weeks or many years. 
Furthermore, in this stage, although resolution is not possible, regression (that is 
improvement but not reversal) of fibrosis improves clinical outcomes.  
Importantly, cirrhosis can be considered a premalignant condition and patients with 
liver cirrhosis are usually at high risk of developing hepatocellular carcinoma (HCC), 
which ranks as the fifth most common cancer, causing over 600 thousand deaths per 
annum worldwide.  
2.2 Causes of CLDs 
The major causes of CLDs include chronic hepatitis virus infections, alcoholic liver 
disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Other less common 
causes of cirrhosis may include: autoimmune disorders, where the immune system 
attacks healthy tissue; blocked or damaged bile ducts; use of certain medicines; 
exposure to certain toxic chemicals; repeated episodes of heart failure with blood 
buildup in the liver and parasitic infection such as schistosomiasis in developing 
countries (Sun and Tang 2004; Liu et al. 2013; Pellicoro et al. 2014). In many patients 
FIGURE 3.  Natural history of chronic liver disease 
Hepatic fibrosis is the wound-healing response of the liver to many causes of chronic injury. Regardless of 
the underlying cause, iterative injury causes inflammatory damage, matrix deposition, parenchymal cell 
death and angiogenesis leading to progressive fibrosis. If the cause of fibrosis is eliminated, resolution of 
early hepatic fibrosis can occur. In cirrhosis, although resolution is not possible, regression of fibrosis 
improves clinical outcomes. Currently, liver transplantation is the only available treatment for liver failure 
or for some cases of primary liver cancer. Hepatocellular carcinoma (HCC) is rising in incidence 
worldwide and is a major cause of liver-related death in patients with cirrhosis. 
(Pellicoro et al., 2014) 
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with chronic hepatitis, no obvious cause can be identified. In some of these patients, 
the sustained hepatic inflammation is the key element (Marra and Tacke 2014).  
Hepatitis viruses have a special tropism toward hepatocytes and an ability to cause 
both acute and chronic liver diseases. There are 5 different hepatitis viruses from A to 
E of which predominantly B and C are the one causing CLDs and HCC. Specifically, 
chronic hepatitis B virus infection (HBV), in spite of the availability of an efficient 
vaccine, is considered a global public issue with more than 78.000 deaths per year. 
Alcohol consumption and abuse are also major causes of CLD, which is a significant 
health problem in the United States and around the world. The pathogenesis of ALD in 
humans is characterized by steatosis (accumulation of fat in hepatocytes) and a 
concomitant inflammatory process (Park et al. 2014; Williams et al. 2014; Chatterjee 
and Mitra 2015). 
NAFLD/nonalcoholic steatohepatitis (NASH) is considered to be a hepatic 
manifestation of metabolic syndrome, and its incidence is rapidly increasing worldwide. 
Sedentary lifestyles, poor food habits and a silent progression have contributed to the 
fatty liver disease epidemic in the Western world. NAFLD is a broad spectrum of 
diseases characterized by accumulation of triglycerides in the liver of patients without a 
history of excessive alcohol consumption. It is classified into simple steatosis and 
NASH, in which in addition to hepatic steatosis, intralobular inflammation and 
ballooning degeneration of hepatocytes are observed. NASH is a progressive disease 
and may lead to liver cirrhosis and HCC (Takahashi et al. 2015). 
2.3 Liver fibrogenesis 
Liver fibrogenesis can be considered the major pathophysiological event driving the 
progression of CLDs, irrespective of etiology (Friedman 2008). 
Liver fibrogenesis is a dynamic tissue, cellular and molecular process that leads 
progressively to an excess deposition of ECM components in an attempt to limit the 
consequences of chronic parenchymal injury (Novo et al. 2015). This process is 
sustained and modulated by a crosstalk occurring between different hepatic cell 
populations, resident or recruited into chronically injured liver, that are involved in the 
synthesis and release of several mediators, including growth factors, cytokines, 
chemokines, adipokines, reactive oxygen species (ROS), vasoactive agents and 
plasma proteins. The cellular and molecular mechanisms of hepatic fibrogenesis have 
been extensively investigated using multiple complementary experimental animal 
model systems (Liu et al. 2013) that have led to the identification of different pro-
fibrogenic mechanisms including chronic activation of the wound healing response; 
oxidative stress; a derangement of epithelial-mesenchymal interactions; epithelial to 
mesenchymal transition (EMT) of parenchymal cells; hepatocytes loss and chronic 
inflammation (Novo et al. 2015). 
The major cell type responsible for cell repair appears to be the activated 
myofibroblast. There are several potential sources of myofibroblasts, including resident 
cells, periportal and pericentral fibroblasts, or quiescent HSC and bone marrow-derived 
cells or circulating mesenchymal cells, which can migrate through the injured liver and 
become myofibroblasts. It is still controversial whether hepatocytes, cholangiocytes or 
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SECs may undergo phenotypic transformation into activated myofibroblats. Evidence 
support a central role for quiescent HSCs that upon activation by cytokine signalling, 
turn into myofibroblast, which then suffer profound changes in behaviour, including 
proliferation, chemotaxis, contractility, altered matrix degradation and production of 
fibrous scar, retinoid loss, and inflammatory signaling  (Friedman 2008; Rockey 2008; 
Zhou et al. 2014; Novo et al. 2015). 
Emerging evidence from studies of renal fibrosis suggests that more than a third of all 
disease-related fibroblasts originate from EMT and EndMT (endothelial-to-
mesenchymal transition) (Kalluri and Neilson 2003; Usunier et al. 2014). EMT and 
EndMT are biological processes by which an epithelial or endothelial cells undergo 
multiple biochemical changes that enable them to assume a mesenchymal cell 
phenotype, which includes enhanced migratory capacity, invasiveness, elevated 
resistance to apoptosis, expression of typical fibroblast markers such as FSP-1 
(fibroblast specific protein-1), α-SMA (α-smooth muscle actin), and vimentin and greatly 
increased production of ECM components (Kalluri and Weinberg 2009). Interestingly, in 
the context of liver fibrosis, Zeisberg et al. demonstrated  that up to 45% of fibroblasts 
in the fibrotic liver derive from hepatocytes via TGF-β (Transforming growth factor 
beta)-induced EMT (Zeisberg et al. 2007). 
TGF-β is a key player during liver fibrosis. It is known that TGF-β triggers the activation 
of HSCs, mediates ECM synthesis, provides cell contraction and migration, induces 
apoptosis in hepatocytes, and its signaling induces oxidative stress and consequently 
inflammation (Fabregat et al. 2016). Importantly, recent evidences show that TGF-β 
also participates in the development of fibrosis through signaling in other liver cell 
types, such as HPCs (Yang et al. 2016). 
2.4 Hepatic inflammation 
Acute inflammation as a defense against noxious stimuli is very important for 
homeostasis in the body, whereas chronic exposure to an inflammatory agent may 
cause a dysregulated or unresolved inflammatory response, which causes chronic 
inflammation. In sustained liver injury, persistent inflammation response is considered 
as one of the major ‘driving forces’ sustaining fibrogenesis, as it precedes and 
accompanies liver fibrosis (Forbes and Parola 2011). Both the innate and the adaptive 
immune systems contribute to the process. Damaged hepatocytes release apoptotic 
bodies, ROS, cytokines such as tumor necrosis factor alpha (TNF-α), vascular 
endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1); and chemokines 
(CXC) that activate endothelial cells, HSCs, and KCs by paracrine stimulation, which 
can in turn maintain/promote inflammatory and fibrogenic responses. Additionally, 
these signals may lead to recruitment and activation of the inflammatory cells.  
It seems clear that liver inflammation during CLD is orchestrated by a complex network 
of cytokine-mediated signaling pathways that contribute to fibrogenesis. 
TNF-α is mainly produced by monocytes, macrophages, HSCs and KCs. It has pro-
inflammatory activities and cytotoxic effects in the cells that produce it; furthermore, 
TNF-α activates HSCs that increases ECM synthesis thus contributing to liver fibrosis 
(Connolly et al. 2009). 
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Interleukins (ILs) are a group of cytokines expressed by CD4 T lymphocytes, 
monocytes, macrophages and endothelial cells. Both KCs and SECs produce ILs in 
response to liver tissue damage (Zhou et al. 2014). ILs can exert both pro-fibrogenic 
and anti-fibrogenic activities. Among the pro-fibrogenic interleukins are IL-1, IL-17 and 
IL-6, although specific roles of IL-6 are controversial (Gieling et al. 2009; Du et al. 
2013). IL-6 has been shown to be produced by hepatoma cells, suggesting that it may 
also be produced by hepatocytes (Michalopoulos 2007). The underlying molecular 
mechanism of the pro-fibrogenic role of IL-6 is not clear, but in vitro studies in dermal 
fibroblasts have associated IL-6 with a hyperactivation of the TGF-β/Smad3 signaling 
(O'Reilly et al. 2014). IL-6 anti-fibrotic actions have been reported in liver; thus IL-6 
reduces CCl4-induced acute and chronic liver injury and fibrosis (Kovalovich et al. 
2000). In addition, pretreatment of fibrotic liver with IL-6 improves hepatic 
microenvironment and primes it for mesenchymal stem cell transplantation, leading to 
improvement in liver injury after fibrosis (Nasir et al. 2013). 
On the other side, IL-10 negatively regulates the inflammatory response and present 
anti-fibrotic effects being its collagenolytic effect attributed to MMP and tissue inhibitor 
of metalloproteinase (TIMP) modulation (Chou et al. 2006). IL-22 has also been shown 
to restrict liver fibrosis and accelerate the resolution of liver fibrosis by inducing HSC 
senescence (Kong et al. 2012). 
2.5 Cirrhosis 
Liver cirrhosis is the final pathological result of CLD. It is characterized by degeneration 
and necrosis of hepatocytes, replacement of liver parenchyma by fibrotic tissue and 
regenerative nodules, and loss of liver function (Zhou et al. 2014). Together with 
mechanisms operating during the progression of liver fibrosis, such as activation of 
myofibroblasts, the major contributor to liver cirrhosis are repeated cycles of apoptosis 
and regeneration of hepatocytes and defenestration of liver sinusoidal endothelial cells, 
indicating an exhaustion of the regenerative capacity of the liver. 
The progression from fibrosis to cirrhosis occurs over decades, with an average of 20–
30 years from the time of initiation of injury (Cohen-Naftaly and Friedman 2011). 
Liver cirrhosis is the main risk factor for the development of HCC, however, the 
mechanism by which liver cirrhosis leads to HCC has not been clarified completely 
(Fattovich et al. 2004). 
2.6 Hepatocellular carcinoma (HCC) 
HCC is the most common primary malignancy of the liver. It is the fifth most common 
cancer in men, worldwide, and seventh among women, with over half a million new 
cases diagnosed annually worldwide. It is the second leading cause of cancer related 
mortality in the world. Approximately 75–80% of HCC frequently occurs in HBV- or 
Hepatitis C virus (HCV)-infected individuals whose disease has progressed to chronic 
stage such as cirrhosis, so that it can be considered the end-stage of CLDs. Any 
condition related to chronic liver inflammation is considered a risk factor because it is 
capable of causing genomic and mitochondrial damage facilitating the development of 
cancer (Berasain et al. 2009; Lachenmayer et al. 2010). 
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Interestingly, Berasain et al. have demonstrated that TNF-α constitutes a novel link 
between inflammatory signals and pro-tumorigenic mechanisms in liver cells; in 
particular, using human HCC and mouse hepatocytes they have shown the ability of 
this inflammatory cytokine to activate the epidermal growth factor receptor (EGFR), a 
key factor in both liver regeneration and hepatocarcinogenesis (Berasain et al. 2012; 
Lopez-Luque et al. 2016). 
Multiple signaling pathways involved in several cellular functions have been described 
to be deregulated a in HCC including Wnt/β-catenin, p53, mitogen-activated protein 
kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of 
rapamycin (mTOR), hepatocyte growth factor (HGF)/c-Met signaling pathway and 
TGFβ (Calvisi et al. 2007; Torrecilla and Llovet 2015). Moreover, although the 
relevance of the EMT in liver fibrogenesis remains controversial, there are no doubts 
that this process is involved in cancer progression (Giannelli et al. 2016). 
2.7 How to study CLDs 
Considering all the above, it seems clear that additional studies are required for a 
better understanding of the molecular process contributing to CLD development and 
progression to develop new therapeutic strategies. Experimental animal models offer 
researchers irreplaceable opportunities to study biological, pathological, and 
histological characteristics of human CLDs. However, although no single animal model 
exhibits all attributes of human liver diseases, it should be recognized that mouse 
models of liver fibrosis that mimic human liver fibrosis have aided study liver 
fibrogenesis (Urtasun et al. 2011; Liedtke et al. 2013). 
According to Liu et al. (Liu et al. 2013), the most commonly used rodent models for 
studying CLDs can be divided into two groups:  
1. Those generally used for studying mechanisms of liver fibrosis irrespective of 
disease etiologies that include: chemically-induced liver fibrosis models using 
hepatotoxins, such as carbon tetrachloride (CCl4), thioacetamide (TAA) and 
dimethyl or diethyl nitrosamine (DMN and DEN); and genetically engineered 
(transgenic/knockout) mouse models. 
2. Those used to mimic specific CLDs including autoimmune and cholestatic liver 
diseases, chronic viral infection, NAFLD, and ALD that include: animal models 
of schistosomiasisl; autoimmune hepatitis; primary biliary cirrhosis; and 
progressive cholestatic liver disease (such as Mdr2 -/- mice and 3,5-
diethoxycarbonyl-1, 4-dihydrocollidine (DDC) diet). 
Animal models allow to (i) comprehensive study of questions that cannot be addressed 
in human studies, (ii) multiple sampling at strategic times during the 
evolution/resolution, (iii) experimental testing with restriction of the number of variables 
to a minimum. In the in vivo model, the whole organ is intact (interactions between 
various cell types and matrix) and  the possible influences derived from other parts of 
the body, such as the nervous system, the endocrine system, the neuroendocrine 
system, the circulatory system, the diet, or the influences gut-derived are taken into 
consideration (Starkel and Leclercq 2011). 
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2.7.1 Carbon tetrachloride (CCl4) 
CCl4 is one of the most widely used hepatic toxins for experimental induction of liver 
injury in laboratory animals. CCl4 directly impairs the functionality of the hepatocytes by 
altering the permeability of different cellular membranes, the plasma, lysosomal and 
mitochondrial membranes.   
CCl4 is transformed into a toxic CCl3- radical by CYP2E1, an enzyme expressed in 
perivenular hepatocytes (Boll et al. 2001). In the presence of oxygen, the CCl3− radical 
is converted to the trichloromethyl peroxy radical, CCl3OO*. This radical, more reactive 
and thus with a shorter half-life than the CCl3− radical, is responsible for initiating the 
process of lipid peroxidation. It is of interest to note that lipid peroxidation may damage 
cellular functions in two ways: by compromising membrane function and by covalent 
binding of reactive intermediates formed during the toxicity reaction (Weber et al. 
2003). Thus, it induces an acute centro-lobular necrosis that triggers a wound healing 
response with recruitment of phagocytic and inflammatory cells to clear necrotic zones, 
activation of fibrogenesis and increased ECM deposition and proliferation of 
parenchymal and non-parenchymal cells to replace dead cells. When the insult is 
repeated, successive rounds of wound healing occur prior to resolution of the previous 
one, resulting in fibrosis accumulation (Weber et al. 2003; Starkel and Leclercq 2011). 
2.7.2 3,5-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet 
DDC feeding in mice is a well-established animal model generally included in the 
second group of rodent models for studying CLDs, particularly for its use in the study of 
Mallory-Denk body formation which are inclusion bodies found in liver cells associated 
with alcoholic and nonalcoholic steatohepatitis, metabolic liver diseases, and chronic 
cholestatic liver diseases (Stumptner et al. 2001; Fickert et al. 2002; Zatloukal et al. 
2004). 
It is known the ability of this compound to induce porphyria in primary cultures of 
mouse hepatocytes, in which DDC treatment results in a marked inhibition of 
ferrochelatase and accumulation of protoporphyrin (Brady and Lock 1992). In vivo, 
DDC feeding leads to increased biliary porphyrin secretion and induction of vascular 
cell adhesion molecule, osteopontin, and TNF-α expression in cholangiocytes (Fickert 
et al. 2007). This xenobiotic-induced liver injury model is useful to investigate the 
mechanisms of chronic cholangiopathies and their consequences, including biliary 
fibrosis (Fickert et al. 2002; Fickert et al. 2007). Moreover, feeding a DDC-containing 
diet is one of the most efficient mouse models for chemical-induced oval cell 
proliferation, although the molecular mechanism remains unknown (Yokoo et al. 1982; 
Wang et al. 2003; Jakubowski et al. 2005; Malato et al. 2011; Yamazaki et al. 2011; 
Weng et al. 2013). 
2.8 The treatment of CLDs 
Treatment of patients with CLDs has been a big challenge for physicians because CLD 
is usually diagnosed at the irreversible stages such as cirrhosis, cancer or liver failure. 
Since the progress of fibrosis is basically similar in all liver diseases regardless of the 
etiology, the development of anti-fibrotic therapies should benefit all patients with 
fibrotic liver injury. The liver's ability to regenerate and its first-pass metabolism allow 
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lower doses of orally administered compounds to achieve a therapeutic response, 
minimizing systemic distribution and non-hepatic side effects, which makes liver 
fibrosis an attractive target for therapy. Potential therapeutic approaches for liver 
fibrosis include: treatment of the primary disease, suppression of hepatic inflammation, 
inhibition of HSCs activation, promotion of matrix degradation, stimulation of HSCs 
apoptosis, and targeted anti-fibrotic therapies. The emerging anti-fibrotic therapies can 
slow, halt or reverse fibrosis progression. Inhibition of TGF-β1 signaling cascade is one 
of the most appealing therapeutic strategies of anti-fibrotic efforts in liver to combat 
CLDs progression, since TGF-beta is a master regulator of the fibrogenic process  
(Fabregat et al. 2016; Giannelli et al. 2016). 
Elimination of the trigger(s) that lead to cirrhosis is likely to retard progression and to 
reduce the incidence of HCC. There is evidence that causal treatment may even 
reverse cirrhosis, although in some of the reports sampling variability cannot be 
excluded. Specifically, it has been demonstrated that alcohol withdrawal, interferon-
based antiviral treatment and long-term treatment with oral inhibitors of HBV 
polymerase may not only retard or reverse cirrhosis but prevent complications of end-
stage liver disease (Schuppan and Afdhal 2008).  
Regarding HCC, a wide variety of non-surgical therapies can result in clinical 
responses in patients with this type of cancer, including ablative techniques, intra-
arterial therapies or chemotherapy (Johnson 2005). No other approaches have 
demonstrated convincing evidence of survival advantage. To date, surgical resection is 
currently considered to be the definitive treatment for HCC and the only one that offers 
the prospect of cure or at least long-term survival (Liu et al. 2013).  
3. HEPATIC PROGENITOR CELLS (HPCs) 
3.1 Generalities 
We previously mentioned that under situations where hepatocytes or biliary epithelial 
cells regenerative capacity is compromised, such as chronic injury states or in the 
presence of substances inhibiting adult hepatocyte proliferation, HPCs are activated to 
support or take over the regenerative process  (Falkowski et al. 2003; Marshall et al. 
2005). 
These cells were first described by E. Faber in 1956 as “small oval cells with scant 
lightly basophilic cytoplasm and pale blue-staining nuclei” with a high 
nuclear/cytoplasmic ratio and an ovoid nucleus, which gave them the name “oval cells”. 
The oval cell-mediated regenerative process is often referred to as “oval cell response” 
or “ductular reaction” due to the fact that proliferating oval cells organize into ductular 
structures or ductules.  
During the oval cell-mediated regeneration, oval cells arise in the periportal region of 
the liver. Although their origin is still under debate, the most accepted theory is that 
they derive from adult liver stem cells located at the canal of Hering, in the smallest 
branches of the biliary tree, therefore considered the niche for the oval cell precursors. 
As other stem cell niches, this is a restricted compartment in a tissue that maintains 
and regulates stem cell behaviour, supporting self-renewal and maintaining the balance 
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between quiescence, proliferation and differentiation required in response to injury 
(Lorenzini et al. 2010; Hsieh et al. 2015). 
Oval cells are bipotential progenitors able to differentiate into both hepatocytes and 
cholangiocytes and therefore replenish cellular loss both in rodents and humans 
(Okabe et al. 2009; Shin et al. 2011). These properties support their role as HPCs 
(Alison et al. 1996; Yang et al. 2002; Roskams et al. 2004; Duncan et al. 2009; Tanaka 
et al. 2011). It is interesting to mention that, apart from their bipotential nature, these 
cells can differentiate in a non-lineage-restricted manner, generating cells of other 
organs when placed in the environment of a different organ, which would evidence their 
multipotency (Cardinale et al. 2011).  
Because of their bipotential nature, oval cells have a unique phenotype and coexpress 
bile duct epithelium markers, as CK19 (cytokeratin 19), A6, OV6 and EPCAM 
(epithelial cell adhesion molecule); and hepatocyte markers, such as CK8 and CK18 
(cytokeratin 8 and 18), ALB (Albumin), c-Met (hepatocyte growth factor receptor), and 
CYP450 (Yin et al. 2002). Furthermore, they express high levels of some hepatoblasts 
markers, such as α-fetoprotein (AFP) and Delta-like protein 1 (Dlk1). Of particular 
interest is the finding that oval cells express markers associated with hematopoietic 
lineages such as Thy-1 (thymocyte differentiation antigen, also known as CD90), CD34 
(Cluster of Differentiation 34), Sca-1 (Stem cell antigen 1) and c-kit (Omori et al. 1997). 
In addition, in their gene expression profile these cells show expression of CD44 
(Yovchev et al. 2007) and CD133 (encoded by the Prom 1 gene) (Dorrell et al. 2011), 
which are stem cell markers that have been identified as putative markers for cancer 
stem cells (Ma et al. 2007; Yin et al. 2007); as well as markers of different lineages, as 
N-CAM (neural cell adhesion molecule) and chromogranin, typical of neuroepithelial 
cell (Libbrecht and Roskams 2002). 
Oval cell differentiation towards hepatocytes or cholangiocytes is associated with a 
progressive loss of oval cell markers and acquisition of a more mature phenotype 
(Gaudio et al. 2009). 
A major problem in characterizing oval cells is the lack of a specific cell surface marker 
to identify and isolate them . Therefore, despite a large number of studies, the exact 
nature of oval cells – including their origin, stemness and bi-directional differentiation – 
is still poorly understood (Okabe et al. 2009). 
3.2 How to study the oval cell response 
Several groups have developed protocols in rodents for the enrichment and expansion 
of HPC (Monga et al. 2001). In mouse, various treatments have been successfully 
used to induce proliferation of oval cells, in some cases even in the absence of 
impaired hepatocytes proliferation. Among these, we find choline-deficient, ethionine-
supplemented diet (CDE) (Tirnitz-Parker et al. 2007), methionine choline-deficient diet 
supplemented with ethionine (MCDA) (Malato et al. 2011), bile duct ligation (BDL) 
(Sackett et al. 2009), and DDC (Preisegger et al. 1999). 
In rat, treatment with CCl4 preferentially induces proliferation of hepatocytes, and the 
activation, proliferation, and differentiation of progenitor cells into hepatocytes requires 
simultaneous administration of D-galactosamine, which blocks RNA and protein 
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synthesis in hepatocytes (Dabeva and Shafritz 1993). Moreover, in rats that had 
undergone PH, the expansion of oval cells is not observed unless 2-acetaminofluorene 
(2-AAF) is supplied; this compound is metabolized by cytochrome P450 into 
hydroxylated metabolites that bind to DNA, hereby blocking cell cycle progression 
before S phase and impairing cell function specifically in hepatocytes and not in HPC 
that lack such enzymes (Dusabineza et al. 2012). 
Ductular reaction in humans is morphologically and immunohistochemically analogous 
to the rodent oval cell response in the periportal regions. Ductular reaction  involves not 
only HPC but also mesenchymal, vascular hematopoietic and inflammatory cells, 
together with ECM modifications. As a consequence, it could result in inflammatory 
infiltration, rich in neutrophil infiltration (cholangiolitis), periportal fibrosis and 
neovascularization. The magnitude of HPC activation corresponds to the severity of 
liver fibrosis and inflammation. Ductular reaction  has been described in severe acute 
liver disease, such as fulminant hepatic failure, and many forms of chronic human liver 
disease such as focal nodular hyperplasia, primary biliary cirrhosis, primary sclerosing 
cholangitis, chronic hepatitis C, alcoholic and non-alcoholic steatohepatitis and cancer 
(Clouston et al. 2005; Richardson et al. 2007; Bird et al. 2008; Gouw et al. 2011; Ye et 
al. 2014).  
3.3 The oval cell response 
Upon activation, oval cells proliferate, invade and expand into liver parenchyma from 
the periportal region. The oval cell response can be divided into 4 phases: activation, 
proliferation, migration, and differentiation (FIGURE 4). 
 
 
 
 
FIGURE 4.  Oval cell response 
Oval cells are induced in severe liver damage conditions. The origin of oval cells is still under debate. 
Chronic injury conditions in the liver are usually associated with inflammation, and the roles of 
lymphocytes and inflammatory responses in oval cell regulation have also been suggested. Moreover, 
mesenchymal cells such as stellate cells have long been suggested to physically interact with oval cells 
and thus considered to induce some signals in them. 
(Modified from Tanaka et al., 2011) 
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The regulation of these different phases of the oval cell response seems to be a very 
complex process involving a number of cytokines and growth factors. These actors that 
impact the oval cell response can do so either directly (acting on the proliferating cells) 
or indirectly by signaling to a non–epithelial cell type, which might, in turn, then act on 
the oval cells. Some of these factors are summarized in the following table (TABLE 2.) 
and include cytokines, like IL-6 or TNF-α, and growth factors such as HGF (hepatocyte 
growth factor), EGF, TGF-β, among others. Hormones (such as insulin, somatostatin), 
adipokines (cytokines released by adipocytes, such as leptin) and neurotransmitters 
(such as serotonin, epinephrine or norepinephrine) have also been reported to regulate 
HPC response or growth. Finally, there is increasing evidence to suggest that 
morphogens (factors playing a critical role during embryonic development) such as Wnt 
and Notch signaling pathways are key regulators of oval cell fate determination in 
rodents and humans (Hu et al. 2007; Apte et al. 2008; Boulter et al. 2012).  
The interactions and signaling crosstalk between these factors and signaling pathways 
are complex and remain poorly understood (Campbell et al. 2001; Nobili et al. 2012; 
Best et al. 2013).  
  
 
Hepatocyte injury triggers the oval cell activation, but the mechanism by which the 
damage is communicated to the oval cell precursors is unknown. Furthermore, the 
specific roles of various hepatic cell types in the signaling process are unclear (Erker 
and Grompe 2007). Therefore, several hypotheses exist regarding the source/s of the 
signal/s that result in the activation of the oval cell precursor: 
I. Direct signaling from damaged hepatocytes; 
II. Indirect signals from hepatic stellate cells in response to hepatocyte injury; 
III. Damage-induced cytokines released from inflammatory cells; 
IV. Endothelial cells as a source of the primary signal; 
V. Multiple cell types may be required and each may contribute to the activation 
process. 
SCF: Stem cell factor; IFN-γ: Interferon-γ; TWEAK: Tumor necrosis factor-like weak inducer of 
apoptosis; FGF-1: Fibroblast growth factor 1; TGF-α: Transforming growth factor alpha; uPA: 
Urokinase-type plasminogen activator; tPA: tissue-type plasminogen activator; LIF: Leukemia 
inhibitory factor; OSM: Oncostatin M and OSMR: OSM Receptor. 
 18 
 
A particularly important role has been given to inflammatory signals. As just mentioned, 
different cytokines involved in the inflammatory response appear to play important roles 
in the oval cell response: IL-6 promotes the phosphorylation of STATs proteins that in 
turn translocate to the nucleus to act as transcription factors, ultimately leading to the 
proliferation of oval cells. Thus, STAT3 is highly active in oval cells expanding in the 
liver after AAF/PH-induced damage (Sanchez et al. 2004) and knock-in mouse models 
have demonstrated that hyperactive STAT3 signaling results in enhanced oval cell 
numbers (Yeoh et al. 2007). 
TNF-α is released at the site of liver injury mainly by KCs. TNF-α activates the tumor 
necrosis factor receptor 1 (TNFR1) on inflammatory cells to release several cytokines. 
Once oval cells have received this signal, they produce TNF-α themselves, generating 
an autocrine loop. Further evidence that TNF-α is involved in oval cell activation is that 
TNFR1 knockout mice have a clearly impaired oval cell response (Knight et al. 2000). 
Other inflammatory cytokines that play a role in this step are the tumor necrosis factor-
like weak inducer of apoptosis (TWEAK) (Jakubowski et al. 2005); IL-18 response that 
results in interferon-γ (IFN-γ) secretion and  IFN-γ itself (Akhurst et al. 2005). 
In addition to the inflammatory cytokines, a combination of genetic studies in rodents 
and in vitro studies has allowed identifying HGF, EGF and TGF-β as key factors in the 
regulation of the oval cell response. Regarding EGF, early gene expression studies 
showed that EGF is overexpressed during the period of active proliferation and 
differentiation of progenitor cells in rat liver following the protocol 2-AAF/PH and this 
increase seems to drive the early proliferation of the progenitor cell compartment. 
Moreover, in vivo infusion of EGF or HGF decreases apoptosis (Nagy et al. 1996). 
Consistently, we have demonstrated that the EGFR signaling promotes oval cells 
proliferation and survival in vitro (Martinez-Palacian et al. 2012).  
On the other hand, Kitade et al. have demonstrated that c-Met signaling is a strong 
inducer of hepatocyte differentiation via activation of AKT and STAT3, whereas EGFR 
is required for NOTCH1-controlled expression of cholangiocyte-specific genes and 
ductular morphogenesis. Both stimulation of NOTCH1 expression and biliary epithelial 
differentiation were reduced during progenitor cell-mediated liver regeneration after 
DDC treatment in EGFR conditional knockout mice, supporting a role of the 
EGFR/NOTCH1 positive feedback loop for commitment of adult HPCs toward biliary 
epithelial cell lineage (Kitade et al. 2013). The effects of HGF on oval cells will be 
discussed in detail in another section of the introduction. 
Contrarily, suppressor effects for TGF-β in the oval cell response have been described. 
Specifically, data from literature show that TGF-β overexpression in vivo in hepatocytes 
and oval cells inhibited the oval cell response following DDC treatment in mice 
(Preisegger et al. 1999). We have also demonstrated proliferation inhibitory and pro-
apoptotic activities of TGF-β in oval cells in vitro (del Castillo et al. 2008). 
Oval cells must move from the periportal zone into the liver parenchyma and 
differentiate. This migratory response involves extensive tissue remodeling. Indeed, a 
number of studies show that the expansion of the oval cell compartment occurs in 
association with ECM remodeling, which involves the participation of many proteins, 
including urokinase-type plasminogen activator (uPA), tissue-type plasminogen 
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activator (tPA), the uPA receptor (uPAR), and plasminogen activator inhibitor 1 (PAI-1) 
(Erker and Grompe 2007; Lorenzini et al. 2010; Lozoya et al. 2011).   
3.4 The contribution of oval cell to liver regeneration 
The role of oval cells in regeneration of the damaged liver has been tested in 
transplantation experiments. Thus, transplanted oval cells derived from rat liver or 
pancreas have proved to proliferate and differentiate into mature hepatocytes, even 
under non-selective conditions (Dabeva et al. 1997). Additionally, repopulation studies 
utilizing an in vivo selection model indicated that mouse oval cells (induced by DDC) 
have an extensive liver repopulation capacity (Wang et al. 2003). These and other 
studies using similar approaches (Suzuki et al. 2008) have convincingly proved their 
regenerative potential. It is also important to mention that using experimental models of 
oval cell induction it has been demonstrated that repeated oval cell reactions facilitates 
their expansion and liver regeneration without increasing the risk of tumorigenesis 
(Papp et al. 2014). 
However, other studies using cell tracing technologies in murine models of 
experimental injuries have revealed that HPC contribution to generate adult 
parenchymal cells during liver regeneration is minor (Malato et al. 2011; Espanol-Suner 
et al. 2012; Rodrigo-Torres et al. 2014; Yanger et al. 2014), so the actual implication of 
oval cell expansion in the regenerative response is nowadays a matter of debate 
(Riehle et al. 2011; Shin and Kaestner 2014). 
One possibility is that oval cell contribution to regeneration depended on the extent of 
damage and/or the specific tissue context. In support of this, using different models it 
has been demonstrated that severe hepatocyte function impairment is necessary to 
elicit a HPC-mediated-regenerative response in rodents (Choi et al. 2014; Lu et al. 
2015). However, this might not faithfully reflect what occurs in humans, where HPCs 
are activated in the majority of liver diseases, even in minimal degrees of liver damage 
(Kohn-Gaone et al. 2016).  
In spite of the controversy, human HPC have been proposed for cellular based therapy 
in decompensated liver cirrhosis, since they are less immunogenic and present a 
higher propagative capacity than adult hepatocytes (Habeeb et al. 2015). 
3.5 The other side of the coin: oval cells and hepatic fibrosis, cirrhosis 
and HCC 
As it was stated before, during chronic injury the HPC response is activated (Pritchard 
and Nagy 2010; Williams et al. 2014). Indeed, a HPC response has been described in 
many forms of chronic human liver disease and in severe acute liver disease. The fact 
that there is an apparent direct correlation between the degree of fibrosis and the 
extent of HPC expansion (Williams et al. 2014) has raised the question of whether 
fibrosis is beneficial for the HPC-triggered regenerative response, which in turn is 
beneficial for resolving the fibrotic process or whether fibrosis is unintentionally 
exacerbated by the progenitor reaction. Clearly, this issue has major implications for 
the development of either anti-fibrotic or pro-regenerative therapies. 
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The functional requirement of a HPC response for fibrogenesis has not been 
established to date. Nevertheless, some researchers have suggested that oval cells 
drive the fibrotic reaction through the increase of collagen deposition (Jakubowski et al. 
2005) or the overexpression of integrin alphavbeta6 (αvβ6), which correlates with 
fibrosis progression in human and experimental liver disease (Patsenker et al. 2008). In 
accordance with this, Kuramitsu et al. propose a vicious circle model in which failure of 
hepatocyte replication and death during fibrotic liver regeneration activates the reserve 
progenitor cell compartment, which in turn elicits a severe fibrogenic response and 
further compromises hepatocyte-mediated liver regeneration in the fibrotic 
microenvironment (Kuramitsu et al. 2013). 
In support of the alternative view that considers fibrosis as a promoting factor for oval 
cell activation, it has been proposed that matrix remodelling could itself drive oval cell 
expansion and therefore HPC-associated regenerative response (Pi et al. 2005; Van 
Hul et al. 2009). These two opposing ideas are not mutually exclusive, and this 
paradox can be resolved by recognizing heterogeneity in the ductular reaction 
activation and evolution (Clouston et al. 2009). 
Besides this, evidence suggest that deregulation of the oval cell 
activation/differentiation pathway can result in malignant transformation of these cells 
that subsequently become tumor-initiating cells and drive hepatocarcinogenesis. 
Several studies based on immunohistochemical analysis of HCCs have concluded that 
about 28–50% of HCCs express markers of progenitor cells (Roskams 2006; Caldwell 
and Park 2009). Interestingly, these tumors carry a significantly poorer prognosis and 
higher recurrence after surgical resection and liver transplantation (Uenishi et al. 2003; 
Lee et al. 2006; Yang et al. 2010; Kohn-Gaone et al. 2016). 
Nevertheless, the question is whether this immature intermediate phenotype 
represents progenitor cell differentiation arrest or dedifferentiation of mature 
hepatocytes. Histological and immunophenotyping studies favour the progenitor cell 
differentiation arrest model, that implies a situation in which HPC subjected to certain 
pathological conditions would evolve to tumor initiating cells, therefore neoplastic 
transformation of HPC should be a critical molecular event during 
hepatocarcinogenesis (Kitisin et al. 2007). Consistently, exposure of oval cells to 
carcinogens results in HCC formation and certain carcinogenic regimes are 
accompanied by oval cells accumulation (Steinberg et al. 1994; Sell and Leffert 2008); 
furthermore, oval cells can become transformed in culture (Dumble et al. 2002; Tang et 
al. 2008; Wu et al. 2012).  
Certainly, HPC constitute a very interesting but still poorly understood cell population. It 
seems evident the need to better understand the mechanisms of regulation and 
transformation of HPC during CLD and the implication of different growth factors in this 
process. Dissecting these pathways is critical for development of drugs and therapies. 
The use of oval cells for cell therapy is an attractive alternative to organ transplantation 
for the treatment of liver disease. One of the main advantages of this type of therapy is 
that it would allow isolation of oval cells from a patient who has a liver disease, further 
expansion in culture and/or manipulation to increase their regenerative potential, and 
autologous transplantion to the patient in order to restore liver function. 
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4. HGF/c-Met SIGNALING PATHWAYS 
4.1 HGF: structure, synthesis, expression and function 
HGF was originally identified as a strong mitogen for mature hepatocytes in vitro in the 
1980s (Nakamura 1989). It is also known as Scatter factor (SF), as it was found, 
independently, as a product of secretion of fibroblasts and smooth muscle cells able to 
induce epithelial cell motility (Stoker et al. 1987); only later it was discovered that the 
two molecules were actually the same (Naldini et al. 1991). 
70 kb human HGF gene is located on chromosome 7q21.1 and is composed by 18 
exons separated by 17 introns. 
HGF is a heterodimeric glycoprotein consisting of a heavy (α) and a light (β) chain with 
approximate molecular weights of 64,000 and 32,000 daltons, respectively. HGF is 
structurally related to the blood proteinase precursor plasminogen. The primary 
structure of HGF is more than 90% homologous in humans and rodents (Nakamura 
1989; Zarnegar et al. 1992). Like plasminogen, HGF is produced as an inactive protein 
(pro-HGF), which is subsequently cleaved. This 728 amino acid precursor form binds to 
the cell surface or the extracellular matrix, presumably via its affinity for heparin-like 
glycosaminoglycans. Limited proteolysis of pro-HGF at the Arg494 - Val495 bond 
yields the active disulfide-linked heterodimer (αβ-HGF): the α chain consists of a 
putative hairpin loop and four kringle domains, each defined by three disulfide bonds, 
while the β chain has homology to the catalytic domain of serine proteases but lacks 
enzymatic activity (Patthy et al. 1984) (FIGURE 5). αβ-HGF binds the c-Met receptor 
with high affinity. 
 
 
 
 
Maturation of secreted pro-HGF into the bioactive form takes place in the extracellular 
environment through a proteolytic cleavage. Different serine proteases have been 
implicated in this proteolytic conversion including HGF activator (HGFA), uPA, tPA, 
FIGURE 5. Synthesis, structure and maturation of HGF 
HGF is produced and secreted as a pro-HGF, which is cleaved at the Arg494 - Val495 bond by 
HGF-activators to form mature HGF. 
(Modified from Nakamura and Mizuno, 2010) 
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blood coagulation factors XIIa and XI, matriptase, hepsin and plasma kallikrein (Naldini 
et al. 1995; Nakamura et al. 2011). 
In general, HGF is produced and secreted by stroma cells or cells of mesenchymal 
origin (such as fibroblasts, macrophages, and smooth muscle cells among others) of 
various organs such as liver, lung, kidney, placenta and brain, both during development 
and the adult stage (Nakamura and Mizuno 2010). Specifically, in normal liver, the 
major cellular source of HGF is the HSC (Maher 1993). HGF acts in a paracrine 
manner, as HGF receptor c-Met is mainly expressed in epithelial cells, although some 
cellular types express both HGF and c-Met showing therefore an autocrine signaling 
(Sonnenberg et al. 1993; del Castillo et al. 2008). 
HGF gene transcription is upregulated by inflammatory modulators such as TNF-α, IL-
1, IL-6, TGF-β and VEGF (Broten et al. 1999). Other molecules that induce the 
production of HGF are norepinephrine, prostaglandins and also growth factors such as 
platelet-derived growth factor (PDGF) and FGF (Matsumoto et al. 1995; Boccaccio et 
al. 1998).  
HGF has been shown to be a mitogen that stimulates growth of various epithelial cells; 
it also enhances motility of epithelial cells; and acts as a morphogen that induces 
epithelial tubule formation. Among other processes in which it is involved, we can cite 
the development of skeletal muscle (Bladt et al. 1995), the development of nervous 
system, bone remodeling and angiogenesis (Birchmeier et al. 2003; Nakamura et al. 
2011). Moreover, HGF stimulates cell invasion and polarization, and inhibits apoptosis 
(Comoglio and Trusolino 2002; Zhang and Vande Woude 2003; Tulasne and Foveau 
2008). Importantly, HGF plays a crucial role in liver, which will be described in detail in 
a subsequent section (see HGF/c-Met signaling pathway in the liver). 
4.2 c-Met: structure, synthesis, expression and function 
The MET proto-oncogene located on chromosome 7q21-31 was first isolated from a 
human osteosarcoma-derived cell line on the basis of its transforming activity in vitro 
(Cooper et al. 1984). A few years later, c-Met was identified as the receptor of HGF 
(Bottaro et al. 1991). 
The c-Met receptor is formed by proteolytic processing of a common precursor into a 
single-pass, disulphide-linked α/β heterodimer (50 kD α-chain and a 145 kD β-chain). 
The entire extracellular α-chain forms a semaphorin (Sema) domain and is linked to the 
extracellular portion of the β-chain, which is composed of three types of domain: the N-
terminal 500 residues form the Sema domain together with the α-subunit; the plexin–
semaphorin–integrin (PSI) domain follows the Sema domain, spans approximately 50 
residues and includes four disulphide bonds. This domain is connected to the 
transmembrane helix via four immunoglobulin–plexin–transcription (IPT) domains, 
which are related to immunoglobulin-like domains. Intracellularly, the c-Met receptor 
contains a tyrosine kinase catalytic domain flanked by distinctive juxtamembrane and 
carboxy-terminal sequences (FIGURE 6).   
The catalytic region contains the catalytic tyrosines Y1234 and Y1235, which upon 
phosphorylation positively modulate the enzymatic activity, while the juxtamembrane 
tyrosine 1003 negatively regulates c-Met by recruiting the ubiquitin ligase casitas B-
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lineage lymphoma (c-CBL). The multifunctional docking site in the C-terminal tail 
contains tyrosines Y1349 and Y1356, which recruit several transducers and adaptors 
when c-Met is active (Benvenuti and Comoglio 2007; Organ and Tsao 2011). For its 
particular structure, c-Met belongs to a family of heterodimeric tyrosine kinases, which 
also includes Ron, Ryk and Sea receptors (Huff et al. 1993; Ronsin et al. 1993; 
Gaudino et al. 1994; Maestrini et al. 1996). 
 
 
 
 
 
 
 
 
 
HGF ligand contains two c-Met binding sites: a high affinity site is located in the α-chain 
and recognizes IPT domains of c-Met independently of the HGF maturation. The low 
affinity site is located in the β-chain, requires HGF processing and interacts with the 
Sema domain (Stamos et al. 2004; Basilico et al. 2008). 
c-Met is expressed in epithelial cells of many organs, including liver, pancreas, 
prostate, kidney, muscle and bone marrow, during both embryogenesis and 
adulthood (Comoglio et al. 2008). Its expression is induced by multiple factors including 
HGF, EGF, IL-1, IL-6, TNF-α, estrogen, progesterone and dexamethasone (Moghul et 
al. 1994; Zarnegar 1995). 
 
 
FIGURE 6. c-Met structure 
The extracellular region of c-Met is composed of three domains: the Sema domain that 
includes the entire α-chain and part of the β-chain; the PSI domain and four IPT domains. 
The intracellular region of c-Met consists of three portions: a juxtamembrane sequence; a 
catalytic region; and a carboxy-terminal multifunctional docking site. 
 (Modified from Faria et al., 2011) 
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4.3 HGF/c-Met signaling pathway 
When HGF binds to c-Met, the receptor undergoes autophosphorylation of the Y1234 
and Y1235 residues in the kinase domain; subsequently, tyrosine residues in the 
docking site (Y1349 and Y1356) become phosphorylated and recruit signalling 
effectors and adaptor proteins such as Growth factor receptor-bound protein 2 (GRB2), 
PI3K, STAT-3, Src homology-2-containing (SHC) and v-crk sarcoma virus CT10 
oncogene homolog (CRK), CRK-like (CRKL) and Src homology domain-containing 5' 
inositol phosphatase (SHIP-2) (Trusolino et al. 2010; Organ and Tsao 2011; Gherardi 
et al. 2012; Granito 2014). These molecules facilitate downstream signalling through 
several pathways. Moreover, unique to c-Met is its association with the adaptor protein 
GRB2-associated binding protein 1 (GAB1), a multi-adaptor protein that, once bound to 
and phosphorylated by c-Met, creates more binding sites for downstream adaptors 
(Weidner et al. 1996). 
c-Met engagement results in the activation of multiple signal transduction pathways 
including the MAPKs cascade (Mitogen Activated Protein Kinases), ERK1 and ERK2, 
JNK (c-Jun N-terminal Kinases) and p38 MAPK; the PI3K-AKT and its downstream 
regulator nuclear factor kappaB (NF-κB); and the activation of STAT-3 pathway  (Sipeki 
et al. 1999; Maroun et al. 2000; Birchmeier et al. 2003). All these signaling pathways 
transmit the information from the cellular membrane to the nucleus to modulate gene 
expression participating in the control of several cellular processes such as 
proliferation, survival, invasion and migration (FIGURE 7). 
 
 
 
 
FIGURE 7. The HGF/c-Met signaling pathway 
Following HGF binding, the kinase activity of c-Met is switched on. This leads to the activation of 
downstream signaling pathways that include MAPK, PI3K/AKT and STAT pathways, which mediate 
c-Met-dependent cell functions. 
(Modified from Granito et al., 2014) 
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Activation of MAPK cascades by c-Met implies the activation of RAS protein through 
the guanine nucleotide exchanger Son of Sevenless (SOS) via binding with SHC and 
GRB2. This leads to the indirect activation of v-raf murine sarcoma viral oncogene 
homolog B1 (RAF) kinases, which can subsequently activate the MAPK effector kinase 
MEK and finally MAPK that  then translocate to the nucleus to activate transcription 
factors responsible for regulating the expression of a large number of genes. In the 
context of c-Met signaling, MAPK signalling drives cell cycle progression,proliferation 
and cell motility (Organ and Tsao 2011). 
The other major arm of c-Met signalling is the PI3K/Akt signalling axis. The p85 subunit 
of PI3K can bind either directly to c-Met or indirectly through GAB1, which then signals 
through AKT/protein kinase B. This axis is primarily responsible for the cell survival 
response to c-Met signalling (Organ and Tsao 2011). 
Furthermore, the direct binding of STAT3 to c-Met results in STAT3 phosphorylation, 
dimerization and its translocation to the nucleus where it regulates gene expression. 
This has been shown to result in tubulogenesis (Boccaccio et al. 1998) and invasion 
(Syed et al. 2011). However, other reports found that, although it is required for c-Met-
mediated tumorigenesis, it has no effect on proliferation, invasion or branching 
morphogenesis (Zhang et al. 2002). Thus, the role of STAT3 in c-Met signaling is 
probably context- and tissue-dependent.  
Cellular migration is also mediated downstream of c-Met by focal adhesion kinase 
(FAK), which is localized to cellular adhesion complexes. FAK is activated through 
phosphorylation by SRC family kinases, which have been shown to associate directly 
with c-Met (Chen and Chen 2006).  
c-Met activity is also subjected to inhibitory regulation. Several protein phosphatases 
have been shown to dephosphorylate either the catalytic tyrosines (PTP1B, protein 
tyrosine phosphatase 1B) or the docking tyrosines (PIP density enhanced 
phosphatase, DEP1) (Gandino et al. 1994; Xu et al. 2012). 
Additionally, c-Met signaling can be modulated by cross-talk between Met and different 
membrane receptors, acting in complex interacting networks (Giordano and 
Columbano 2014). Thus, c-Met interacts with adhesive receptors, such as CD44 
(Orian-Rousseau et al. 2002) and the α6β4 integrin (Trusolino et al. 2001), with 
semaphorin receptors (Giordano et al. 2002), receptor tyrosine kinases (RTKs), such 
as members of the EGF receptor Family (EGFR and HER2) (Jo et al. 2000) and the 
VEGF receptor (VEGFR) (Sulpice et al. 2009; Lu et al. 2012), among others. 
4.4 HGF/c-Met signaling pathway in the liver 
In the liver, HGF/c-Met pathway comprises a complex and unique signaling network 
that plays a pivotal role in liver development, stimulating cell growth, motility, 
differentiation and morphogenesis of hepatocytes (Stoker et al. 1987; Hilberg et al. 
1993; Fausto et al. 1995; Nakamura et al. 2011). This signaling cascade is not only 
crucial in hepatic tissue remodeling during fetal development, but also during liver 
regeneration and the resolution of fibrotic processes. Moreover, it has been 
demonstrated that the constitutive or prolonged activation of c-Met is involved in tumor 
growth and cancer progression. 
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Regarding the essential role of the HGF/c-Met axis in liver development, animal studies 
have shown that HGF and c-Met provide essential signals for survival and proliferation 
of hepatocytes during embryogenesis, since HGF or c-Met knockout mice display 
profound alterations in the embryonic liver (Bladt et al. 1995; Schmidt et al. 1995; 
Uehara et al. 1995).  
While homozygous null mice for either HGF or c-Met die in utero at day 13 and 16, 
respectively, due to impaired organogenesis (Uehara et al. 1995) when HGF or c-Met 
are knocked down at later phases during the development, the livers of these mice are 
reduced in size as a result of decreased hepatocyte proliferation and increased 
susceptibility to apoptosis.  
It is known that in normal liver, the major cellular source of HGF is the HSCbut after 
liver injury, HGF expression has been thought to increase markedly in proliferating liver 
sinusoidal endothelial cells (LSECs) (Kinoshita et al. 1989; Maher 1993) and the 
degree of induction of HGF mRNA correlates well to the degree of liver damage; thus, 
these findings suggest that HGF is produced by the non-parenchymal liver cells after 
an injury and HGF, acting in a paracrine manner, stimulates the growth of hepatocytes 
to regenerate the liver. 
In the adult animals, loss of c-Met is not critical for hepatocyte function under 
physiological conditions, however, c-Met becomes critical in response to hepatic 
injuries. In fact, using MetLivKO mouse models, several studies demonstrated that c-
Met activation in hepatocytes promotes mitogenic and antiapoptotic responses for 
organ repair. Indeed, selective ablation of the c-Met gene in adult mouse hepatocytes 
dramatically affects the reparative responses of the liver to acute injury in vivo. 
Furthermore, c-Met-deleted hepatocytes contribute to the disruption of tissue 
remodeling and are responsible for the conversion of a normally acute injury into a 
chronic lesion. In the same line of evidence, transgenic overexpression of HGF in mice 
results in enhanced regeneration and increased liver size (Shiota et al. 1994).  Thus, 
these evidence demonstrate that HGF is key for a successful regenerative response 
after acute and chronic liver damage (Borowiak et al. 2004; Huh et al. 2004; Phaneuf et 
al. 2004).  
In addition, an essential anti-fibrogenic role for HGF/c-Met has also been demonstrated  
(Xia et al. 2006; Marquardt et al. 2012). Thus, HGF/c-Met signaling has a 
hepatoprotective effect attenuating liver fibrosis by inhibiting TGF-β pro-fibrotic 
responses and promoting ECM resolution  (Ueki et al. 1999; Inagaki et al. 2008; 
Kanemura et al. 2008; Giebeler et al. 2009). Furthermore, HGF induces apoptosis in 
myofibroblast, a cell type that as mentioned before plays a central role during the  
fibrotic process. The work done by Marquardt et al. showed that genetic loss of c-Met 
in hepatocytes induces a state of “organ stress” characterized by multi-factorial 
changes both in parenchymal and non-parenchymal cell compartments in the liver. 
These include reduced hepatocyte proliferation, excessive activation of HSC and 
increased expression of pro-fibrotic molecules, such as TGF-β, thereby aggravating 
liver fibrosis.  
In conclusion, the pro-regenerative role of HGF/c-Met signaling pathway is the 
consequence of its powerful anti-fibrotic and anti-apoptotic activities. Although more 
work is required to determine the exact contribution of HGF to each of these 
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processes, these studies strongly support current efforts directed to the modulation of 
the HGF/c-Met signaling pathway in CLD in therapeutic settings. 
Finally, the HGF/c-Met axis has been also implicated in hepatocarcinogenesis through 
multiple mechanisms, many of which are still being elucidated (Goyal et al. 2013). 
Although gene amplification is found only at a very low frequency, overexpression of 
HGF and c-Met is observed in 20-50% of human HCC  (Boix et al. 1994; Kiss et al. 
1997), although the prognostic utility of these markers is uncertain. Thus, c-Met 
overexpression was found to be associated with poorly differentiated HCC and a c-Met 
regulated gene expression signature was found to define a subset of human HCC with 
poor prognosis and aggressive phenotype (Daveau et al. 2003; Kaposi-Novak et al. 
2006). Further insights have led to propose that HGF/c-Met activation is important for 
the acquisition and maintenance of a mesenchymal phenotype and cancer stem cell 
features (You et al. 2011). Importantly, crosstalk between c-Met and other RTKs, 
EGFR and VEGF, is also implicated in promoting tumor survival (Venepalli and Goff 
2013). Nevertheless, although the tumor promoting effects are the most prominent, we 
must keep in mind that specific growth inhibitory and pro-apoptotic effects have been 
described for this signaling axis in some tumor cells, including HCC cells (Tulasne and 
Foveau 2008). 
4.5 HGF/c-Met signaling pathway in oval cells 
Regarding the role of HGF as a regulator of liver oval cells, it is known that HGF is 
expressed by HSC that are proliferating in close proximity to oval cells during liver 
regeneration and it was also reported that HGF accelerates oval cell proliferation after 
2-AAF/PH. In fact, in vivo activation of oval cell compartment in the AAF/PH liver injury 
model in rat is accompanied by an increased expression of HGF. Furthermore, HGF 
infusion during liver regeneration in this model increases oval cell proliferation (Shiota 
et al. 2000). Using a conditional c-Met knock-out mouse model specific for the liver, it 
was demonstrated that loss of c-Met completely abolishes the oval cell-mediated 
regenerative response. Interestingly, absence of c-Met targeted multiple cellular 
processes required for regeneration, including oval cell proliferation, survival, 
differentiation and migration (Ishikawa et al. 2012). 
In addition, HGF induces mitogenic and morphogenic responses in oval cells in vitro. 
We have shown that HGF/c-Met signaling promotes oval cells survival via autocrine 
and paracrine mechanisms involving PI3K activation. Thus, HGF/c-Met/PI3K signaling 
axis plays a central role in protecting oval cells against TGF-β-induced oxidative stress 
and apoptosis by acting as an antioxidant signal (Martinez-Palacian et al. 2013). 
Furthermore, our group has recently demonstrated that HGF promotes a 
morphogenetic response in oval cells in vitro that includes a migratory and invasive 
response through a mechanism involving PI3K activation and MMPs expression and 
activation (Suarez-Causado et al. 2015). 
 
 
 
 
 
 
 28 
 
5. BONE MORPHOGENETIC PROTEINS (BMPs) 
5.1 BMPs: generalities 
BMPs (Bone Morphogenetic Proteins) are multifunctional cytokines that belong to the 
TGF-β superfamily, being in fact the largest TGF-β subfamily comprising more than 15 
ligands in mammals (Herrera et al. 2014). 
BMP ligands have been classified into 4 different subgroups according to their 
sequence similarity and functions: (i) BMP2 and 4; (ii) BMP5, 6, 7, 8a and 8b; (iii) 
BMP9 and BMP10. All BMPs belonging to these three subgroups show osteogenic 
properties. The other proteins, BMP3, 3b, 11, 12, 13, -14, 15, and 16, that belong to the 
last group (iv), do not possess osteogenic properties and, in some cases, can even 
inhibit BMP function. Finally, BMP1 is actually a metalloprotease and it is not 
considered a member of the family (Lissenberg-Thunnissen et al. 2011). The 
nomenclature of BMPs is complex including BMPs, Growth and Differentiation Factors 
(GDFs), and other names depending on the method used to identify them. 
 
 
 
 
Members of the BMP family are synthesized as large dimeric pro-proteins containing a 
signal peptide for secretion. The pro-domain is cleaved at a consensus Arg-X-X-Arg 
site by serine endoproteases within the trans-Golgi network to produce the mature 
protein, which is subsequently secreted. It has been recently shown that the 
downstream sequence adjacent to the cleavage site determines the cleavage 
efficiency, while the N-terminal region controls the stability of the processed mature 
protein (Ducy and Karsenty 2000). Cleavage of the pro-protein does not occur in all 
BMP ligands: exceptions are BMP9 and GDF8 (Myostatin), in which the pro-region 
remains attached to the mature protein, even after secretion. Therefore it is known that 
BMP9 circulates in plasma either as an unprocessed inactive form unable to bind its 
receptor that can be further activated by furin, a serine endoprotease, or as a mature 
and fully active form (composed of the mature form associated with its pro-domain) 
(Sieber et al. 2009; Bidart et al. 2012). BMPs form homodimers or heterodimers to 
become active molecules. Strikingly, both in vitro and in vivo evidence demonstrate 
FIGURE 8. General structure of BMPs.  
Full-length BMP consists of a signal sequence, a pro-peptide, and the mature region. 
(modified from  Carreira et al., 2014) 
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that several BMP heterodimers present an increased potency as compared to BMP 
homodimers, as shown for BMP4/7, BMP2/6, BMP2/7, BMP15/GDF9 and BMP2b/7 
(Little and Mullins 2009; Carreira et al. 2014; Sanchez-Duffhues et al. 2015). 
BMPs were originally discovered for their capacity to induce bone and cartilage 
formation and fracture repair and regulate growth and differentiation of chondroblast 
and osteoblast cells in vitro (Urist 1965). Their role in early development is also well 
documented, including dorsal-ventral patterning, organogenesis and cell differentiation, 
being BMPs therefore considered as potent morphogens (Wagner et al. 2010). More 
recently, a role for BMPs in adult tissue homeostasis have started being revealed. 
Studies from transgenic and knockout mice and from animals and humans with 
naturally occurring mutations in BMPs and related genes have shown that BMP 
signaling plays critical roles in heart, neural and cartilage development. BMPs also play 
an important role in postnatal bone formation. 
To date it is known that BMPs regulate several cellular processes, including cell 
proliferation, differentiation, chemotaxis, apoptosis and migration in many different cell 
types. Recent evidence indicates that the liver is also an important target of BMPs.  
A well-studied aspect about the BMPs effect in liver physiology is undoubtedly their key 
role in the control of iron homeostasis, where BMP6 binds to its receptors and co-
receptor (hemojuvenin) in hepatocytes to regulate hepcidin expression through a Smad 
dependent mechanism (Finberg 2013). Additionally, an implication of BMPs in CLD has 
been suggested, although their physiopathological role and importance remain to be 
further explored. Thus, the role of BMP7 in CLD is somehow controversial. Some 
studies suggest that BMP7 has a pro-fibrogenic role in liver. Particularly, it has been 
shown that systemic and hepatic BMP7 is elevated in patients with CLD, which may 
contribute to progression of liver fibrogenesis in vivo since it is able to stimulate HSC 
proliferation and ECM production in vitro (Tacke et al. 2007). Contrarily, an anti-
fibrogenic effect of BMP7 in liver has also been suggested in agreement with its action 
in renal fibrosis; in fact, BMP7 through its TGF-beta antagonizing activity significantly 
inhibits progression of liver fibrosis in the CCl4-model (Zeisberg et al. 2003). Beneficial 
effects of BMP7 have been also proposed in the liver regenerative process, since 
BMP7 has been shown to enhance liver regeneration after PH (Sugimoto et al. 2007). 
On the other hand, another member of this family, BMP4 has been recently described 
as an inhibitor of this process (Do et al. 2012). Although more work is needed to clarify 
the exact contribution of BMPs to the fibrogenic and regenerative processes in the 
liver, evidence support the concept that this organ is indeed a target of BMP action, 
and therefore dysregulation of BMP signaling most likely has pathological 
consequences in the liver (Herrera et al. 2014). 
5.2 BMP9: structure, synthesis, expression and function 
In this very complex context, we are particularly interested in one of the members of 
this family, the bone morphogenetic protein-9 (BMP9), also known as Growth 
Differentiation Factor 2 (GDF2), the most recently discovered member of the BMPs 
family.  
BMP9 contains an N-terminal TGF-β-like pro-peptide (pro-domain) (residues 56–257) 
and a C-terminal TGF-β superfamily domain (325–428). It is synthesized as a 
precursor protein (Pre-pro-BMP9) composed of 429 amino acids that include a 22 
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amino acids signal peptide, a 297 amino acids pro-domain (33 kDa) and a 110 amino 
acids mature protein (12.5 kDa). After secretion, pro-BMP9 homodimerizes and is 
subsequently cleaved by serine endoproteases. This generates two active forms: the 
short mature form (25 kDa) and the complexed form (100 kDa) in which the pro-domain 
remains associated with the mature form in an open-armed conformation (pro-domain 
(2 X 35 kDa) + mature peptide (2 X 12.5 kDa) (Bidart et al. 2011) (FIGURE 9). 
 
 
 
 
 
It is well known that BMP9 is highly expressed in the liver and at much lower levels in 
the brain and lung (more than 100-fold less). Initial studies reported that BMP9 is 
specifically expressed in NPC (i.e., endothelial, Kupffer and HSC) in rat liver (Miller et 
al. 2000). In contrast, in recent studies performed in mouse and human liver, BMP9 
mRNA was not detected in liver endothelial cells, nor in HSC, but rather in hepatocytes 
and biliary epithelial cells (Bidart et al. 2012), and considering the relative proportion of 
these two populations authors suggest that hepatocytes are the major cellular source 
of circulating BMP9. The reasons for these discrepancies are not clear, but it is 
plausible to think that BMP9 expression differs across species.  
BMP9 has been shown to be involved in several biological functions, including the 
induction of the cholinergic phenotype of embryonic basal forebrain cholinergic 
neurons, the inhibition of the hepatic glucose production and the induction of the 
expression of key enzymes of lipid metabolism (Chen et al. 2003; Lopez-Coviella et al. 
FIGURE 9. Structure of BMP9 
BMP9 is synthesized as a precursor protein (Pre-pro-BMP9). After secretion, pro-BMP9 
homodimerizes and is subsequently cleaved by serine endoproteases. This generates two active 
forms: the short mature form (25 kDa) and the complexed form (100 kDa) in which the prodomain 
remains associated with the mature form. 
 (Modified from Bidart et al., 2011) 
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2005; Truksa et al. 2006). Moreover, BMP9 is one of the most potent BMPs able to 
induce orthotopic bone formation in vivo (Xiang et al. 2012). But by far, the most 
studied BMP9 role is that exerted in endothelial cells (Scharpfenecker et al. 2007; 
David et al. 2008). Nevertheless, its effects on angiogenesis remain controversial. It 
was shown that BMP9 inhibited neo-angiogenesis in vivo in the mouse sponge assay 
and inhibited blood circulation in the Chorioallantoic Membrane (CAM)-assay, a system 
used to study the effect of BMP9 on vascularization (David et al. 2008). In contrast with 
this, Suzuki et al. found that BMP9 enhances proliferation of three other kinds of 
endothelial cells: mouse embryonic-stem-cell-derived endothelial cells (MESECs); 
mouse normal endothelial cells and tumor associated endothelial cells (TECs), 
proposing BMP9 as pro-angiogenic factor (Suzuki et al. 2010). In spite of this, the most 
accepted hypothesis is that BMP9 is a pro-angiogenic factor, in fact, inhibiting the 
ALK1/BMP9 signaling pathway seems to be a useful alternative antiangiogenic therapy 
in the treatment of inflammation, cancer and vascular dysfunction (Cunha and Pietras 
2011). 
5.3 BMP9 signaling pathway in the liver 
BMP9 binds to heterotetrameric complex receptors located in the cell membrane and 
are composed of two different subtypes of transmembrane serine-threonine kinase 
receptors:  type I (also known as Activin like kinase receptor, ALK) and type II 
receptors. Among type I receptors, BMP9 can bind ALK1 (ACVRL1) and ALK2 
(ACVRIA); furthermore, BMP9 can also bind three type II receptors, namely BMP type 
II receptor (BMPRII), activin type II receptor A (ActRIIA) and activin type II receptor B 
(ActRIIB) (Herrera et al. 2012). 
Although the high affinity type I receptor for BMP9 is ALK1, receptor mainly expressed 
in endothelial cells, it has been demonstrated that BMP9 can also bind ALK2 in non-
ECs (endothelial cell), such as myoblasts and breast tumor cells (Scharpfenecker et al. 
2007). Interestingly, recent data support the hypothesis that BMP9 can bind to both 
type I and type II receptors with rather equally high affinity (Townson et al. 2012). 
The expression of the BMP9 receptors ALK1, ALK2, BMPRII, ActRIIA and ActRIIB is 
observed in liver tissue indicating that BMP9 may play biological roles in liver cells 
through these receptors (Herrera et al. 2014). 
Like other BMPs, BMP9 binding to its receptors triggers the phosphorylation of 
Smad1,5,8, which subsequently bind to the Co-Smad, Smad4. The resulting R-
Smads/Co-Smad complex translocates to the nucleus, where it recruits specific 
transcriptional coactivators or corepressor factors to regulate transcription of BMP-
responsive genes. This pathway is known as canonical pathway or Smad-dependent 
signaling and its activation by BMP9 has been documented in all cellular types 
analyzed up to date, including hepatocytes and HCC cells regardless of the receptors 
utilized by BMP9 (Herrera et al. 2013; Li et al. 2013). 
Recently, some authors have described that BMP9 can also trigger Smad2/3 
phosphorylation, which is classically associated with TGF-β signalling, in different 
endothelial cells (Sieber et al. 2009). No similar observations have been reported in 
liver cells (Herrera et al. 2014). 
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Additionally, in certain cellular models, BMP9 can also activate non-canonical 
pathways, referred to as non-Smad pathways that include MAPK (p38, ERK and JNK), 
PI3K/AKT, and Wnt, and regulates several microRNAs. The canonical and non-
canonical signaling pathways have been shown to be induced simultaneously and/or 
sequentially, which enables them to modulate different biological functions (Sieber et 
al. 2009; Herrera et al. 2012) (FIGURE 10). 
 
 
 
 
  
BMP9 signaling, like other BMPs, is modulated by the presence of co-receptors and 
extracellular regulators. Among the co-receptors, endoglin seems to be of special 
relevance. Endoglin is a transmembrane protein with large extracellular domains and 
serine/threonine-rich cytoplasmic regions. It cannot bind ligand on its own but does 
bind BMP9 in the presence of type I or type II signaling receptors (Scharpfenecker et 
al. 2007; Castonguay et al. 2011). It has been postulated that endoglin inhibits BMP9 
interaction with type II receptor, thereby blocking BMP9 signaling (Castonguay et al. 
2011). However, most of the data in the literature indicate that endoglin enhances 
BMP9 signaling, being therefore required for maximal phosphorylation of Smad1. Other 
regulator is crossveinless2 (CV2), a member of the chordin family, which binds to 
BMP9 and inhibits its activity (Yao et al. 2012). However, interestingly, noggin is unable 
to bind BMP9 and to inhibit BMP9 osteogenic activity in mesenchymal cells. 
FIGURE 10. Canonical and non-canonical BMP9 signaling pathways 
Upon ligand binding, receptor complexes activate the canonical Smad pathway and several non-
canonical signaling pathways, among these p38, ERK, JNK MAPKs, as well as PI3K, NF-kB, 
and Wnt pathways. 
 
(Modified from Herrera, Curr Pharm Des. 2012) 
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We have mentioned before that BMP9 is produced by the liver although the specific 
cellular source is not clear. 
The first work on the role of BMP9 in hepatocytes was published in 1995 (Song et al. 
1995). This study described that high concentration of BMP9 may slightly promote 
proliferation of both rat hepatocytes in primary culture and human tumor cells (HepG2 
cell line). Subsequently, our group has shown that BMP9 triggers phosphorylation of 
Smad1,5,8 and decreases cell viability of normal non-transformed adult mouse 
hepatocytes in primary culture whereas it did not have any effect in non-tumoral 
immortalized human hepatocytes. In addition, we have also demonstrated that BMP9 is 
a proliferative and survival factor for human HCC cells (Herrera et al. 2013; Garcia-
Alvaro et al. 2015). In regard to its role in HCC cells, our collaborators have 
demonstrated that the BMP9/Smad1 signaling pathway is involved in the induction of 
EMT, a key process in tumor invasiveness (Li et al. 2013). 
Data in the literature suggest also an involvement of BMP9 in the regulation of glucose 
homeostasis. In a screening for insulin like activity compounds, BMP9 was found to 
exert an anti-diabetic effect both in vitro and in vivo (Chen et al. 2003). In this work 
authors found that recombinant BMP-9 injection decreases glycemic levels in normal 
and diabetic mice, with slower kinetic than insulin. The ability of BMP-9 to lower 
glucose levels seems to be associated with its ability to promote insulin release in 
pancreatic β-cells, to regulate metabolic signaling through glycogen synthase kinase 
(GSK) in muscle, and to inhibit hepatic glucose production. Moreover, it has been 
demonstrated that BMP9 mRNA and protein content were regulated by oral glucose 
administration, probably as a consequence of the direct and combined actions of 
insulin and glucose in the liver (Caperuto et al. 2008). 
Interestingly, unpublished data from our group show that BMP9 not only interferes with 
the liver regenerative response but it is directly involved in liver fibrosis, therefore 
acting as a pro-fibrogenic factor (Katja Breitkopf-Heinlein et al., manuscript under 
revision). 
To date nothing is known about the possible role of BMP9 on other liver cell types, in 
particular HPCs and its contribution to the HPC-mediated regenerative process. This 
thesis aims to elucidate these aspects for the first time. 
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1. ROLE OF BMP9 IN HEPATOCARCINOGENESIS 
The study of BMP´s role in tumorigenic processes, and specifically in the liver, has 
gathered importance in the last few years.  
It is known that BMP9 regulates the cell growth of immortalised ovarian surface 
epithelial cells (IOSE) and epithelial ovarian cancer (EOC) cells (Herrera et al. 2009). In 
this paper, published by Dr. Herrera in 2009, they demonstrated that BMP9 functions 
as a proliferative factor for these two cellular types via an ALK2/Smad1/Smad4 
pathway. Furthermore, immunohistochemistry analysis of human ovarian cancer 
tissues indicated that 25% of EOC samples express BMP9 in vivo. These findings 
indicate that BMP9 acts as a positive regulator of IOSE and EOC cells proliferation and 
suggests that BMP9 represents a novel target for therapeutic intervention in EOC. 
However, the role played by BMP9 in hepatic cells was completely unknown. 
Three years ago, it was shown that BMP9 is overexpressed in about 40% of HCC 
patients (Li et al. 2013). In this line, our lab also demonstrated the role of BMP9 in the 
promotion of HCC cell growth, effect that was not observed in non-transformed 
hepatocytes (Herrera et al. 2013)  (Figure 11). 
 
 
 
 
 
 
It was also demonstrated that BMP9 impairs low serum-triggered apoptosis in the liver 
cancer cell line HepG2. Importantly, using different approaches we also showed that in 
addition to the paracrine signaling, HepG2 cells presented an autocrine BMP9 
production. Altogether, our findings provided new clues for a better understanding of 
BMP9 contribution in HCC pathogenesis.   
FIGURE 11. BMP9 increases cell number of HCC cell lines but not of immortalized human 
hepatocytes. 
Huh7, Hep3B and HepG2 liver cancer cells and immortalized human hepatocytes (THLE3) were 
incubated in the absence or in the presence of 5 ng/ml BMP9 in 0.1% FBS media and counted at day 
4. Data from 3 independent experiments performed in triplicate (mean ± S.E.M.) are shown.  Statistical 
analysis was carried out using the paired t-test and data were compared to untreated samples, 
* = P<0.05, ** = P<0. 01, *** = P<0.001 (Herrera et al. 2013). 
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In an attempt to search for the signaling mechanisms driving BMP9 effects, we have 
recently found that BMP9 induces canonical and non-canonical signaling pathways in 
HepG2, specifically PI3K/AKT and p38MAPK, but only the p38MAPK pathway 
contributes to the growth-promoting activity of BMP9 (Garcia-Alvaro et al. 
2015) (Figure 12). 
 
 
 
 
Furthermore, using genetic and pharmacological approaches, we have demonstrated 
that p38MAPK activation, although dispensable for the BMP9 proliferative activity, is 
required for the BMP9 pro-survival effect in HepG2 cells (Figure 13): 
 
 
 
 
 
FIGURE 12. BMP9 activates both canonical and non-canonical pathways in HepG2 cells.  
HepG2 cells were incubated for one hour with different concentrations of BMP9 (1–10 ng/mL) 
in 0% FBS media or for different periods of time −/+ BMP9 (5 ng/mL) in 0% FBS media. 
Western blots were performed with antibodies that recognize phospho-Smad1,5,8, phospho-
AKT, phospho-p38 and β-actin (loading control). A representative experiment of two is shown 
(Garcia-Alvaro et al. 2015). 
FIGURE 13. p38MAPK is involved in the BMP9 survival effect on serum starvation-triggered 
apoptosis in HepG2 cells. 
HepG2 cells were treated with SB203580 (10 µM) (one hour pre-incubation) and −/+ BMP9 (5 
ng/mL) in 0% FBS media for 72 h. A. Nuclear DNA content was analyzed by flow cytometry, and 
the percentages of hypodiploid (apoptotic) cells were obtained. Data are from three independent 
experiments performed in triplicate (mean ± S.E.M.), displayed as the percentage of untreated 
cells. B. Apoptotic nuclei were visualized and counted after PI staining under a fluorescence 
microscope. A minimum of 1000 nuclei were counted per condition. Data from two independent 
experiments performed in triplicate (mean ± S.E.M.) displayed as the percentage of untreated 
cells. Statistical analysis was carried out using the paired t-test, and data were compared to 0% 
FBS samples, * p < 0.05, ** p < 0.01, *** p < 0.001 or as indicated, 
&&&
 p < 0.001 (Garcia-Alvaro et 
al. 2015). 
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2. REGULATORY EFFECTS OF RTKs (HGF AND EGF) AND TGF-β ON 
OVAL CELLS 
One of the main objectives of the research conducted in Dr. Sánchez laboratory in the 
last ten years has been to study the regulation of the multifaceted behavior of oval 
cells, focusing on characterizing some of the signals and mechanisms regulating their 
biology and function. Particularly, major efforts have been put forth in characterizing the 
relevance of the HGF/c-Met pathway and its interaction with other signaling pathways, 
specifically the EGF/EGFR and TGF-β pathways. 
Using c-Metflx/flx mice generated in Dr. S.S.Thorgeirsson´s lab (Huh et al. 2004) oval 
cell lines expressing a functional or non-functional c-Met receptor that lacks tyrosine 
kinase activity, the Metflx/flx and Met-/- oval cells respectively, were established. It was 
shown that oval cells harbouring a genetically inactivated Met tyrosine kinase 
(Met−/−oval cells) are more sensitive to both serum-starvation and TGF-β-induced 
apoptosis than cells expressing a functional Met (Metflx/flx), demonstrating that the 
HGF/c-Met axis plays a pivotal role in oval cell survival (del Castillo et al. 2008) 
(FIGURE 14 A). Importantly, Met antiapoptotic activity involves both paracrine and 
autocrine signaling, since autocrine production of HGF and activation of Met kinase is 
detected in oval cells (FIGURE 14 B and C). 
 
 
 
 
 
 
 
FIGURE 14. HGF reduces the TGF-β-induced apoptosis in Met
flx/flx
 but not in 
Met
−/−
 oval cells with both paracrine and autocrine signaling  
A. Apoptotic index in oval cells treated with TGF-β (T; 1 ng/ml) for 48 hours in the 
absence or presence of HGF (H; 20 ng/ml). A total of 1000 to 2000 cells were counted 
per dish after PI staining under a fluorescence microscope in a blinded manner. Black 
bars, Met
flx/flx
 cells. White bars, Met
−/−
 cells. Data are mean ± S.E.M. of three 
experiments. ***P < 0.001 (versus T, Met
flx/flx
) ++P < 0.01 (versus T, Met
flx/flx
). B. Basal 
expression of the hgf mRNA as detected by RT-PCR analysis in Met
flx/flx 
and Met
 -/-
 oval 
cells. Bl, Blank, no reverse transcription. β-actin was used for normalization. C. Kinetics 
of Met activation in Met
flx/flx 
cells cultured in the serum-free medium or conditioned 
serum-free medium (CM). Whole protein extracts were used for immunoprecipitation of 
Met protein. Phosphorylation was detected by immunoblotting with anti-P-tyrosine 
antibody using Met as a loading control (del Castillo et al. 2008). 
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Then, the apoptotic response elicited by TGF-β in oval cell and the mechanisms 
mediating the c-Met-dependent anti-apoptotic activity were characterized. Our results 
demonstrated that TGF-β induces a mitochondrial apoptotic cell death in oval cells, 
with up-regulation of BIM and BMF proteins, two BH3-only members of the Bcl-2 
family, but only BMF is essential for TGF-β-induced apoptosis. Furthermore, we 
revealed a signaling pathway in which TGF-β induces oxidative stress associated with 
an up-regulation of Nox4 and down-regulation of the intracellular antioxidant defenses, 
which leads to Bmf up-regulation and subsequent cell apoptosis. In addition, the 
pharmacological inhibition of PI3K did increase sensitivity of Metflx/flx oval cells to TGF-β 
by enhancing oxidative stress, mimicking Met-/- oval cells and impaired HGF-driven 
protection against TGF-β-induced apoptosis. These results revealed that HGF/c-Met 
signaling requires PI3K to promote oval cell survival against TGF-β-induced oxidative 
stress and apoptosis (Martinez-Palacian et al. 2013). 
  
 
 
 
 
 
 
 
FIGURE 15. PI3K activation is involved in the migratory and invasive effect of HGF in oval cells 
A. Scatter assays. Metf
lx/flx 
oval cells were cultured at low density on plastic dishes with or without HGF 
treatment (40 ng/ml). Representative phase contrast images of a randomly selected area of the dish 
are shown. Scale bar=100 μm. B. Quantitative analysis of wound closure after 48 h. Data are 
expressed as % of closure and are the mean ± S.E.M. of four independent experiments. **P < 0.01 
HGF-treated vs untreated Met
flx/flx
. C. Effect of MMP inhibition on oval cell invasion. Invasion assays in 
the absence or presence of HGF (40 ng/ml) and/or marimastat (10 μM) were conducted. Data 
represent number of invaded cells expressed as fold change with respect to untreated cells and are 
mean ± S.E.M. of 2 independent experiments run in duplicate-triplicate. ***P < 0.001. D. Effect of p85 
silencing on HGF-induced oval cell invasion. 24 h after transfection with non-targeting siRNAs (NT) or 
p85 specific siRNAs (si p85) cells were trypsinized and seeded on transwell chambers coated with 
matrigel and cultured for 24 h with or without HGF (40 ng/ml). Data are expressed as fold change with 
respect to control and are mean ± S.E.M. of 5 independent experiments run in duplicate–triplicate. *P < 
0.05; **P < 0.01. E. Effect of p85 silencing on HGF-induced MMPs expression. 24 h after transfection 
with non-targeting siRNAs (NT) or p85 specific siRNAs (si p85) cells were serum-starved and treated 
or not with HGF (40 ng/ml) for 24 h. Total RNA was isolated and used for qRT-PCR analysis. Data 
represent RQ values and are mean ± S.E.M. of 2 experiments. P < 0.05; **P < 0.01; ***P < 0.001 
(Suarez-Causado et al. 2015). 
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However, ongoing studies in our lab evidence that oval cells are not only targets of the 
suppressor effects of TGF-β, but also suffer EMT in response to either acute or chronic 
treatment with this factor that leads to profound changes in oval cell properties. More 
importantly, we have data in support of a functional crosstalk between TGF-β and c-
Met after EMT since Met kinase activity appears to be critical to allow cell expansion 
post-EMT (unpublished results). Further research is being conducted in the lab to 
better characterize these processes. 
On the other hand, we have also contributed to show that HGF/c-Met signaling in oval 
cells does much more than just protecting against TGF-β apoptotic effects. Indeed, we 
have demonstrated that HGF promotes a migratory and invasive response in oval cells 
that ultimately leads to cell rearrangement rather than to cell scatter and emulates the 
morphogenic response occurring in vivo during oval cell-mediated regeneration. 
Additionally, we have explored the signaling mechanisms mediating HGF invasive 
response and have proved an essential role for PI3K activation and MMPs expression 
and activation to achieve such response (FIGURE 15) (Suarez-Causado et al. 2015). 
The signaling mechanisms mediating MMPs regulation by HGF remain elusive. 
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OBJECTIVES 
Given that BMP9 has shown to be an important regulator of hepatocytes and also of 
other liver cells and the interesting emergent role of BMP9 as a regulator of liver 
regeneration and fibrogenesis, the general objective of this work was to characterize 
the role played by BMP9 in oval cell biology and to elucidate its contribution to the liver 
regenerative response involving these cells. 
To achieve this general aim, we proposed the following specific objectives: 
SPECIFIC OBJECTIVES: 
1. To analyze the effect of BMP9 deletion in the expansion of oval cells in vivo after 
induction of liver damage and the overall effect on the outcome of the regenerative 
response. 
2. To characterize the signaling pathways and biological activities triggered by BMP9 
in oval cells and the potential crosstalk with the HGF/c-Met pathway using an in vitro 
model of oval cell lines. 
2.1 To analyze the effect of BMP9 on oval cell proliferation, survival and 
migration/invasion. 
2.2 To investigate the potential functional crosstalk between BMP-9 and HGF/c-
Met signaling pathways and to try to identify the mechanisms involved in this 
interaction. 
2.3  To analyze the effect of chronic exposure to BMP9 in oval cells phenotype 
and properties.  
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1. CELL CULTURE 
1.1 Cell models 
Metflx/flx and Met-/- oval cell lines were generated from a conditional knockout mouse for 
c-Met by using Cre-loxP-mediated gene targeting (Huh et al. 2004). Inactivation of the 
mouse c-Met gene was accomplished by a conditional deletion of exon 16 containing a 
critical ATP-binding site in the intracellular TK domain, essential for the activation of c-
Met signaling. The removal of this region leads to the expression of a c-Met receptor 
lacking its tyrosine kinase activity. 
To induce oval cell expansion, nine-week-old male Metflx/flx mice were maintained on 
0.1% DDC-supplemented diet for 13 days (Preisegger et al. 1999) and then the oval 
cell-enriched non-parenchymal cell fraction was isolated (del Castillo et al. 2008). In 
order to generate Met-/- oval cells, in vitro inactivation of c-Met, was achieved by 
infecting the parental oval cell lines with adenovirus expressing the Cre recombinase 
under the control of the cytomegalovirus promoter (Ad-CMV-Cre). Once isolated, these 
cells were phenotypically and functionally characterized and validated (del Castillo et 
al. 2008).  
HepG2, a human HCC epithelial cell line, was obtained from the European Collection 
of Cell Cultures (ECACC).  
1.2 Cell culture conditions and cryopreservation 
All cell lines were grown in DMEM (Dulbecco's Modified Eagle Medium) (4.5 g/l 
glucose) medium (BioWhittaker, BE12-604F) supplemented with 10% fetal bovine 
serum (FBS) (Life Techologies, 10270106), 20 mM Hepes (pH 7.4) (Sigma, H3375) 
and antibiotics: penicillin (120μg/ml) (Sigma, P3032), streptomycin (100μg/ml) (Sigma, 
S9137) and amphotericin B (2,5μg/ml) (Gibco, 15290-026). 
Cells were maintained in a humidified incubator at 37ºC and 5% CO2 atmosphere. 
Medium was replaced every three days and cells passaged at 90% confluency. In the 
case of oval cell lines, only early passage cells (passages 1 to 10) were used for the 
experiments. For HepG2, cells were not maintained more than 20 passages. 
Cells were stored in 10% (v/v) DMSO (Dimethyl sulfoxide)/FBS in liquid nitrogen 
(storage below -170ºC), using cryotubes (Nunc). They were frozen down slowly using 
the Mr. Frosty freezing container (Thermo Scientific); first, vials containing cells in cold 
freezing medium were transferred to the freezing container filled with isopropanol, then 
moved to a -80°C freezer for one day and finally transferred to the liquid nitrogen tank.  
Thawing was performed quickly by immersion of cryotubes in a water bath at 37ºC and 
cells were rapidly diluted into culture medium in tissue culture dishes. When cells were 
attached, medium was replaced by fresh medium to completely remove the DMSO. 
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The growth factors used in this work are listed in the table below (TABLE 3):  
Subconfluent (90%) cells were serum starved for 3-15 hours before treatment. Cells 
were treated with the following growth factors: 
 HGF: 40 ng/ml. When combined with BMP9, HGF was added 15 hours before 
BMP9 treatment.  
 BMP9: different concentrations of BMP9 have been used (1 ng/ml BMP9 for 
B9T-OC maintaining and 2 ng/ml BMP9 for experiments, except for cell death 
assays in which 5 ng/ml BMP9 was used). 
 TGFβ1: 2 ng/ml. 
For long-term treatment, growth factors were re-added every 48 hours. 
2. BMP-9 KO MICE 
2.1 Generation and genotyping of BMP9-KO mice  
The BMP9 knockout mouse model (BMP9-KO) was supplied by Dr. Se-Jin Lee (Johns 
Hopkins University School of Medicine, Baltimore, MD). BMP9-KO mice were obtained 
by homologous recombination in R1 embryonic stem cells such that exon 2 encoding 
the entire mature C-terminal region was replaced by a neomycin resistance cassette. 
Heterozygous offspring of chimeras were mated out 9 generations to C57BL6/J. BMP9-
KO adult mice are viable and fertile, and pups are grossly normal, although 
arteriovenous malformations and skeletal abnormalities have been described (Ricard et 
al. 2012). 
Mice were genotyped by polymerase chain reaction (PCR) of genomic tail DNA using 
specific primers that specifically detect the presence or absence of wild type (228 bp) 
or knockout (440 bp) alleles (FIGURE 16). 
 
 
FIGURE 16. Genotyping of BMP9-KO mice 
The presence or absence of wild type (228 bp) or knockout (440 bp) alleles was detected by PCR. 
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Primer sequences used for the amplification were (TABLE 4): 
 
The use of animals complied with the institutional and European legislation concerning 
vivisection, the use of genetically modified organisms, animal care and welfare 
(European Directive 2010/63/UE adopted by the European Parliament and the Council 
of the EU on September 22, 2010). Animals were housed in a temperature-controlled 
environment, with 12 hours light/dark cycles and with access to standard chow and 
water ad libitum. The experimental protocols were approved by the Institutional and 
regional Committee for animal care and use (For CCl4 protocol the reference is PROEX 
120/14 and for DDC treatment is PROEX 129/16). 
2.2 DDC feeding-induced liver injury mouse model 
8-12 weeks mice from each genotype (BMP9-KO and WT) were randomly divided into 
experimental groups (5-10 animals per group) and fed with either a normal diet (control 
group) or the diet supplemented with 0.1% DDC (Cymit Quimica). The diet was 
produced by Indigo Laboratories and properly preserved in our laboratory. A scheme of 
the experimental protocol is shown (FIGURE 17):  
 
 
Blood and livers samples were collected (see subsection 4.4 of “Material and 
methods”) after 1, 2, 4 and 6 weeks of DDC or control diet feeding for further analysis. 
 
 
FIGURE 17. General scheme of the DDC protocol 
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2.3 CCl4-induced liver fibrosis mouse model 
8-12 weeks BMP9-KO and WT male mice were randomly assigned to two experimental 
groups (5-10 animals per group): a control group, injected only with the vehicle (mineral 
oil, Sigma) and a CCl4 group, injected with the CCl4 diluted in mineral oil. CCl4-treated 
mice received 0.48 gr/kg body weight of CCl4 by intraperitoneal injection twice per 
week for 8 weeks. Control animals were injected with the same volume of mineral oil. 
Mice were sacrificed 72 hours after last injection to eliminate acute effects of CCl4. 
2.4 Sample collection process 
The thoracic cavity of an anesthetized mouse was opened to expose the heart. Blood 
was obtained by cardiac puncture using a 1 ml hypodermic syringe and needle and 
placed in ice-cold heparinized tubes. Blood samples were allowed to clot at room 
temperature and centrifuged at 1800 rpm for 10 min at room temperature for serum 
separation. Serum was immediately frozen at -80°C for further analysis. 
The liver was removed and weighted. Part of the liver lobes were thinly sectioned and 
fixed in 10% formalin solution (Sigma) overnight. The remaining portions of the liver 
were collected in RNase-free tubes and immediately snap-frozen in liquid nitrogen for 
RNA and protein extraction. 
2.5 The liver to body weight ratio 
The liver to body weight ratio was estimated based on the following formula: %=100 × 
Ml/Mb, where Ml is the liver weight and Mb is the total animal weight, at the time of 
sacrifice. 
2.6 Histological Analyses 
10% buffered formalin fixed liver tissues were embedded in paraffin and stained with 
hematoxylin and eosin (H&E). The preparation of these tissue samples in paraffin was 
performed by Patricia Saperas (Hospital Clínico San Carlos (HCSC) of Madrid. 
Liver sections were evaluated and scored according to the Knodell Histological Index 
(Knodell HAI) by Dr. Julian Sanz Ortega, Head of molecular pathology and anatomical 
pathology department of HCSC. The Knodell Histological Index (Knodell HAI), the first 
of this kind and the most widely used system, was used to provide a numerical score to 
both staging and grading of liver injury, thus providing a semi-quantitative assessment 
of the observed histological features in this animal model. Briefly, this was based on 
the assessment of portal/periportal activity with or without bridging necrosis, 
intralobular necrosis, portal inflammation and fibrosis. The table below shows the 
Knodell Histology Activity Index (HAI) (Knodell et al. 1981) (TABLE 5). 
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NOTE: HAI score is the combined scores for necrosis, inflammation, and fibrosis. 
*
Degeneration: acidophil bodies, ballooning; focal necrosis-scattered foci of hepatocellular necrosis. 
$
Loss of normal hepatic lobular architecture with fibrous septae separating and surrounding nodules. 
+
Bridging is defined as >=  2 bridges in the liver biopsy specimen. 
(Modified by Knodell RG et al., 1981) 
2.7 Quantitative morphometric analysis of oval cells expansion 
Image J was used to quantify  oval cell expansion from H&E stained tissue sections. 
Areas of oval cell expansion from 12 periportal non-overlapping fields of each animal 
(at least five animals per group) were outlined and measured at original magnification 
100X. Data are expressed as the average percentage of expansion area respect to the 
untreated group. 
2.8 Analysis of serum parameters  
Total bilirubin, L-aspartate aminotransferase (L-AST) and L-alanine aminotransferase 
(L-ALT) activities were measured in a Clinical Analysis Laboratory (UCM) using gold-
standard methods and a Cobas Integra 400 Plus Chemistry Analyzer (Roche). 
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3. DNA ANALYSIS BY PCR 
3.1 DNA isolation 
Genomic DNA was extracted from tail using a specific lysis buffer: 100 mM Tris-HCl 
(pH 8.5), 200 mM NaCl, 5 mM EDTA, 0.2% SDS and 100 μg/ml Proteinase K. Briefly, 
we cut about 1-1.5 cm tail and place it in an eppendorf tube with lysis buffer. Tubes are 
introduced in a hybridization tube and incubated overnight in an oven at 55°C with 
agitation. DNA was precipitated by isopropanol. Finally, samples were resuspended in 
TE buffer pH=8 (10 mM Tris-HCl and 1 mM EDTA). DNA was stored at -20°C until it 
was processed. DNA concentration was determined spectrophotometrically at 260 nm. 
An absorbance of 1 unit at 260 nm corresponds to 50 μg of DNA per ml. 
Genotyping was assessed by PCR using specific primers (see Generation and 
genotyping of BMP9-KO mice). An amount of DNA of approximately 1 µg was used. 
3.2 PCR conditions 
PCR analysis was used to evaluate the mice’s genotype. PCR reactions were carried 
out using 0.4 μM specific primers (TABLE 4), dNTPs at 200 μM each, 2 mM MgCl2 
and 1 unit of Taq Polymerase (BIOLINE, BIO-21040). PCR conditions were: 94°C, 2 
min; 94°C, 30 sec and 68°C, 3 min for 35 cycles; 68°C, 3 min and 4°C, hold. 
The obtained PCR products were analyzed in 1% agarose gels containing Gel Red 
Nucleic Acid Stain (Biotium, 41003). 
4. mRNA EXPRESION ANALYSIS BY RT-PCR 
4.1 Total RNA extraction 
Cells were washed twice with cold PBS and total RNA was isolated using RNeasy Mini 
Kit (Quiagen) following manufacturer instructions. DNase (Quiagen, 79254) treatment 
was included to avoid possible genomic DNA contamination. RNA was eluted with 
ultrapure water and stored at -80ºC until use. RNA concentration was determined by 
spectrophotometry absorbance measurement at 260 nm (1 unit of absorbance at 260 
nm corresponds to 40 μg of RNA per ml). To estimate RNA purity, the ratio between 
the absorbance at 260 and 280 nm was calculated. A ratio A260/A280 of 1.8-2 was 
accepted as pure RNA.  
4.2 cDNA synthesis 
Total RNA (1 μg) was reverse-transcribed to generate the cDNA using the Super Script 
III RT kit (Invitrogen, 18080-040) following instructions from the manufacturer. 
Essentially, RNA was incubated with oligo (dT) (0.5 mM) and random primers (2.5 μM) 
at 65 ºC for 5 min to ensure RNA denaturation and then, placed on ice for at least one 
min. cDNA synthesis mix (5X RT buffer, 20 Units of RNase inhibitor, 5 mM dithiothreitol 
(DTT) and 200 Units of SuperScript III) was added to each sample followed by 
incubation at 50ºC for 1 hour. 
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The reaction was stopped by heating at 70 ºC for 15 min to inactivate the enzyme and 
the cDNA was stored at -20 ºC. 
4.3 Quantitative PCR (qPCR) 
Real time PCR or quantitative PCR (qPCR) was performed using specific primers 
(TABLE 6.) and Fast Start Universal SYBR Green Master (Rox) (Roche, 
04913850001) to detect DNA in the 7900 Fast Real Time System (Life Technologies). 
PCR reactions were done in triplicate. Gusb was used as a housekeeping gene; 
different negative controls were prepared using RNA or water instead of cDNA. 
During the exponential phase of real-time PCR, a fluorescence signal threshold was 
determined, so that it was significantly greater than background fluorescence. The 
fractional number of PCR cycles required to reach this threshold is defined as the cycle 
threshold, or Ct. Based on this, quantification of RNA levels was performed through 
calculation of RQ (2-ΔΔCt). First, ΔCt value for each sample and gene is obtained as 
follows: Ct for a gene minus -Ct for GusB=ΔCt under a particular experimental 
condition and then, this is referred to control ΔCt values (sample ΔCt-control ΔCt= 
ΔΔCt) to calculate the RQ value.  
 
5. 
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PROTEIN EXPRESSION ANALYSIS BY WESTERN BLOT 
5.1 Cell extract preparation 
Cells were washed twice with cold PBS and lysed with the IP buffer (TABLE 7). 
 
Cells were detached from the plate by scraping, collected in an eppendorf tube and 
maintained on ice for 20 min. Every 5 min, tubes were vigorously shaken using a 
vortex. Then, cell lysates were centrifuged at 13000 rpm for 10 min at 4°C. The 
supernatant (total protein extracts) was transferred to a new tube and stored at -80°C. 
5.2 Tissues extracts preparation 
25-30 mg of frozen mouse liver tissue were disrupted in a RIPA buffer (TABLE 8), with 
a mortar and pestle. 
 
Every 5 min, tubes were vigorously shaken using a vortex; the digestion take 30 
minutes. Then, tissue lysates were centrifuged at 13000 rpm for 10 min at 4°C. The 
supernatant (total protein extracts) was transferred to a new tube and stored at -80°C. 
 (*) Protease inhibitors are added immediately before use. 
 (*) Protease inhibitors are added immediately before use. 
 57 
 
5.3 Protein quantification 
Protein quantification was performed using the method described by Bradford in 1976. 
After addition of Bradford reagent (diluted 1:5 in ultrapure water) (Bio-Rad) to the 
samples, absorbance at 595 nm was measured using a plate reader (Powerwave XS, 
Biotek). Bovine serum albumin (BSA) (0 to 5 μg/μl) was used as a protein standard to 
generate a standard curve. 60-100 µg of proteins were loaded in each gel. 
5.4 Protein electrophoresis 
Protein electrophoresis was performed using SDS-polyacrylamide (SDS-PAGE) gels 
with different acrylamide concentration (6-15%) depending on the size of the protein to 
be analyzed (TABLE 9.).  
 
 
Protein samples were prepared by adding Laemmli buffer 2X (Tris-HCl 125 mM pH 6.8, 
20% (w/v) glycerol, 4% (w/v) SDS, 0.004% (w/v) bromophenol blue and 10% β-
mercaptoethanol) to the protein extracts. Then, they were heated at 95ºC and loaded 
into the gel, as well as the molecular weight markers (SeeBlue Plus2, Invitrogen).  
Electrophoresis was developed at constant voltage (80-120 V) using the following 
running buffer: 25 mM Tris-HCl (pH 8.3), 200 mM Glycine and 0.1% SDS. 
5.5 Protein transfer 
Proteins from the gels were transferred to a nitrocellulose membrane using a wet 
transfer apparatus. Then, an electric current of 0.3 A for 90-110 minutes (depending on 
the number/size of gels) was applied in a transfer buffer (20% methanol, 25 mM Tris, 
190 mM glycine). To confirm the efficiency of protein transfer, membrane was stained 
with a Ponceau S solution (0.5% in 1% acetic acid glacial). 
 
 
 
 
APS: Ammonium Persulfate; TEMED: Tetramethylethylenediamine. 
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5.6 Immunodetection 
After transfer, membranes were washed with distilled water, and then with TTBS (20 
mM Tris-HCl, 150 mM NaCl, pH 7.5 (TBS) with 0.05% Tween-20). 
Then, they were incubated in the blocking solution (either 5% non-fat dry milk or 5% 
BSA in TTBS) for 1 hour at room temperature (RT). After blocking, membranes were 
rinsed with TTBS and incubated with the primary antibody overnight at 4ºC in 5% milk-
TTBS or BSA-TTBS  at the dilution indicated in TABLE 10. Then, membranes were 
washed 3 times with TTBS (5 min/each) and incubated with the secondary antibody at 
a dilution of 1:5000 in 5% milk TTBS for 1 hour at RT. Finally, they were washed 3 
times with TTBS and incubated with a chemiluminescent solution (ECL from 
Amersham Biosciences) to visualize proteins in an X-ray film. 
The following antibodies were used (TABLE 10):  
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6. TRANSCRIPTIONAL REPORTER ASSAY 
Cells (12500 cells/sq cm) were seeded in 6-well plates. The next day, cells were 
transiently transfected using the plasmid pGL3 BRE Luciferase (pGL3(BRE)-luc; 
Promega). After 36 hours, cells were serum starved overnight and treated with BMP9 
(2 ng/ml). Luciferase activity was determined after 6 hours of stimulation. Specifically, 
luciferase activity was quantified using the luciferase assay (Promega) with a Victor 
luminometer (Wallac), as previously described by Dr. Peter ten Dijke’s group 
(Korchynskyi and ten Dijke 2002). In all transfections, protein quantification served as 
internal control to normalize the luciferase activity. 
7. GENE SILENCING BY shRNA AND siRNA 
Stable ALK1 and ALK2 knockdown in oval cells was achieved by infection with mouse 
ALK1 and ALK2 shRNA Lentiviral Particles. Briefly, cells were seeded in a 6-well plate 
one day prior to the viral infection at a density that guaranteed 50-60% confluence the 
next day. Cells were incubated with the virus for 24 hours, and then cells  were 
maintained with puromycin (2 µg/ml) to select clones expressing the shRNA. Clones 
were picked, expanded and analyzed for ALK1 and ALK2 expression. Cells transfected 
with the empty vector (plKO) were also generated and used as a control.  
For ALK1 knockdown three different target-specific constructs were used (Sigma, #1 
TRCN0000022540-553, #2 TRCN0000231253-8405 and #3 TRCN0000231254-8403), 
inserted in the pLKO.1-puro plasmid. For ALK2 knockdown, only one construct was 
used (Sigma, TRCN0000000441). All of them were kindly supplied by Dr. Peter ten 
Dijke’s group. 
Transient Smad1 knockdown was performed by transfection with a siRNA targeting 
mouse Smad1 (Dharmacon, L-055765-00). siControl non targeting (NT) siRNA pool 
(Dharmacon, D-001210-03-05) was used as negative control. For siRNA transfection 
we used TransITsiQuest reagent (Mirus) according to the manufacturer´s 
recommendation and a final siRNA concentration of 100 nM. After transfection, cells 
were incubated for 24 hours in complete medium to allow efficient target down-
regulation prior to protein harvesting or cell replating for further experiments (48 hours 
post transfection). 
8. [125I] BMP-9 binding assay 
[125I] BMP-9 binding assay was performed in the laboratory of Dr. Peter ten Dijke. 
Iodination of BMP-9 was performed according to the chloramine T method and cells 
were subsequently affinity-labeled with the radioactive ligand as described by Dr. Peter 
ten Dijke’s group (van Meeteren et al. 2012). In brief, cells were incubated on ice for 2 
hours with the radioactive ligand. After incubation, cells were washed and crosslinking 
was performed using 54 mM disuccinimidyl suberate (DSS) and 3 mM 
bis(sulfosuccinimidyl)suberate (BS3, Pierce) for 15 min. Cells were washed, scraped 
and lysed. Lysates were incubated with the respective antisera for 2.5 hours and 
immune complexes were precipitated by adding protein A Sepharose (Amersham). 
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Samples were washed, boiled in sample buffer and subjected to SDS-PAGE. Gels 
were dried and scanned with the STORM imaging system (Amersham).  
9. ANALYSIS OF PROLIFERATION, CELL VIABILITY AND APOPTOSIS 
9.1 Thymidine Incorporation Assay 
Cells were plated at a density of 17,500 cells/sq cm in DMEM with 10% FBS. The 
following day, cells were serum starved and incubated for 48 hours with or without 
BMP9 (2 ng/ml). After 6-8 hours of treatment, we added to the plates a mixture of 
radioactive thymidine (0.5 μCi/ml [3H]-thymidine, GE Healthcare) and cold thymidine (1 
µM, Sigma). After 24 hours of incubation with this mixture, we removed the radioactive 
medium and washed the plates with cold PBS. Then, we covered cells with TCA 
(trichloroacetic acid) 10% solution (w/v) for 20 minutes at 4°C, to precipitate protein and 
nucleic acids and we washed the plates twice with ethanol 70% (v/v), allowing them to 
dry completely. Finally, the precipitate was collected using a solution 0.1 N NaOH, 2% 
Na2CO3 and 0.5% SDS. An aliquot was transferred to scintillation vials containing 
scintillation liquid (Perkin Elmer) and radioactive nucleotide incorporation was read in a 
liquid scintillation counter (LKB Wallac, model 1209 Rackbeta). The results are 
expressed as counts per minute (cpm) in each experimental condition. 
9.2 Analysis of cell number 
Oval cells (15000 cells/sq cm) were seeded in 12 multiwell plates in triplicate. The 
following day cells were serum deprived and treated with the stimulus. Cells were 
counted daily for 4 days. For that, medium was removed, cells were washed twice with 
PBS, detached using trypsin and finally counted after staining with Trypan Blue using a 
Neubauer chamber. 
9.3 Analysis of apoptosis by propidium iodide staining 
Oval cells (about 30000 cells/sq cm) were seeded in 35 mm plates in triplicate. After 
treatment, they were washed twice with cold PBS and fixed using a mixture of 
methanol and acetic acid (3:1) for 30 minutes at room temperature. Then, they were 
washed twice with PBS and stained for 20 minutes at 37°C with a solution of propidium 
iodide (PI) (Sigma) containing PI 5 μg/ml, 0,1% Triton X-100, EDTA 0,1 M and 25 U/ml 
RNAsa (Sigma). Finally, dishes were washed with PBS and coverslipped using Mowiol 
mounting medium. Cells undergoing apoptosis were scored under inverted 
fluorescence microscope (Eclipse TE300, Nikon) at high magnification (x60) following 
standard morphological criteria. Apoptotic indices were calculated after counting a 
minimum of 1,000 cells per treatment in a blinded manner  
9.4 Analysis of caspase -3 activity 
Cell were scrapped in PBS, collected by centrifugation at 5,000 rpm for 5 minutes at 
4ºC and lysed in 5 mM Tris-HCl (pH 8), 20 mM EDTA, 0.5% Triton X-100 for 30 
minutes on ice vortexing every 5 minutes. Lysates were centrifuged at 13,000 rpm for 
10 minutes to remove residual membrane and stored at -80°C, previously separating 
aliquots to assess the protein concentration. The protein concentration was measured 
using the Bradford method, explained above. Then, 20 µg protein were incubated for 2 
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hours at 37°C in the dark in the presence of the synthetic substrate of caspase-3 Ac-
DEVD-AMC (BD Pharmingen) at a 20 μM concentration in a reaction buffer whose 
composition is: 20 mM HEPES (pH 7.5), 10% Glicerol and 2mM DTT. Proteolysis of the 
synthetic substrate by active caspase 3 present in the lysates liberates the fluorogenic 
compound AMC, whose fluorescence was measured in a fluorimeter (Perkin Elmer LS-
50, Excitation/Emission (nm): 380/440). A unit of caspase activity is the amount of 
enzyme that will lead to a one unit increase in the fluorescence intensity. Results are 
expressed as units of activity per microgram of protein. 
10. CLONOGENIC ASSAY 
To measure the colony-forming and self-renewal capacity, cells (100) were seeded in a 
6 cm dishes. After 8-10 days, the medium was removed and cell colonies were fixed 
and stained with a 0.2% crystal violet w/v in 2% ethanol solution. The total number of 
clones was quantified using Image J program and their size using Open CFU program. 
11. MIGRATION AND INVASION ASSAYS 
11.1 Wound healing assay 
Cells (34000 cells/sq cm) were seeded in 35mm-cell culture dishes and grown to 
confluence in complete medium. A sterile 10 µl pipette tip was used to make a wound 
across a cell culture monolayer. Cell debris was removed by discarding the medium 
and washing three times with PBS. Cells were then incubated in DMEM-0% for 24 
hours. Multiple photographs of the wound were taken immediately after wounding (0 
hours) and 4, 8, 12 and 24 hours under a phase-contrast microscopy using Eclipse 
TE300 Nikon microscope coupled to a digital sight DS-U2 camera. The efficiency of the 
wound healing process was determined by calculating the area of the cell gap using 
TScratch software. Three images were used for each wound at each experimental 
point.  
11.2 Invasion assay 
In vitro invasion assays were performed using transwell inserts (24-well plate inserts; 8 
µm pore size; cell growth area 0.3 sq cm, BD Bioscience) coated with type IV collagen 
(7.5 µg/ml) according to the manufacturer's recommendation. 67000 cells/sq cm were 
added to the upper chamber and incubated in the presence of the different treatments 
in DMEM-0% FBS. After 24 hours in culture, cells in the upper chamber were carefully 
removed with a cotton swab and the cells that had invaded the membrane were fixed 
with paraformaldehyde (PFA) 4% (20 minutes) and stained with crystal violet 0.2% 
(Sigma Ref C-0775) in water for 20 minutes. Several representative photographs of 
each well were taken. Quantification of the invasion process was done by counting 
stained invaded cells in at least 10 fields/insert using phase-contrast microscopy 
(Eclipse TE300, Nikon) and a 10X objective. Each experiment was run in triplicates to 
confirm reproducibility of data. 
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12. QUANTITATIVE DETERMINATION OF UREA 
Quantitative determination of urea concentrations in cell culture medium was done 
using the SPINREACT kit, according to the manufacturer´s recommendation. 
Briefly, cells (1 × 106 cells) were seeded on 100mm plate. The following day, the cells 
were left with a minimal amount of medium (3 ml) overnight. The next day, culture 
media were collected and measured. To perform the assay, 10 μL of sample were 
transferred into 1cm cuvette with the working reagent (WR), mixed and incubated 10 
minutes at room temperature. Then, sodium hypochlorite (NACIO) was added to each 
cuvette and mixed quickly. The reaction was incubated for 10 minutes at room 
temperature. Optical density (OD) at 580 nm was measured using a plate reader 
(Powerwave XS, Biotek). The concentration of a standard urea sample containing 50 
mg/dL urea was also measured. 
The urea concentration in the sample was calculated from the OD values: 
𝑚𝑔
𝑑𝑙
[𝑈𝑟𝑒𝑎] =
OD Sample − OD Blank
OD Standard − OD Blank
𝑋 [𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑]
𝑚𝑔
𝑑𝑙
 
where OD Sample, OD Standard, and OD Blank are OD580 nm values of the sample, 
standard, and water blank, respectively. [Standard] is the concentration of the urea 
standard (50 mg/dL or 0.1665 mmol/L). The values obtained are expressed as mg/dl of 
urea in the sample respect to the cell number. 
13. STATISTICAL ANALYSIS 
Data have been represented as the mean value of 3-10 independent experiments ± 
S.E.M. When only one experiment was shown, data have been represented as the 
mean value ± S.D. (standard deviation). When comparisons were made between two 
experimental groups, unpaired Student's t-test was used. To compare more than two 
groups, analysis of variance (ANOVA) was performed. 
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1. BMP9 REGULATES OVAL CELL EXPANSION IN VIVO  
Previous experiments performed in our laboratory and studies from other groups 
described that BMP9 regulates the function of different liver cell populations. As 
indicated in the “group background” section, BMP9 is a proliferative and survival factor 
for human HCC cells (Herrera et al. 2013). Moreover, it has been reported to be 
produced by the healthy liver (Miller et al. 2000; Bidart et al. 2012) and to be 
overexpressed in liver tumors (Herrera et al. 2013; Li et al. 2013). Its role in other 
pathological conditions is a matter of study.  
However, nothing is known about its regulatory role in another hepatic cell population, 
the oval cells. As mentioned before, expansion of hepatic progenitors in the liver has 
been observed in chronic liver injury (Lowes et al. 1999; Fausto and Campbell 2003; 
Duncan et al. 2009; Riehle et al. 2011) and this process is considered as the second 
line of defense against liver injury. Taking into consideration the emergent role of 
BMP9 in liver pathophysiology, we decided to investigate the role of BMP9 in oval cells 
in chronic liver injury and the potential implications in the context of liver regeneration. 
1.1 Lack of BMP9 leads to an amplified ductular response after DDC 
treatment  
To analyze whether genetic deletion of BMP9 has any effect on oval cell expansion, we 
used a model of liver injury induced by a diet containing the porphyrogenic agent DDC, 
that has been shown to activate oval cells (Preisegger et al. 1999; Wang et al. 2003) 
(Yamazaki et al. 2011). BMP9-KO mice were generated in Dr. Lee laboratory and their 
phenotype is described in “Material and methods” section. Thus, WT and BMP9-KO 
mice were fed a 0.1% DDC supplemented diet for 1, 2, 4 and 6 weeks. 
Histological analysis, in particular H&E staining, showed the typical periportal ductular 
reactions with oval cells, identified as small cells with an oval nucleus and scant 
cytoplasm, expanding from the periportal regions in the liver of WT and BMP9-KO 
treated mice (FIGURE 18). Interestingly, H&E staining showed an increase in oval cell 
number in the BMP9-KO liver when compared to WT at 6 weeks of DDC feeding 
(FIGURE 18 A). To confirm the visual observation and quantify the oval cell expansion, 
periportal ductular reaction areas were measured from H&E stained sections as 
described in “Material and methods” section. Quantitative analysis demonstrated that 
the ductular reaction after 6 weeks of DDC feeding was more pronounced in BMP9-KO 
than in WT mice (FIGURE 18 B). We also analyzed the expression of two well-
established oval cells markers, Epcam and cytokeratin 19 (Krt19), in livers of untreated 
and DDC-treated WT and BMP9-KO mice. In order to do this, total RNA from liver 
tissues was obtained followed by qRT-PCR analysis of Epcam and Krt19 mRNA levels. 
We observed an increase in the expression of both oval cell markers in WT and BMP9-
KO mice submitted to DDC diet (FIGURE 18 C). Importantly, the up-regulation of 
Epcam and Krt19 expression was more pronounced in BMP9-KO compared to WT 
mice at 6 weeks. The differential expression of Epcam observed in BMP9-KO was 
confirmed at the protein level, by western blot analysis performed with liver protein 
extracts obtained in the same conditions (FIGURE 18 D, right and left panels). 
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FIGURE 18. More pronounced ductular response in BMP9-KO compared to WT mice after DDC 
feeding 
A. Representative images of H&E staining in liver tissues of WT and BMP9-KO livers untreated or after 
2 and 6 weeks of DDC diet. Images are shown at 100x magnification. B. Quantitative morphometric 
analysis of oval cells expansion using ImageJ software. Areas from 12 periportal regions of each 
animal (at least five animals per group) were measured, and the percentage respect the untreated 
group was calculated. C. Total mRNA was isolated from the livers of WT or BMP9-KO mice untreated 
or after DDC treatment for 2 or 6 weeks. Epcam and Krt19 mRNA levels were determined by 
quantitative RT-PCR and normalized to Gusb. Data are expressed relative to untreated samples 
(assigned an arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals. D. Protein was isolated 
from the livers of WT or BMP9-KO mice untreated or after DDC treatment for 2 or 6 weeks. Western 
blot analysis was performed using an antibody that recognizes EPCAM and β-ACTIN (used as loading 
control). A representative experiment of 9 is shown (left panel). Optical density values relative to 
loading control were calculated. Data are expressed relative to non-treated samples (assigned an 
arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals (right panel). E. The liver to body 
weight ratio was estimated based on the following formula: %=100 × Ml/Mb, where Ml is the liver 
weight and Mb is the total animal weight. Data are expressed as the mean ± SEM of at least 5 animals 
for group. *p<0.05, **p<0.01 and ***p<0.001. 
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The evaluation of liver-to-body weight ratio is used to examine the degree of liver 
damage (Best et al. 2013) but it is as well predictive of an enhanced liver regeneration. 
In fact, the liver-to-body weight ratio is significantly lower in rats with a deficient liver 
function (Dusabineza et al. 2012). Consistently, the impairment of liver regeneration 
and function observed in DDC-treated c-Met deficient mice was associated with a lack 
of increase in liver-to-body weight ratio along the DDC treatment (Ishikawa et al. 2012). 
Taking this into consideration, we measured this parameter in both WT and BMP9-KO 
mice at the different time points of treatment. Consistent with a damage-induced 
compensatory regenerative response, we saw an increase in the liver-to-body weight 
ratio in those mice submitted to the diet, but this increase was higher in BMP9-KO as 
compared to WT mice after 6 weeks (FIGURE 18 E), further supporting a greater 
expansion of the oval cell population in the absence of BMP9.  
All these data together evidence that BMP9-KO present a greater expansion of the oval 
cell population than WT in response to a DDC diet, which suggest a negative 
regulatory role for BMP9 on the oval cell expansion.  
1.2 BMP9 signaling is decreased in DDC fed mice during oval cell 
expansion 
To further explore the potential role of BMP9 as a negative regulator in oval cell 
expansion, we next analyzed BMP9 expression levels during this process in WT mice 
fed with a DDC diet. qRT-PCR analysis revealed a significant decrease of Bmp9 
mRNA levels during the in vivo expansion of oval cells. This decrease was observed as 
early as one week after initiation of DDC diet and was sustained up to 6 weeks of 
treatment (FIGURE 19 A). Analysis of BMP9 protein levels by western blot gave similar 
results (FIGURE 19 B). In addition to BMP9, we analyzed the activation of SMAD1,5,8 
and we found a significant decrease of SMAD1,5,8 phosphorylation after DDC 
treatment compared to the untreated animals. Moreover, we also detected a significant 
downregulation of important BMP9 type I (Alk1 and Alk-2) and type II (Bmpr2) 
receptors during the DDC treatment (FIGURE 19 C). 
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Collectively, these findings indicate that BMP9 and its major signaling components are 
downregulated during the ductular reaction in the DDC model and suggest that BMP9 
signaling downregulation might be critical to allow in vivo expansion of oval cells. 
 
FIGURE 19. Decreased expression of BMP9 and its signalling components in DDC-treated 
mice 
A. Total mRNA was isolated from the livers of WT mice untreated or after DDC treatment for 1, 2, 
4 or 6 weeks. Bmp9 mRNA levels were determined by quantitative RT-PCR and normalized to 
Gusb. Data are expressed relative to non-treated samples (assigned an arbitrary value of 1) and 
are mean ± S.E.M. of at least 5 animals. B. Protein was isolated from the livers of WT mice after 
DDC treatment for 1, 2, 4 or 6 weeks. Western blot analysis was performed using an antibody that 
recognizes BMP9 or phosphorylated SMAD1,5,8 (P-SMAD1,5,8). β-ACTIN was analyzed as 
loading control. A representative experiment of 2 is shown (left panel). Optical density values 
relative to loading control were calculated. Data are expressed relative to non- treated samples 
(assigned an arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals (right panel). C. 
Total mRNA was isolated from the livers of WT mice after 6 weeks of DDC treatment. Alk1, Alk-2 
and Bmpr2 mRNA levels were determined by quantitative RT-PCR and normalized to Gusb. Data 
are expressed relative to non-treated samples (assigned an arbitrary value of 1) and are mean ± 
S.E.M. of at least 5 animals. Data were compared with the untreated condition. *p<0.05, **p<0.01 
and ***p<0.001. 
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1.3 Increased activation of AKT and ERK1/2-MAPKs in BMP9-KO livers 
during oval cell expansion. Regulation of HGF/c-Met pathway.  
Next, we wanted to explore the mechanisms responsible for the amplified oval cell 
expansion observed in BMP9-KO mice. Since AKT and ERK1/2-MAPKs have been 
extendedly involved in the regulation of cell proliferation, survival and motility in 
hepatocytes and oval cells (Michalopoulos and DeFrances 1997; Coutant et al. 2002; 
Okano et al. 2003; Fremin et al. 2007; Martinez-Palacian et al. 2013; Utley et al. 2014; 
Suarez-Causado et al. 2015), we performed a comparative analysis of the activation of 
these two pathways in WT and BMP9-KO liver obtained from mice submitted to the 
DDC diet. Interestingly, BMP9-KO animals showed a significant increase in the levels 
of both activated AKT and ERK1/2-MAPKs along the DDC treatment (FIGURE 20) 
suggesting a role for these kinases in promoting expansion of oval cells in these mice. 
 
 
 
 
 
FIGURE 20. Increased activation of AKT and ERK1/2-MAPKs in BMP9-KO after DDC treatment 
A. Protein was isolated from the livers of WT and BMP9-KO mice untreated or after DDC treatment for 
2, 4 or 6 weeks. Western blot analysis was performed using an antibody that recognizes 
phosphorylated AKT (P-AKT) and phosphorylated ERK1/2-MAPKs (P-ERKs1/2). β-ACTIN was 
analyzed as loading control. A representative experiment of 3 is shown. B. Optical density values 
relative to loading control were calculated. Data are expressed relative to non-treated samples 
(assigned an arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals. Data were compared 
with the untreated condition or as indicated. **p<0.05, **p<0.01 and ***p<0.001. 
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It is well known that HGF/c-Met signaling pathway plays a critical role in liver 
regeneration including the regenerative response mediated by oval cells (Borowiak et 
al. 2004; Huh et al. 2004; Michalopoulos 2010; Riehle et al. 2011; Ishikawa et al. 
2012). Indeed, using the DDC model, it has been shown that loss of c-Met decreases 
oval cell pool, migration and differentiation (Ishikawa et al. 2012). Interestingly, c-Met 
mutant livers failed to activate AKT and ERK1/2-MAPKs after DDC diet. This prompted 
us to check whether the amplified oval cell expansion seen in BMP9-KO mice 
submitted to the DDC diet was somehow associated with alterations in the activation of 
HGF/c-Met pathway (FIGURE 21). 
 
 
 
 
 
 
 
 
FIGURE 21. Increased expression of Hgf and activation of c-Met in BMP9-KO mice under 
DDC diet 
A. Total mRNA was isolated from the livers of WT and BMP9 KO mice untreated or after DDC 
treatment for 2, 4 or 6 weeks. Hgf mRNA levels were determined by quantitative RT-PCR and 
normalized to Gusb. Data are expressed relative to non-treated samples (assigned an arbitrary 
value of 1) and are mean ± S.E.M. of at least 5 animals. B. Protein was isolated from the livers of 
WT and BMP9 KO mice after DDC treatment for 1, 2, 4 or 6 weeks. Western blot analysis was 
performed using an antibody that recognizes phosphorylated-MET (P-MET). β-ACTIN was 
analyzed as loading control. A representative experiment of 3 is shown (upper panel). Optical 
density values relative to loading control were calculated. Data are expressed relative to non- 
treated samples (assigned an arbitrary value of 1) and are mean ± S.E.M. of at least 5 animals 
(lower panel). Data were compared with the untreated condition or as indicated, *p<0.05 and 
**p<0.01. 
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As shown in FIGURE 21 A, BMP9-KO mice expressed higher levels of hepatic Hgf 
compared to WT at 6 weeks of DDC treatment, coinciding with the increase in oval cell 
expansion. To study whether this increase in Hgf was associated with an increased 
activation of the pathway, we analyzed the phosphorylation levels of c-MET using a 
phospho-MET (Tyr1234/1235) antibody. c-MET phosphorylation was much higher and 
more prolonged in BMP9-KO mice than in WT mice (from 2 weeks and up to 6 weeks 
of treatment) (FIGURE 21 B). These data suggest that the absence of BMP9 results in 
an increased activation of the HGF/c-Met pathway and lead us to speculate on a 
possible functional interaction between these two signaling pathways operating to 
adequately regulate oval cell expansion in mice. 
1.4 Enhanced hepatic inflammatory response in DDC fed BMP9-KO mice 
Different evidence have shown that oval cell proliferation in vivo is associated with 
inflammation (Libbrecht et al. 2000; Knight et al. 2005; Viebahn and Yeoh 2008). 
Indeed, there are in vitro and in vivo data in the literature indicating that inflammatory 
cytokines, including IL-6, IFN-γ, TNF-α and TWEAK, induce oval cell proliferation 
(Brooling et al. 2005; Jakubowski et al. 2005; Knight et al. 2005; Nguyen et al. 2007; 
Viebahn and Yeoh 2008; Kitade et al. 2016). On this basis, to further investigate the 
mechanisms behind the amplified oval cell response in BMP9-KO mice, we next 
analyzed the inflammatory response in WT and BMP9-KO mice (FIGURE 22).  
First, we checked the hepatic expression of two pro-inflammatory cytokines, Il6 and 
Tnfa in WT and BMP9-KO mice submitted to the DDC diet. We found that the DDC 
treatment did not result in changes in Il-6 expression levels in WT animals, whereas 
Tnfa was upregulated. In contrast, in BMP9-KO mice both Il6 and Tnfa were 
upregulated in response to the DDC diet and in the case of Il6, this increase was 
statistically significant when compared with WT (FIGURE 22 A). In addition, we 
analyzed STAT3 activation as a way to measure cytokine-driven signaling. The levels 
of the phosphorylated form of STAT3 were higher in BMP9-KO mice than in WT in 
response to liver injury (FIGURE 22 B). These results, all together, suggest that there 
is an enhanced hepatic inflammatory response in BMP9-KO mice, which could 
contribute to the oval cell expansion and proliferation. 
To further analyze the inflammatory status, coded histological liver sections of WT and 
BMP9-KO animals fed with the DDC diet were scored independently by a single 
pathologist using the Knodell HAI (Knodell et al. 1981). As described in “Material and 
methods”, this system evaluates different parameters: periportal bridging necrosis, 
intralobular inflammation, portal inflammation and bridging fibrosis portal. The results of 
Knodell scoring system are presented in the table (FIGURE 22 C). According to the 
total score, the cases were divided into five groups (Mushtaq et al. 1997). According to 
the Knodell scoring system, no differences were observed in untreated WT and BMP9-
KO (animals included in groups 0 and I). DDC-fed BMP9-KO mice fell into the category 
III, scoring 9-12, with severe portal inflammation and moderate intralobular 
inflammation (three of the four animals analyzed have score 3 for the intralobular 
inflammation parameter). On the contrary, DDC-fed WT analyzed showed the same 
degree of portal inflammation but a mild degree of intralobular inflammation (indeed, in 
this case three of the four animals analyzed have score 1 for the intralobular 
inflammation parameter). No differences emerged in terms of periportal necrosis and 
fibrosis.  
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From the analysis of these data, we concluded that the intralobular inflammation is 
increased in BMP9-KO mice compared to WT in response to DDC treatment. 
FIGURE 22. Enhanced hepatic inflammatory response in BMP9-KO livers submitted to DDC 
diet 
A. Total mRNA was isolated from the livers of WT and BMP9 KO mice untreated or after DDC 
treatment for 6 weeks. Il6 and Tnfa mRNA levels were determined by quantitative RT-PCR and 
normalized to Gusb. Data are expressed relative to non-treated samples (assigned an arbitrary 
value of 1) and are mean ± S.E.M. of at least 5 animals. B. Protein was isolated from the livers of 
WT and BMP9 KO mice after DDC treatment for 2 or 6 weeks. Western blot analysis was performed 
using an antibody that recognizes phosphorylated-STAT3 (P-STAT3) and total STAT3. β-ACTIN 
was analyzed as loading control. One experiment is shown (left panel). Optical density values 
relative to total STAT3 normalized levels were calculated. Data are expressed relative to non-
treated samples (assigned an arbitrary value of 1) and are mean ± S.E.M. (right panel). Data were 
compared with the untreated condition or as indicated, *p<0.05 and **p<0.01. C. The table showed 
the results of Knodell scoring system for the samples analyzed; 4 animals for each condition have 
been used. 
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In summary, using different approaches, we have shown that BMP9-KO mice display a 
greater inflammation concomitant with an amplified oval cell expansion compared to 
WT in response to DDC diet, further supporting the hypothesis that the inflammatory 
process could have a role in the promotion of oval cell expansion. 
1.5 Reduced liver damage in BMP9-KO mice under DDC diet 
So far, our results show a greater oval cell expansion in mice lacking BMP9, but we do 
not know the consequences of this phenomenon for the progression and outcome of 
the liver injury process. As mentioned in previous sections, recent evidence in the 
literature suggest that a sustained oval cell response may aggravate fibrosis (Pritchard 
and Nagy 2010; Chobert et al. 2012; Kuramitsu et al. 2013). 
Thus, authors postulate that activation of oval cell-mediated regeneration in fibrotic 
livers is associated with a more pronounced fibrogenic response. This prompted us to 
study the degree of fibrosis in our mouse model after DDC treatment by analyzing the 
expression levels of a panel of fibrogenic markers such as Tgfb1, Tgfb2, procollagen α 
1(I) (Col1a1) and α-smooth muscle actin (Acta2). 
 
 
 
 
 
Consistent with an induction of hepatic damage, all the markers analyzed were 
increased in WT mice after DDC treatment, showing a peak of induction at 4 weeks, 
whereas in BMP9-KO mice this increase in pro-fibrogenic markers was very mild or 
even absent as in the case of Acta2 (FIGURE 23). 
FIGURE 23. Reduced hepatic fibrosis markers in BMP9-KO mice under a DDC diet.  
Total mRNA was isolated from the livers of WT and BMP9 KO mice untreated or after DDC treatment 
for 2, 4 and 6 weeks. Tgfb1, Tgfb2, Col1a1 and Acta2 mRNA levels were determined by quantitative 
RT-PCR and normalized to Gusb. Data are expressed relative to non-treated samples (assigned an 
arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals. Data were compared with the 
untreated condition or as indicated, *p<0.05, **p<0.01 and ***p<0.001. 
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Although these data suggested that liver injury triggered by DDC treatment was 
reduced in BMP9-KO as compared to WT mice, to unequivocally evaluate liver 
damage, we measured serum blood liver function parameters, in particular alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin total levels, in 
serum of DDC fed mice (FIGURE 24). These parameters were elevated in response to 
DDC, with a peak at 2 weeks of treatment and decline over time, which is likely related 
to the oval cell mediated regenerative response that contribute to restore liver function. 
The profile was similar in BMP9-KO mice but clearly the increase in ALT, AST and 
bilirubin was attenuated, being these values statistically different from those obtained in 
WT mice at 6 weeks of DDC treatment, providing strong evidence that liver damage is 
attenuated in BMP9-KO mice. 
 
 
 
 
 
 
Collectively, our data indicate that the absence of BMP9 in vivo not only results in a 
greater expansion of the oval cell compartment and an accentuation of inflammation 
but also in a significant attenuation of liver fibrosis and damage, evidencing a more 
efficient regeneration in BMP9-KO livers in response to DDC-induced damage. Hence, 
our data suggest that BMP9 may act as a negative regulator of the oval cell mediated 
liver regeneration. 
 
 
 
 
FIGURE 24. Reduced serum ALT, AST and total bilirubin levels in BMP9-KO mice under a 
DDC diet 
ALT, AST and bilirubin serum levels of WT and BMP9 KO mice untreated or after DDC treatment for 
2 and 6 weeks. Data are mean ± S.E.M. of at least 3 animals per group. Data were compared with 
the untreated condition or as indicated, *p<0.05, **p<0.01 and ***p<0.001. 
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2. RELEVANCE OF BMP9-MEDIATED SIGNALING IN OVAL CELL 
FUNCTION. CROSSTALK WITH THE HGF/c-Met PATHWAY 
To further study this novel potential role of BMP9 as a suppressor factor for oval cell 
expansion and to characterize the molecular mechanisms mediating such effect, we 
performed additional experiments using an in vitro model of oval cells previously 
established and characterized in our laboratory. 
2.1 BMP9 induces the canonical signaling pathway in oval cells in vitro 
First, we checked if oval cells respond to BMP9 with an activation of the canonical 
SMAD pathway (FIGURE 25). We found that BMP9 induced SMAD1,5,8 
phosphorylation in a dose dependent manner in oval cells. When we performed a time 
course analysis of SMAD1,5,8 phosphorylation, we found that activation occurred after 
30 minutes of BMP9 treatment, with a maximum at 2 hours. To test the SMAD-
dependent transcriptional response to BMP9, we transfected the cells with the plasmid 
pGL3 BRE Luciferase (pGL3(BRE)-luc) containing a reporter construct consisting of a 
BMP-response element (BRE) from the Id1 promoter fused to a luciferase reporter 
gene. Indeed, BMP9 increased BRE-luciferase activity in oval cells (FIGURE 25 B) and 
consistently, it also enhanced Id1 mRNA expression (FIGURE 25 C), a well-studied 
target gene of the BMP/SMAD signaling pathway. 
 
 
 
 
 
 
 
 
 
FIGURE 25. BMP9 induces the SMAD1,5,8 signaling pathway in oval cells  
A. Oval cells were incubated with different concentrations of BMP9 for 1 hour (left 
panel) or for different periods of time with BMP9 (2 ng/ml) (right panel) in 0% FBS 
media. Western blots were performed with antibodies that recognized P-SMAD1,5,8 
and β-ACTIN as loading control. A representative experiment of 3 is shown. B. Oval 
cells were transfected with a pGL3(BRE)-luciferase reporter construct and then were 
serum starved and treated for 15 hours with BMP9 (2 ng/ml). Luciferase activity was 
normalized to cell number. Data are shown as fold change (relative to untreated cells) 
and are pooled from three experiments (n = 6) (mean ± S.E.M).
 
C. Oval cells were 
incubated ± BMP9 (2 ng/ml) for different periods of time in 0% FBS media and Id1 
levels were analyzed by qRT-PCR and normalized to Gusb. Data are shown as fold 
induction (relative to untreated cells) and correspond to one representative 
experiment (n=3) out of 3 performed (mean ± S.D.). Data are expressed as fold 
induction (relative to untreated cells) and are pooled from 4 independent experiments 
performed in triplicate (mean ± S.E.M). *p<0.05, **p<0.01 and ***p<0.001. 
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2.1 BMP9 reduces oval cell number and increases invasion 
As BMP9 has been shown before to control hepatic cell growth (Herrera et al. 2013), 
we analyzed the response of oval cells to BMP9 in terms of cell growth.  
We incubated oval cells with BMP9 for different periods of time in the absence of 
serum, and we found that BMP9 moderately but significantly decreases oval cell 
number (FIGURE 26 A). The effect of BMP9 in oval cell growth seems to be due to 
combination of two effects, a cell proliferation inhibitory effect, measured by [3H] 
thymidine incorporation assay (FIGURE 26 B) and a pro-apoptotic effect. In fact, we 
measured the caspase-3 activity and the apoptotic index in cells treated with BMP9 
and our data reveal that BMP9 is capable of inducing a mild but significant apoptotic 
cell death (FIGURE 26 C and D). Altogether, these results confirm that BMP9 has 
suppressor effects in oval cells. 
 
 
 
 
 
 
 
 
Oval cell expansion in the injured liver not involves only cell proliferation and survival 
but also other biological processes, such as migration and invasion through liver 
parenchyma. Data from the literature indicated that other BMP members regulate cell 
invasion (Maegdefrau and Bosserhoff 2012; Chen et al. 2014; Haasters et al. 2014; 
Kim et al. 2014). Also BMP9 has been recently reported to induce EMT and increase 
cell migration in transformed hepatic cells (Li et al. 2013).  
FIGURE 26. BMP9 reduces oval cell proliferation and induces apoptosis in vitro 
A. Oval cells were incubated with 2 ng/ml BMP9 in 0% FBS media and counted at day 2, 4 
and 6. Data from 5 independent experiments with n=3 displayed as percentage of untreated 
cells (mean ± S.E.M.).  B. DNA synthesis as determined by thymidine incorporation in oval 
cells cultured for 24 hours with BMP9 (2 ng/ml). Data are mean ± S.E.M. of 3 independent 
experiments and are displayed as fold induction (relative to untreated cells). C-D. Oval cells 
were serum-starved and incubated in the absence or presence of BMP9 (2 ng/ml) for 24 
hours. C. Cells were lysed and caspase-3 activity was measured. Data are expressed as 
fold induction (relative to untreated cells) and are pooled from 2 independent experiments 
performed in duplicate (mean ± S.E.M). D. Apoptotic nuclei were visualized and counted 
after PI staining under a fluorescence microscope. A minimum of 1000 nuclei was counted 
per condition. Data are expressed as fold induction (relative to untreated cells) and are 
pooled from 4 independent experiments performed in triplicate (mean ± S.E.M).   *p<0.05, 
**p<0.01 and ***p<0.001. 
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Based on this evidence, we questioned whether BMP9 could also regulate oval cell 
migration and invasion. To address this question, we assayed the migratory/invasive 
capacity of oval cells through extracellular matrix substrates in response to BMP9 using 
transwells coated with collagen IV (FIGURE 27). 
 
 
 
 
 
 
 
Results demonstrated a significant increase in the number of oval cells that migrated 
and invaded to the bottom side of the filters upon BMP9 treatment as evidenced by the 
microcopy images and quantitative analysis. 
2.2 ALK2 mediates BMP9-triggered signaling and suppressor effects in 
oval cells 
We have shown before that BMP9 triggers the canonical pathway in oval cells 
(FIGURE 25), as it has been described in other liver cell types (Herrera et al. 2013; Li 
et al. 2013). In an effort to further elucidate BMP9 signaling pathway in oval cells, we 
next studied the receptors involved. As other members of the BMP family, BMP9 binds 
to a heterotetrameric transmembrane receptor complex comprised by type I and type II 
serine threonine kinase receptors. ALK1 is the high affinity receptor for BMP9, but 
ALK2 has been described to mediate BMP9 signaling in some cell types (Herrera et al. 
2009; Luo et al. 2010). 
FIGURE 27. BMP9 increases oval cell invasion 
Oval cells were plated in the upper chamber of transwell-24 well plate covered with collagen 
in serum-free medium ± BMP9 (2 ng/ml). Each well contained approximately 2 × 10
4
 cells. 
Medium without FBS (0%) was placed in the lower chamber. Cells were allowed to pass 
through collagen for 24 hours and then were fixed in PFA and stained with crystal violet. A. 
Representative images of invading cells after staining with crystal violet (phase contrast 
microscope) of the different culture conditions are shown. Scale bar= 100 µm. B. Histograms 
show the mean value ± S.D. of the number of invading cells respect to control from one 
representative experiment (n=3) out of 3 performed. ***p<0.001. 
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To define which specific receptors were required for BMP9 signaling in oval cells, cells 
were incubated with 125I_BMP9 and crosslinked receptor complexes were 
immunoprecipitated with ALK1, ALK2 and BMPR2 specific antibodies. Results show 
that BMP9 binds to ALK2 and BMPRII but not to ALK1 in oval cells (FIGURE 28 A). We 
also checked the relative expression of ALK1 and ALK2 in oval cells. To do this, we 
compared the dCt values, the normalized Ct value of the target gene. Specifically, we 
calculated the dCt for each gene (Alk1 and Alk-2), and then we calculated the relative 
gene expression using this formula: %RG (Relative gene) expression for Gene1= 100 x 
2^(-dCt gene1). Results show that Alk-2 is expressed at higher levels than Alk1 in oval 
cells  (FIGURE 28 B). 
 
 
 
 
 
 
As an additional approach to further confirm that ALK2 is the main type I receptor for 
BMP9 in oval cells, we perform stable knockdown experiments; Alk-2 shRNA lentiviral 
vector was used to generate oval cells with reduced levels of this receptor. Using this 
strategy we obtained cells with a 60% reduction of Alk-2 expression levels (FIGURE 29 
A). shALK2 cells failed to phosphorylate SMAD1,5,8 in response to BMP9 and also 
showed a complete inhibition of SMAD-dependent transcriptional activity (FIGURE 29 
B and C). Moreover, in shALK2 cells the suppressor effect of BMP9 was completely 
abolished as evidenced by the fact that oval cells with reduced levels of Alk-2 did not 
present a decrease in cell number after BMP9 treatment (FIGURE 29 D). Altogether 
these data indicate that ALK2 mediates BMP9 suppressor effects in oval cells. 
 
FIGURE 28. BMP9 binds to ALK2 and BMPRII in oval cells 
A. Oval cells were affinity-labelled with 
125
I_BMP9 and crosslinked ligand-
receptors complexes were immunoprecipitated with specific antisera as 
indicated and subjected to SDS-PAGE and autoradiography. B. RNA from 
oval cells was isolated and Alk1 and Alk-2 levels were analyzed by qRT-
PCR and normalized to Gusb. Data are expressed as relative gene 
expression and are from 8 independent experiments (n=3) (mean ± 
S.E.M.).  ***p<0.001. 
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FIGURE 29. ALK2 mediates BMP9-triggered signaling and suppressor effect in oval 
cells 
A-D. Alk-2 knockdown oval cells were generated by stable infection with lentiviral vectors 
expressing an ALK2 targeting short hairpin (shALK2) or a non-targeting short hairpin (NT). A. 
Alk-2 mRNA levels were determined by quantitative RT-PCR. Data expressed relative to NT 
cells (assigned an arbitrary value of 1). B. NT and shALK2 stable cells were treated with 
BMP9 (2 ng/ml) for 30 minutes in 0% FBS media. Western blots were performed with 
antibodies that recognized P-SMAD1,5,8 and β-ACTIN as loading control. A representative 
experiment of 2 is shown. C. NT and shALK2 stable oval cells were transfected with 
pGL3(BRE)-luciferase reporter construct and then were serum starved and treated for 15 
hours with BMP9 (2 ng/ml). Luciferase activity was normalized to cell number. Data are 
shown as fold change (relative to NT untreated cells) and are from 1 representative 
experiment (n = 6) (mean ± S.D.). D. NT and shALK2 stable oval cells were treated with BMP9 
(2 ng/ml) in 0% FBS and counted at day 2. Data are from 3 independent experiments 
performed in triplicate, displayed as percentage of NT untreated cells (mean ± S.E.M). Data 
were compared with the untreated condition or as indicated. *p<0.05, **p<0.01 and 
***p<0.001. 
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2.3 HGF/c-Met signaling inhibits BMP9-triggered suppressor effects in 
oval cells in vitro 
Our in vivo data have revealed an over-activation of the HGF/c-Met pathway in BMP9-
KO livers as compared to WT upon DDC feeding (FIGURE 21)  providing the first 
evidence of a potential functional crosstalk between BMP9 and HGF/c-Met pathways in 
the regulation of oval cells. Interestingly, signaling crosstalk between HGF and other 
BMPs has been already reported in other cell types (Imai et al. 2005; Ye et al. 2007; Ye 
et al. 2008; Tsai et al. 2012; Shibasaki et al. 2015). Based on all this, we then aimed to 
deepen in the analysis of this potential crosstalk. 
 
 
 
 
 
 
 
 
 
FIGURE 30. HGF/c-Met signaling inhibits BMP9-triggered suppressor effects in oval cells in vitro 
A. Met
flx/flx 
oval cells were incubated with BMP9 (5 ng/ml) in the absence or presence of HGF (40 ng/ml) in 
0% FBS media and counted at day 4. Data from 4 independent experiments with n=3 displayed as 
percentage of untreated cells (mean ± S.E.M.). B-C. Met
flx/flx 
oval cells were incubated with BMP9 (5 ng/ml) 
in absence or presence of HGF (40 ng/ml) in 0% FBS media for 24 hours. B. Caspase-3 activity was 
measured. Data are expressed as fold induction (relative to untreated cells) and are from 4 independent 
experiments (mean ± S.E.M). C. Apoptotic index was calculated by counting apoptotic nuclei after PI 
staining under a fluorescence microscope. A minimum of 1000 nuclei was counted per condition. Data 
from 2 independent experiments performed in triplicate (mean ± S.E.M.) are shown. D. Met
flx/flx 
and Met
-/-
 
oval cells were incubated with different concentrations of BMP9 in 0% FBS media and counted at day 4. 
Data from 7 independent experiments with n=3 displayed as percentage of untreated cells (mean ± 
S.E.M.). E-F. Met
flx/flx 
and Met
-/-
 oval cells were incubated with BMP9 (2 ng/ml) in 0% FBS media for 24 
and 48 hours. E. Caspase-3 activity.. Data are expressed as fold induction (relative to untreated cells) and 
are from 3 independent experiments performed in duplicate (mean ± S.E.M). F. Apoptotic nuclei.. Data are 
from 3 independent experiments performed in triplicate (mean ± S.E.M.). Data were compared with the 
untreated condition or as indicated. *p<0.05, **p<0.01 and ***p<0.001. 
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In a first step, we treated oval cells with BMP9 in the presence of HGF and check the 
effects in cell growth. We found that HGF is able to prevent the BMP9 inhibitory effects, 
both in terms of cell loss (FIGURE 30 A) and apoptotic effect (FIGURE 30 B and C). 
As a complementary approach, we took advantage of an in vitro model of oval cells 
that express a mutated inactive form of c-Met receptor lacking tyrosine kinase activity 
(Met-/-), previously developed in our laboratory (del Castillo et al. 2008). We evaluated if 
the absence of a functional c-Met had any effect on the BMP9 inhibitory activity in oval 
cells. As shown in FIGURE 30 D, Met-/- oval cells were more sensitive to BMP9 
suppressor actions as evidenced by an increase in cell loss and apoptotic index in  
Met-/- oval cells compared to their normal counterparts (FIGURE 30 E and F). Jointly, 
these results further support a potential functional crosstalk between BMP9 and HGF/c-
Met signaling pathways in oval cells.  
In a next step, we investigated whether this functional crosstalk could reflect a signaling 
interaction between BMP9 and HGF/c-Met in oval cells. In order to solve this question, 
we compared the BMP9-triggered signaling response in Metflx/flx and Met-/- oval cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 31. BMP9 and HGF/c-Met signaling crosstalk in oval cells 
A. Met
flx/flx 
and Met
-/- 
oval cells were incubated with BMP9 (2 ng/ml) in 0% FBS media for different periods of time. 
Western blots were performed with antibodies that recognized P-SMAD1,5,8 and β-ACTIN as loading control. A 
representative experiment is shown (upper panel). Optical density values relative to loading control were calculated. 
Untreated samples were assigned an arbitrary value of 1. Data are mean ± S.E.M of 4 different experiments 
(bottom panel). B. Met
flx/flx 
and Met
-/- 
oval cells were incubated with BMP9 (2 ng/ml) in 0% FBS media for different 
periods of time and Id1 levels were analyzed by qRT-PCR and normalized to Gusb. Data are shown as fold 
induction (relative to untreated cells) and are from 2 independent experiments (mean ± S.E.M). C. Met
flx/flx
 oval cells 
were incubated with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml) in 0% FBS media for 30 minutes. 
Western blots were performed with antibodies that recognized P-SMAD1,5,8 and β-ACTIN as loading control. A 
representative experiment is shown (upper panel). Optical density values relative to loading control were calculated. 
Untreated samples were assigned an arbitrary value of 1. Data are mean ± S.E.M of 8 different experiments 
(bottom panel). D. Met
flx/flx
 oval cells were incubated with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml) 
in 0% FBS media for 15 hours and Id1 levels were analyzed by qRT-PCR and normalized to Gusb. Data are shown 
as fold induction (relative to untreated cells) and are from 4 independent experiments (mean ± S.E.M). Data were 
compared with the untreated condition or as indicated. *p<0.05, **p<0.01 and ***p<0.001. 
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Interestingly, our result show that BMP9-induced phosphorylation of SMAD1,5,8 was 
reduced in Met-/- oval cells compared to Metflx/flx oval cells (FIGURE 31 A), effect that 
was consistent with a significant attenuation of Id1 up-regulation (FIGURE 31 B). 
Conversely, using a complementary approach, we found that HGF potentiates BMP9-
triggered SMAD1,5,8 signaling in Metflx/flx cells (FIGURE 31 C), which is associated with 
a stronger Id1 up-regulation (FIGURE 31 D). These data suggest that HGF/c-Met 
positively modulates BMP9-triggered SMAD1,5,8 signaling in oval cells.   
2.4 BMP9 and HGF/c-Met signaling crosstalk in oval cells is dependent on 
ALK1/SMAD1 
Once we had evidenced that a functional signaling crosstalk between BMP9 and 
HGF/c-Met pathways was operating in oval cells, we aimed at characterizing the 
mechanism mediating this interaction. We hypothesized that the increased 
phosphorylation of SMAD1,5,8 observed upon combined treatment of HGF and BMP9, 
could be due to changes in the expression of the BMP9 receptors in oval cells. In order 
to check this possibility, we analyzed the expression of Alk1, Alk-2 and Bmpr2 in 
Metflx/flx oval cells in the absence and presence of HGF and BMP9. 
Neither Alk-2 nor Bmpr2 expression were modulated by BMP9 or HGF or the 
combination of both. However, interestingly, Alk1 expression levels were increased in 
response to BMP9 and HGF and the up-regulation was further enhanced under the 
combined treatment  (FIGURE 32).  
 
 
 
 
Based on this result, we wondered if ALK1/SMAD1 could have a role in the crosstalk 
between  BMP9 and HGF/c-Met in oval cells. To answer this question, we performed 
stable knockdown experiments using an Alk-1 shRNA lentiviral vector to generate cells 
with reduced levels of this receptor. Using this strategy we obtained an 80% reduction 
of Alk-1 expression levels in oval cells (FIGURE 33 A). Alk1 knockdown did not affect 
BMP9-induced SMAD activation or decrease in oval cell number (FIGURE 33 B, C and 
D). However, HGF-mediated amplification of BMP9-triggered SMAD1,5,8 
phosphorylation  and subsequent SMAD-dependent transcriptional activity were lost 
FIGURE 32. Effect of HGF and/or BMP9 treatment on BMP9 receptors expression in oval cells 
Metf
lx/flx 
oval cells were incubated with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml) in 0% 
FBS media for 1 hour and Alk1, Alk-2 and Bmpr2 levels were analyzed by qRT-PCR and normalized to 
Gusb. Data are shown as fold induction (relative to untreated cells) and are from 2 independent 
experiments (mean ± S.E.M). Data were compared with the untreated condition or as indicated. *p<0.05, 
**p<0.01 and ***p<0.001. 
 83 
 
(FIGURE 33 B and C). Moreover, in the absence of Alk1, HGF was not able to prevent 
BMP9 suppressor effect in oval cells (FIGURE 33 D). Hence, we next decided to 
perform transient Smad1 knock-down using a Smad1 siRNA in oval cells and check its 
consequences in oval cell number.We reached up to 70% reduction of total Smad1 
expression levels in oval cell upon siRNA-mediated Smad1 silencing (FIGURE 33 E). 
In the absence of Smad1, BMP9 was still able to decrease cell number but the 
protective effect of HGF against BMP9 was blocked (FIGURE 33 F). 
 
 
 
 
 
 
 
 
 
 
FIGURE 33. ALK1/SMAD1 drives the BMP9/c-Met signaling crosstalk and the protective effect of 
HGF in oval cell 
A-D. Alk1 knockdown oval cells were generated by stable infection with lentiviral vectors expressing an 
Alk1 targeting short hairpin (shALK1) or a non-targeting short hairpin (NT). A. Alk-1 mRNA levels were 
determined by quantitative RT-PCR. Data expressed relative to NT cells (assigned an arbitrary value of 
1). B. NT and shALK1 stable cells were treated with BMP9 (2 ng/ml) in absence or presence of HGF (40 
ng/ml) in 0% FBS media for 30 minutes. Western blots were performed with antibodies that recognized P-
SMAD1,5,8 and β-ACTIN as loading control. A representative experiment of 2 is shown. C. NT and 
shALK1 stable oval cells were transfected with pGL3(BRE)-luciferase reporter construct and then were 
serum starved and treated for 15 hours with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml). 
Luciferase activity was normalized to cell number. Data are shown as fold change (relative to untreated 
cells) and are from 2 independent experiments (n = 6) (mean ± S.E.M). D. NT and shALK1 stable oval 
cells were treated with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml) in 0% FBS media and 
counted at day 2. Data from 2 independent experiments performed in triplicate, displayed as percentage 
of NT untreated cells (mean ± S.E.M). Data were compared with the untreated condition or as indicated. 
E-F. Smad1 knockdown oval cells were generated by transient infection with siRNA (siSmad1) or a non-
targeting siRNA (NT). E. SMAD1 protein levels were determined by western blot analysis in oval cells 
with (siSmad1) or without (NT) Smad1 knockdown. A representative experiment of 2 is shown. The 
proteins levels were normalized with β-ACTIN and western blots quantification is shown. F. NT and 
siSmad1 oval cellss were incubated with BMP9 (5 ng/ml) in the absence or presence of HGF (40 ng/ml) 
in 0% FBS media and counted at day 4. Data from 2 independent experiments with n=3-6 displayed as 
percentage of untreated cells (mean ± S.E.M.). Data were compared with the untreated condition or as 
indicated. *p<0.05, **p<0.01 and ***p<0.001. 
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These results suggest that ALK1/SMAD1 is required for HGF-mediated potentiation of 
BMP9 signaling as well as for HGF protective effects on BMP9-suppressor action in 
oval cells. 
2.5 HGF/c-Met signaling potentiates the pro-invasive activity of BMP9 in 
oval cells 
Since both BMP9 (FIGURE 27) and HGF (Suarez-Causado et al. 2015) regulate oval 
cell invasion and our data indicate that HGF potentiates BMP9-triggered SMAD1,5,8 
signaling, we wonder whether the BMP9/HGF crosstalk could also participate in the 
regulatory control of the invasive properties of oval cells. 
Confirming our previous results, data in FIGURE 34 show an increased invasive 
capacity of oval cells in the presence of  HGF or BMP9 but more importantly, cell 
invasion was significantly increased with respect to individual treatments in response to 
the combined treatment (HGF + BMP9).   
 
 
 
 
 
 
 
Cell invasion is a complex response that involves many different cellular proteins. 
Among them, the relevance of MMPs for extracellular matrix degradation during cell 
migration/invasion has been extensively demonstrated (Bourboulia and Stetler-
FIGURE 34. Effect of HGF and/or BMP9 treatment in oval cell invasion 
Metf
lx/flx 
oval cells were plated in the upper 24-well transwell units with 8-µm chamber covered with 
collagen in serum-free medium. Each well contained approximately 2 × 10
4
 cells. Medium without 
FBS (0%), was placed in the lower chamber. Cells were allowed to pass through collagen for 24 
hours and then were fixed in PFA and stained with crystal violet. A. Representative images of 
invading cells after staining with crystal violet (phase contrast microscope) of the different culture 
conditions are shown. Scale bar= 100 µm. B. Histograms show the mean value ± S.E.M. of the 
number of invading cells respect to control (n=3). Data were compared with the untreated condition 
or as indicated, *p<0.05 and **p<0.01. 
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Stevenson 2010; Kessenbrock et al. 2010). Their expression and activity can be 
modulated by growth factors and cytokines. In fact, HGF has been reported to increase 
the expression of several members of the MMP family to mediate tubulogenesis or to 
increase tumor cell invasiveness (Kadono et al. 1998; Monvoisin et al. 2002). In 
particular, our group have shown that HGF increases oval cell invasion through 
extracellular matrix, process that is at least partly mediated by expression and 
activation of some MMPs (Suarez-Causado et al. 2015). 
This prompted us to analyze the expression of various MMPs, including MMP3, 9, 10, 
13 and other molecules involved in migration and invasion, CTGF and LAMININ (Pyke 
et al. 1995; Liu and Korc 2012; Xiu et al. 2012). 
 
 
 
 
As shown in FIGURE 35, BMP9 and HGF alone were able to induce the expression of 
some of these genes but combined treatment resulted in maximal induction, particularly 
Mmp10, 13, Lama3 and Ctgf mRNAs, which showed significant changes with respect 
to single treatment. These results suggest a role for these genes in the increased 
invasive response observed in oval cells upon combined treatment.  
 
 
FIGURE 35. Analysis of the expression of different MMPs in response to HGF and/or BMP9 in 
oval cell 
Met
flx/flx 
oval cells were incubated with BMP9 (2 ng/ml) in absence or presence of HGF (40 ng/ml) in 
0% FBS media for 1 hour and Mmp3, 9, 10, 13, Ctgf and Lama3 levels were analyzed by qRT-PCR 
and normalized to Gusb. Data are shown as fold induction (relative to untreated cells) and are from 
at least 3 independent experiments performed in triplicate (mean ± S.E.M). Data were compared 
with the untreated condition or as indicated, *p<0.05, **p<0.01 and ***p<0.001. 
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2.6 Smad1 is required for the migratory response of oval cells to BMP9 
alone or with HGF 
As it is well known, SMADs proteins are the major mediators of BMPs/TGF-β ligands 
actions. Previously, we observed that BMP9-triggered SMAD1,5,8 activation is 
amplified by HGF, in parallel to increased cell invasion. These results opened the 
question of which is the precise role of SMAD1,5,8 in the oval cell invasive response to 
BMP9 and HGF. Hence, we next decided to perform transient Smad1 knock-down 
using a Smad1 siRNA in oval cells and to study its effects on oval cell invasion 
mediated by BMP9 and/or HGF.   
 
 
 
 
 
 
 
 
FIGURE 36. Smad1 is required for the  migratory response of oval cells to BMP9 alone or with 
HGF 
A-B. NT and siSmad1 oval cells were incubated with BMP9 (5 ng/ml) in the absence or presence of 
HGF (40 ng/ml) in 0% FBS media and plated in the upper 24-well transwell units coated with collagen 
I in serum-free medium. Each well contained approximately 2 × 10
4
 cells. Medium without FBS (0%), 
was placed in the lower chamber. Cells were allowed to pass through collagen for 24 hours and then 
were fixed in PFA and stained with crystal violet. A. Representative images of invading cells after 
staining with crystal violet (phase contrast microscope) of the different culture conditions are shown. 
Scale bar= 100 µm. B. Histograms show the mean value ± S.E.M. of the number of invading cells 
respect to control. Data from two independent experiments performed in triplicate. Data were 
compared with the untreated condition or as indicated. *p<0.05, **p<0.01 and ***p<0.001. 
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Smad1 silencing blocked BMP9-induced oval cell invasion and also abolished the 
enhancement in cell invasion induced by combined treatment; however, the pro-
invasive effect of HGF alone on oval cell migration was not affected (FIGURE 36 A and 
B). Thus, Smad1 appears to play an essential role in the pro-invasive response 
triggered in oval cells by BMP9 alone or in combination of HGF.  
3. EFFECT OF BMP9 CHRONIC TREATMENT ON OVAL CELL 
PHENOTYPE AND FUNCTION 
The role of BMP9 in liver fibrosis is currently poorly understood, although there are 
some indirect evidences that have linked BMP9 with this process (Li and Liu 2007; Bi 
and Ge 2014; Munoz-Felix et al. 2016). Consistent with this, results from our laboratory 
indicate that BMP9 and Id1 mRNA levels are increased in the CCl4-induced liver 
fibrosis experimental model (FIGURE 37), that suggest a correlation between BMP9 
and liver fibrosis. 
 
 
 
 
 
 
Given that chronic liver disease is also associated with oval cell expansion (see 
introduction) we wanted to study the effect of a chronic exposure of oval cells to BMP9, 
as an in vitro approach to resemble the in vivo liver fibrosis context. In fact, we and 
others have previously used this approach in the laboratory to evaluate the effects of 
the chronic exposure to TGF-β in different types of liver cells, such as rat fetal 
hepatocytes (Valdes et al. 2002; Kaimori et al. 2007), human HCC cells  (Bertran et al. 
2009; Caja et al. 2011) and oval cells (unpublished data). Hence, following a modified 
version of a protocol established in our laboratory, we generated an oval cell line 
chronically treated with BMP9 (thereafter referred to as B9T-OCs that stands for 
BMP9-treated oval cells) and then we characterized them phenotypically and 
functionally in order to clarify the implications for liver fibrosis. 
FIGURE 37. Bmp9 and Id1 hepatic expression in the CCl4-induced chronic liver injury 
mouse model 
Total mRNA was isolated from the livers of WT mice untreated or after 8 weeks of CCl4 
treatment. BMP9 and Id1 mRNA levels were determined by quantitative RT-PCR and 
normalized to Gusb. Data are expressed relative to untreated samples (assigned an 
arbitrary value of 1) and are mean ± S.E.M. of at least 4 animals. Data were compared with 
the untreated condition. *p<0.05. 
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3.1 Generation of B9T-OCs 
Oval cells were first treated for 96 hours (4 days) with a high concentration of BMP9 (5 
ng/ml) capable of inducing a maximum apoptotic response in the absence of serum (as 
described in FIGURE 26). After that, remaining cells were cultured in medium 
supplemented with serum in the presence of BMP9 until they reached confluency 
(passage 0 or p0), which was considered the starting point for subculture. Then, cells 
were submitted to subsequent passages. After four passages (approximately 2 weeks 
after beginning of the generation process) it was already considered a stable and 
chronically treated line (B9T-OCs). B9T-OC population was maintained and sub-
cultured in complete DMEM supplemented with a BMP9 maintenance dose (1 ng/ml) 
(FIGURE 38). 
 
 
 
 
 
 
3.2 Phenotypic characterization of B9T-OCs 
Once the B9T-OC were established, we aimed to perform a detailed phenotypic 
characterization of these cells. For that, we isolated mRNA from cells at different 
passages and analyze the expression of an array of phenotypic markers in comparison 
with the parental (normal) oval cells. Among the analyzed markers we included EMT 
markers, such as Snail, E-cadherin and N-cadherin, since previous observations had 
shown that BMP9 is capable of inducing an EMT process in liver cells (Li et al. 2013). 
We also included hematopoietic stem cell markers expressed by oval cells, Cd34 and 
Thy-1; and other hepatic lineage and differentiation markers, such as albumin (Alb) and 
α-fetoprotein (Afp), two plasma proteins secreted by hepatocytes and liver progenitors; 
hepatic transcription factors such as forkhead box protein A2 (Foxa2 or Hnf-3B), 
hepatocyte nuclear factor 4 alpha (Hnf4A), hepatocyte nuclear factor-1-beta (Hnf1B), 
onecut transcription factor (Hnf6), forkhead box protein A1 (Foxa1 or Hnf-3A), 
FIGURE 38. Generation of BMP9-treated oval cells (B9T-OC) 
A. Scheme of the protocol for the generation of B9T-OCs. B. Contrast microscopy images 
corresponding to Met
flx/flx 
B9T-OCs and the parental line (Met
flx/flx
) during the generation process. 
Scale bar= 100 µm. 
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tryptophan 2,3-dioxygenase (Tdo), a key enzyme in the physiological regulation of 
tryptophan metabolism, which is commonly used as a marker of functionally mature 
hepatocytes; and cytokeratin 18 (Krt18), a cytoskeleton protein characteristic of 
epithelial cells that is present in hepatocytes and liver progenitors.  We found a 
significant decrease in the mRNA levels of Snail and the mesenchymal marker N-
cadherin and increase in E-cadherin levels after chronic treatment with BMP9. In 
addition to this, the expression of Cd34 and Thy1 was profoundly downregulated 
whereas most of the hepatic lineage markers, except for Foxa1, as well as the 
epithelial marker Krt18 were significantly induced (FIGURE 39).  
 
 
FIGURE 39. Gene expression profile of B9T-OC 
RNA from parental oval cells (CTRLs) and from B9T-OC at different passages was obtained 
(passage 0, 2 and 4) and qRT-PCR was performed to analyse gene expression. Gusb was used 
for normalization. Data are expressed relative to oval cell (CTRL) (assigned an arbitrary value of 
1) and are mean ± S.E.M of 2 independent experiments performed in triplicate. Data were 
compared with the untreated condition. *p<0.05, **p<0.01 and ***p<0.001. 
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The up-regulation of albumin and E-cadherin expression in B9T-OCs was also 
confirmed at the protein levels by western blot analysis (FIGURE 40). 
 
 
 
 
 
Altogether, these results discarded the acquisition of a mesenchymal and a stem-like 
phenotype in chronically BMP9-treated oval cells and suggest oval cells suffer a switch 
towards a more epithelial and mature hepatic phenotype. 
As a functional test for oval cell differentiation toward hepatocyte lineage in B9T-OCs 
we evaluated urea production, since it is one of the most commonly used test to 
measure liver specific functions in cells in vitro.  
 
 
 
 
 
 
 
 
FIGURE 40. ALBUMIN and E-CADHERIN expression are increased in B9T-OCs 
 
Parental oval cells (CTRL) and B9T-OCs (B9T) were maintained in the absence of serum for 15 
hours and then, total proteins were isolated. Western blot analysis was performed using 
antibodies that recognize E-CADHERIN, ALBUMIN and β-ACTIN analyzed as loading control. A. 
A representative experiment is shown. B. Optical density values relative to loading control were 
calculated. Data are expressed relative to CTRL samples (assigned an arbitrary value of 1) and 
are mean ± S.E.M.of 3 independent experiments. Data were compared with the untreated 
condition. *p<0.05. 
FIGURE 41. Production of urea in parental oval cells and B9T-OCs  
Urea levels in parental oval cells (CTRL) and B9T-OCs supernatants were measured after an 
overnight culture with a minimal amount of medium. HepG2 cells were used as positive control. 
The concentration of urea was expressed as mg/dl/10
5
cells plated. Data represent the mean ± 
SEM of 3 independent experiments performed in duplicate. Statistical analysis was carried out 
using the paired t-test and data were compared to normal oval cells (CTRL). 
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The level of urea produced by normal oval cells was very low as expected for 
undifferentiated hepatic progenitor cells. After BMP9 chronic treatment, urea production 
was significantly increased and reached levels of 3 mg/dl/105cells. We included HepG2 
cells as a reference of a differentiated hepatic cell line, because it is widely used for 
liver functionality/cytotoxicity tests. Consistent with their differentiated phenotype, these 
cells reached the highest levels of urea synthesis in vitro under the same culture 
conditions (FIGURE 41). 
These data provided additional evidence supporting that oval cells chronically exposed 
to BMP9 acquire hepatocyte-like specific functions.  
3.3 Effect of BMP9 chronic treatment on oval cells growth capacity  
In order to deepen our understanding on the effects of chronic treatment with BMP9 in 
oval cell properties and behavior, we next evaluated the cell growth capacity in the 
absence or in the presence of serum (FIGURE 42). 
 
 
 
 
 
 
The growth curve in the presence of 10% FBS highlights that B9T-OCs have acquired 
growth advantage over their normal counterparts in response to the mitogenic signals 
present in the serum. Even more interesting is the profile obtained in the absence of 
serum. In fact, while parental oval cells display a decrease in cell number, which is a 
consequence of the previously shown apoptotic response elicited by serum withdrawal 
(del Castillo et al. 2008), B9T-OC show a progressive increase in cell number along 
time in culture that could be associated to an intrinsic greater capacity to proliferate and 
perhaps also acquisition of apoptosis resistance. This process remains to be further 
analyzed. 
FIGURE 42. B9T-OC growth capacity in the absence and presence of serum 
Parental oval cells (CTRL) and B9T-OC (B9T) were cultured in the presence (A) or absence 
(B) of 10% FBS for different periods of time and then the number of cells was counted. Data 
are expressed respect to control (mean ± S.E.M) and are from 2 independent experiments 
(n= 6-10). Data were compared with the untreated condition or as indicated. *p<0.05, 
**p<0.01 and ***p<0.001. 
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In addition to the standard growth curves, we performed clonogenic assays to test the 
clonal growth capacity of B9T-OC in comparison to normal parental oval cells (FIGURE 
43). 
 
 
 
 
As shown in FIGURE 43 D, chronic treatment with BMP9 results in a slight decrease in 
clonogenic growth. In addition to colony number counting, we measured the diameter 
of the colonies using Image J software. This type of analysis demonstrated that the 
size of B9T-OC-formed colonies was bigger that the colonies formed by parental oval 
cells (FIGURE 43 E). Further analysis is necessary to determine whether differences in 
size are due to differences in clonal cell growth or it is the consequence of alterations in 
cell morphology. 
3.4 BMP9 chronic treatment promotes cell migration and invasion 
As our data indicated that BMP9 regulates oval cell invasion in acute treatment 
(FIGURE 27), we wanted to investigate whether BMP9 chronic treatment could have 
any effect on oval cell migratory and invasive capacity. To examine cell migration, 
wound-healing assays were carried out in parental oval cells and B9T-OC. These 
assays showed that oval cells have an intrinsic capacity to migrate towards the wound 
FIGURE 43. Clonogenic growth of B9T-OC 
Clonogenic assays of parental oval cells (CTRL) and B9T-OCs (B9T). A. Representative images 
of clones from a plate and representative phase contrast microscope images of B. clones from a 
plate and C. individual foci. Scale bar= 100 µm (second column) and scale bar= 50 µm (third 
column). D. The number of clones. Data are expressed respect to CTRL (mean ± S.E.M) and 
are from 1 experiment (n= 6). E. Area of clones. The areas of 10 different clones were 
measured. Data were compared with the CTRL (normal OCs). *p<0.05. 
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(as previously reported by (Suarez-Causado et al. 2015) but this capacity was 
increased in B9T-OC, as evidenced by a faster wound closure (FIGURE 44). 
 
 
 
 
 
 
 
 
 
However, considering that these cells have the ability to grow in the absence of serum 
(see FIGURE 42 B) and that we could not use mitomycin in the assay due to its toxic 
effects in oval cells, we cannot exclude that this phenomenon may be due at least 
partially to cell proliferation. Other approaches should be performed to further analyze 
B9T-OC migratory capacity. 
We next examined the invasiveness capacity of B9T-OCs. In agreement with migration 
data, we found a significant increase in the number of cells that invade through 
collagen in the BMP9T-OC as compared with parental oval cells (FIGURE 45). 
 
FIGURE 44. BMP9 chronic treatment increases oval cell migration 
Wound healing assay. A straight scratch was performed and cells were allowed to migrate 
in the presence of serum free medium. A. Representative phase contrast microscopy 
images at 0, 24, 48 and 72 hours of migration. Scale bar= 50 µm. B. Histograms show the 
quantitative analysis of wound closure after 24, 48 and 72 hours. Data are expressed as % 
of closure and are the mean ± S.E.M. of 2 independent experiments performed in duplicate.  
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These results demonstrate that BMP9 chronic treatment promote cell migration and 
invasion in oval cells through a mechanism that remains to be characterized. 
3.5 B9T-OCs ARE MORE RESISTENT TO SUPPRESSOR FACTORS (TGF-β 
AND BMP9) 
Results in FIGURE 42 B have shown that B9T-OCs do not die when cultured in the 
absence of serum but rather grow along time in culture. These results prompted us to 
perform additional studies to analyze cell behavior in the presence of different 
cytostatic and/or pro-apoptotic stimuli. As previous work from our group have already 
shown that TGF-β induces an apoptotic cell death in oval cells (Del Castillo et al. 
2006), we studied the effect of TGF-β treatment on B9T-OCs population, in terms of 
cell number and apoptotic index. 
 
 
 
 
FIGURE 45. BMP9 chronic treatment increases oval cell invasion 
Parental oval cells (CTRL) and B9T-OCs were plated in serum-free medium in the upper 24-well transwell 
units coated with collagen. Each well contained approximately 2×10
4
 cells. Medium without FBS (0%) was 
placed in the lower chamber. Cells were allowed to pass through collagen-coated filters for 24 hours and 
then were fixed in PFA and stained with crystal violet. A. Representative images of invading cells after 
staining with crystal violet (phase contrast microscope). Scale bar= 100 µm.  B. Histograms show the 
mean value ± S.D of the number of invading cells respect to control (n=3). Data were compared with the 
parental oval cells, ***p<0.001. 
FIGURE 46.  B9T-OCs are more resistant to TGF-β-induced apoptosis than parental oval cells 
Parental oval cells (CTRL) and B9T-OCs were serum-starved and incubated in the presence of TGF-β 
(2 ng/ml) for 48 hours. A. Cells were counted. Data from 2 independent experiments (n= 4-6) are 
shown and expressed as percentage of untreated cells (mean ± S.E.M). B. Apoptotic index was 
calculated by counting apoptotic nuclei after PI staining under a fluorescence microscope. A minimum 
of 1000 nuclei was counted per condition. Data from 2 independent experiments performed in triplicate 
(mean ± S.E.M.) are shown. Data were compared with the normal oval cellss, *p<0.05, **p<0.01 and 
***p<0.001. 
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As shown in FIGURE 46, chronic treatment with BMP9 significantly decreased both the 
percentage of cell loss and the apoptotic index upon TGF-β treatment compared to 
parental oval cells, clearly evidencing that chronic exposure to BMP9 make oval cells 
more resistant to the cytostatic and pro-apoptotic effects of TGF-β. 
To clarify if the higher resistance to TGF-β actions of B9T-OCs could be related to 
alterations in TGF-β-induced signaling, B9T-OC and normal oval cells were incubated 
in the presence of TGF-β and western blot was performed using an anti-phospho-
SMAD2 (Ser645/467) antibody. 
 
 
 
 
 
 
 
 
As shown in FIGURE 47, no significant differences in the levels of phospho-SMAD2 
were observed upon TGF-β treatment between the two cell lines. These data discarded 
an association between a decreased apoptotic response to TGF-β and a decreased 
activation of the SMAD signaling pathway. 
We also tested the cell response to an acute treatment with BMP9, again in terms of 
cell number and apoptotic index.  
Our data show that BMP9 effects on oval cell viability and apoptosis are practically 
abolished in B9T-OCs (FIGURE 48), demonstrating that these cells present a higher 
capacity to resist to the BMP9-suppressor effects. 
 
 
 
 
 
 
 
FIGURE 47. No differences in TGF-β-triggered SMAD2 phosphorylation in B9T-OC 
and normal oval cells 
Parental oval cells (CTRL) and B9T-OCs were serum starved for 16 hours. Then, cells were 
treated with TGF-β (2 ng/ml) for 0.5, 2 and 6 hours. Western blot analysis was performed 
using antibodies that recognize P-SMAD2 and β-ACTIN was analyzed as loading control. A. 
A representative experiment is shown. B. Optical density values relative to loading control 
were calculated. Data are expressed relative to untreated samples (assigned an arbitrary 
value of 1) and are mean ± S.E.M.of 3 independent experiments. 
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When we analyzed SMAD signaling in B9T-OC after acute treatment with BMP9 no 
significant differences in the levels of phospho-SMAD1,5,8 were observed (FIGURE 
49). 
 
 
 
 
 
 
 
 
 
 
Nevertheless, we cannot rule out that the altered cell response to both TGF-β and 
BMP9 was correlated with changes in activation of other non-SMAD pathways. Future 
experiments will clarify this issue. 
 
FIGURE 48. B9T-OCs are more resistant to suppressor actions of BMP9 than parental oval 
cells 
A. A. Parental oval cells (CTRL) and B9T-OCs were serum-starved and incubated in the presence of 
BMP9 (2 ng/ml) for 24 and 48 hours. Cells were counted. Data from 2 independent experiments (n= 
4-6) are shown and expressed as percentage of untreated cells (mean ± S.E.M). B. Apoptotic index 
was calculated by counting apoptotic nuclei after PI staining under a fluorescence microscope. A 
minimum of 1000 nuclei was counted per condition. Data from 2 independent experiments performed 
in triplicate (mean ± S.E.M.) are shown. Data were compared with the untreated condition or as 
indicated. *p<0.05, **p<0.01 and ***p<0.001. 
FIGURE 49. No differences on BMP9  triggered-SMAD1,5,8  phosphorylation in B9T-
OC and parental oval cells  
Parental oval cells (CTRL) and B9T-OCs were serum starved for 16 hours. Then, cells were 
treated with BMP9 (2 ng/ml) for 0.5, 2 and 6 hours. Western blot analysis was performed 
using antibodies that recognize P-SMAD1,5,8 and β-ACTIN was analyzed as loading control. 
A.  A representative experiment is shown. B. Optical density values relative to loading 
control were calculated. Data are expressed relative to untreated samples (assigned an 
arbitrary value of 1) and are mean ± S.E.M.of 3 independent experiments. 
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In summary, our data evidence that oval cell chronically exposed to BMP9 have a more 
differentiated hepatocyte-like phenotype, higher proliferative, migratory and invasive 
capacities and are more resistant to pro-apoptotic stimuli, such as serum withdrawal 
and treatment with BMP9 or TGF-β. Further experiments are required to better 
elucidate the importance of these changes in oval cells properties in an in vivo 
physiopathological context. 
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1. BMP9 REGULATES OVAL CELL EXPANSION IN VIVO AND IN VITRO.  
The purpose of this study was to elucidate the role of BMP9 during liver regeneration 
mediated by oval cells in the DDC-induced cholestatic liver disease model and to 
examine the effects of BMP9 on oval cell biology. 
Understanding the signaling and molecular regulation of liver regeneration is of high 
interest because it gives us the basis to improve or modulate the liver regenerative 
capacity, thus opening new avenues in therapeutic intervention in CLDs aside from 
orthotopic liver transplantation, which could potentially help to decrease mortality. In 
the last ten years pieces of evidence have accumulated linking BMP signaling to the 
regenerative process in the liver. For instance, both BMP2 and BMP4 are 
downregulated following PH in rats and mice, respectively, which suggests that 
reduced levels of these factors may be necessary for hepatocyte proliferation. In fact, 
maintenance of BMP4 expression after PH inhibits hepatocyte proliferation (Xu et al. 
2006; Do et al. 2012). Contrariwise, BMP7 has been reported to function as a hormone 
that facilitate liver regeneration enhancing hepatocyte proliferation (Sugimoto et al. 
2007). Less data are available about the role of BMPs in oval cell-mediated liver 
regeneration. Nakasutka et al have reported a transient expression of BMP2 in oval 
like-cells after acute treatment with CCl4 (Nakatsuka et al. 2007), although it should be 
noted that this is not a good model for oval cell-mediated regeneration. On the other 
hand, BMP4 alone is able to induce differentiation of WB-F344 rat liver epithelial stem 
like cells into hepatocyte-like cells (Wang et al. 2015). More interestingly, BMP7 seems 
to be a key molecule in the butylidenephthalide-promoted reduction of liver fibrosis 
induced by thioacetamide (Chuang et al. 2016). This BMP7 anti-fibrotic effect is 
associated with inhibition of TGF-β and EMT and an increase in proliferation of oval 
cells. Nevertheless, whether or not BMP7 has direct effects on the oval cell population 
is not clarified. 
But, what about BMP9? BMP9 was first isolated in developing mouse liver (Celeste 
1994). Nowadays, we know that BMP9 is primarily expressed in the liver in 
physiological conditions although the hepatic cell population responsible for its 
production is still a matter of debate (Miller et al. 2000; Bidart et al. 2012). Importantly, 
BMP9 expression appears to be modulated in different pathological contexts: (i) BMP9 
is differentially expressed in liver tissues from HCC patients (Herrera et al. 2013; Li et 
al. 2013); (ii) it has been recently speculated that BMP9 could have a regenerative role 
in the human liver based on the presence of BMP9’s receptors on the surface of 
human hepatocytes and on BMP9 expression in Dissè’s spaces, which might serve as 
an important hepatic stem cell niche (Sosa et al. 2011); (iii) finally, we and others have 
demonstrated that BMP9 is upregulated in experimental models of liver fibrosis 
(Breitkopf-Heinlein et al., Gut, under revision). These data provide evidence of a link 
between BMP9 and liver regeneration after various insults, but a potential link with oval 
cell biology and function in the regenerating liver is absent. Here we found that the 
expression of BMP9 and its receptors are decreased upon cholestatic injury (FIGURE 
19) and more importantly, we demonstrate that the absence of BMP9 in the liver results 
in an amplified oval cell expansion from the periportal regions (FIGURE 18 A and B) 
followed by an improved liver regeneration in DDC-treated mice, further confirmed by 
the increase in liver-to-body mass ratio along DDC treatment (FIGURE 18 E). 
Histologically, the most striking difference between WT and BMP9-KO livers was that 
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BMP9-KO livers developed a more extensive network of branching oval cell ducts 
radiating from the periportal areas toward the parenchyma. This increased oval cell 
expansion seen in histological sections is demonstrated by the increased expression of 
oval cells markers (Krt19 and Epcan) (FIGURE 18 C). Altogether, these data constitute 
the first evidence supporting a role for BMP9 as a negative regulator of  oval cell 
expansion and oval cell-mediated liver regeneration. 
Supporting the beneficial effects of BMP9 deletion on the regenerative process, we 
show a strong activation of PI3K/AKT and ERK1/2 signalling after DDC diet in BMP9-
KO mice (FIGURE 20). Strikingly, we do not see activation of ERKs nor PI3K/AKT in 
WT mice during the DDC treatment at the time points analyzed. Most likely, it is due to 
different kinetics since a clear regenerative response is taking place in these mice. A 
more detailed time course analysis of the activation of these signals will clarify this 
issue. In any event, our data seem consistent with a major role of these kinases in 
promoting oval cell expansion during liver regeneration. Indeed, Ishikawa et al. 
(Ishikawa et al. 2012) using the same model of chronic liver injury showed that c-Met 
mutant livers, which showed impaired oval cell expansion and liver regeneration, were 
unable to activate AKT and ERK MAPKs signaling pathways. Interestingly, some 
authors have pointing out differential roles for these kinases in HPCs, such that 
ERK1/2 activation increases cell self-renewal while AKT together with STAT3 drive 
HPC differentiation toward hepatocytes (Kitade et al. 2013). However, ERK signaling 
pathway is also critical during differentiation of ESC-derived hepatic progenitors into 
hepatocytes (Gao et al. 2014). Our data show a delayed activation of ERKs as 
compared to AKT in BMP9-KO mice, which could be consistent with a differential role 
for them during the oval cell response but this issue remains open for further 
investigation.  
Interestingly, concomitant with ERK and PI3K/AKT overactivation, we also found an up-
regulation of Hgf levels and an increase in the levels of active phosphorylated c-Met in 
DDC-treated BMP9-KO mice (FIGURE 21). The overactivation of c-Met in BMP9-KO 
livers suggests that this signaling pathway plays a role in the amplification of oval cell 
expansion and oval cell-mediated regeneration observed in the absence of BMP9. A 
key role of c-Met in stem-cell-mediated liver regeneration was elegantly demonstrated 
by utilizing mice harboring c-Met floxed alleles and Alb-Cre or Mx1-Cre transgenes. 
Indeed, the absence of c-Met signaling severely altered stem cell/oval cell micro-
environment and impaired stem cell-mediated liver regeneration, finally leading to the 
death of mice (Ishikawa et al. 2012). 
To the best of our knowledge, a thorough time-course analysis of phosphorylation of c-
Met during the DDC-induced experimental chronic injury model has not been 
previously performed. Here we show that the activation of c-Met takes place coinciding 
with the peak of oval cell expansion (around two weeks of treatment), with a similar 
kinetics to the AKT activation. It is well established that one of the major arms of c-Met 
signaling is the PI3K/AKT signaling axis, and that this axis is primarily responsible for 
the cell survival response to c-Met signaling in hepatocytes and in oval cells (Schulze-
Bergkamen et al. 2004; Moumen et al. 2007; Martinez-Palacian et al. 2013). Although 
we and others have also reported AKT-dependent proliferative and migratory/invasive 
activities in oval cells (Okano et al. 2003; Suarez-Causado et al. 2015). On the other 
hand, Factor et al. in a very interesting work demonstrated that c-Met signaling in 
hepatocytes is essential for sustaining long-term ERK1/2 activation throughout liver 
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regeneration, and alternative pathways may account for the early ERK1/2 activation 
(Factor et al. 2010). Based on all this, it is tempting to speculate that HGF/c-Met 
signaling is responsible for the strong activation of PI3K/AKT and ERKs. However, the 
contributions made by other growth factors, such us the EGF/EGFR axis, remains to be 
investigated, especially in light of the fact that EGF and HGF trigger common but 
independent signaling pathways in mouse oval cells, through their respective 
receptors, EGFR and c-Met, and both RTKs have shown to be important to drive oval 
cell proliferation and survival (Martinez-Palacian et al. 2012). Regardless of the identity 
of the growth factor/s contributing to over-activation of these signals, our data clearly 
show that deletion of BMP9 signaling results in amplification of the HGF signaling 
pathways, which suggest for the first time a potential negative crosstalk between these 
pathways during oval cell expansion in vivo. 
Our data show that DDC treatment results in an inflammatory response, based on the 
increase in the expression of inflammatory markers (TNF-α and IL-6) and identification 
of infiltrating inflammatory cells by histological examination of WT and BMP9-KO livers 
(FIGURE 22). IL-6 and TNF-α upregulation has been already described in this model of 
chronic cholestatic liver injury. Thus, upregulation of these cytokines together with an 
increase in STAT3 phosphorylation was observed at 2 and 12 weeks of DDC treatment 
(Plum et al. 2010). Here, we confirm the enhanced expression of inflammatory 
cytokines although we analyzed a different time point (6 weeks of DDC diet). At this 
time point, WT animals display an increased expression of TNF-α, but not IL-6, 
whereas in BMP9-KO mice both cytokines are strongly elevated. Expression of 
inflammatory cytokines is associated with STAT3 phosphorylation in both WT and 
BMP9-KO mice but once again it was higher in BMP9-KO mice. Furthermore, using the 
Knodell Histological Index (Knodell HAI), a system to grade and stage chronic liver 
damage, we have been able to corroborate that BMP9-KO livers show a greater 
inflammatory response than the WT. These data provide solid evidence of an 
enhanced hepatic inflammatory response in DDC-fed BMP9-KO mice. 
Although it is clear that inflammation accompanies the oval cell response during 
chronic liver injury, how exactly these inflammatory cytokines influence oval cell 
activation, expansion and fate is not well known. Based on the fact that the increased 
inflammation is concomitant with an ameliorated liver damage, as evidenced by 
decreased expression of fibrosis markers and decreased serum levels of biochemical 
markers of liver damage (FIGURE 24), our data suggest that the inflammatory 
response could have a positive role in oval cell-mediated liver regeneration, as it has 
been previously proposed by other authors (Evarts et al. 1992; Knight et al. 2005; 
Xiang et al. 2012). Thus, Xiang et al., in the 2-AAF/PH model showed that 
macrophage-depletion significantly inhibited hepatic expression of IL-6 and TNF-α, 
along with a lack of STAT3 phosphorylation during the early stages following PH, 
seriously compromising the oval cell expansion and impairing the process of liver 
regeneration. 
We have not addressed the question of whether, and how, BMP9 could modulate the 
production of IL-6 and TNF-α and no information is available in the literature in this 
respect. However, recent analyses of BMP9-dependent responses in endothelial cells 
implicate BMP9 in the regulation of chemokine signaling pathways. In particular, BMP9 
stimulation is able to repress the inflammatory chemokine axis CCL2/CCR2, effect that 
is mediated by both endoglin and ALK1 (Young et al. 2015). The CCL2/CCR2 axis 
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plays a critical role in hepatic recruitment of monocytes during injury (Marra and Tacke 
2014). Additionally, combination of microarray and system biology approaches has 
recently allowed to show that Ccl2, a key gene in the chemokine branch of the NF-kB 
signaling pathway, is up-regulated during rat liver regeneration and ultimately results in 
enhanced oval cell proliferation by promoting the expression of cell proliferation 
stimulatory gene CCND1, and restraining the expression of cell proliferation inhibitory 
gene DUSP1 (Zhao et al. 2016). All these data stimulate further research to clarify the 
role of BMP9 in regulation of inflammatory chemokines and cytokines during liver 
regeneration and how this might be determinant for the regeneration outcome.  
In addition to changes in the inflammatory response, BMP9-KO mice also show 
evidence of alterations in the degree of fibrosis based on the decreased expression of 
fibrogenic markers (FIGURE 23), which suggests a pro-fibrogenic role for BMP9 in the 
liver. Evidences in the literature supporting a connection between BMP9 and fibrosis 
are scarce and indirect. Recently, it has been published that BMP9 induces an 
increase in collagen, fibronectin and CTGF expression in cultured mice fibroblasts 
(Munoz-Felix et al. 2016). Moreover, BMP9-KO mice present a defect in matrix 
deposition (Levet et al. 2015), which is a key process in fibrogenesis, serving therefore 
as an indirect evidence of a role for BMP9 in this process. Although additional 
approaches are being carrying out to fully demonstrate the pro-fibrogenic role of BMP9 
in the DDC model, results presented in this thesis are consistent with a work done in 
collaboration between our lab and others revealing a direct connection between 
BMP9 and liver fibrosis. BMP9 is upregulated in experimental models of liver fibrosis 
(we also show here increase of BMP9 after CCl4 treatment) but more importantly, loss 
of BMP9 signaling (BMP9-KO and ALK1-Fc mice) results in a significant decrease in 
the fibrotic process, as evidenced by lower Col1a1 expression and decreased collagen 
fibers in the tissue, and lower SMA protein levels in the liver (Breitkopf-Heinlein et al., 
Gut, under revision). Our results also bring up an important issue of discussion in the 
liver regeneration field nowadays, which refers to the exact role played by oval cells 
during the regenerative response. It is out of the question that the ductular reaction 
constitutes the basic regenerative response to chronic liver injury and that liver fibrosis 
occurs when repairs become deregulated. The pro-regenerative potential of oval cells 
has been demonstrated (Wang et al. 2003; Strick-Marchand et al. 2004; Papp et al. 
2014). However, a direct correlation between fibrosis stage and oval cell number was 
also observed (Roskams et al. 2003). At that time, it was not determined whether it was 
a cause or consequence relationship, but recently, a number of studies have 
suggested that oval cells actually drive the fibrotic reaction (Jakubowski et al. 2005). In 
our experimental model, we observe that an amplified ductular reaction (in BMP9-KO 
mice) correlates with reduced expression of fibrogenic markers and reduced levels of 
liver damage parameters in serum, further supporting a beneficial, rather than 
detrimental, role of oval cell expansion in the liver regeneration process. Question 
remains unanswered, but it is plausible to think that the specific microenvironment 
surrounding oval cells in different liver injuries might determine cell fate and the 
outcome of the regenerative response.  
Based on all these results, it is clear that BMP9 has a regulatory role on oval cell 
biology in vivo. Using the DDC liver injury model we have shown that BMP9 is a major 
determinant of adult hepatic stem cell biology. Lack of BMP9 promotes the expansion 
of oval cells in vivo, probably supported by increased inflammation, and reduces liver 
fibrosis and the overall degree of liver damage. Altogether, data support a more 
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efficient regenerative response in BMP9-KO mice during cholestatic liver injury, 
highlighting a direct relationship between stronger oval cell expansion and a better 
regeneration outcome in terms of recovering the hepatic function (FIGURE 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further studies will be required to elucidate the dynamic interaction of oval cells with 
the liver microenvironment in this regenerative context. We believe this could be critical 
not only in this particular pathophysiological context but others as well and would open 
the door to future therapeutic approaches based on inhibiting BMP9 pathway in order 
to strengthen the regenerative response in different acute and chronic liver diseases. 
The in vivo observations evidencing a negative effect of BMP9 on oval cell expansion 
have been complemented by in vitro studies that allowed us to confirm such effect 
while deepening in its overall regulatory role on these cells and the underlying 
molecular mechanisms. By using oval cell lines we have shown that oval cells indeed 
respond to BMP9, and in agreement with in vivo observations, BMP9 exerts a 
suppressor action on these cells.  
We have shown for the first time that oval cells respond to BMP9 treatment with an 
activation of SMAD1,5,8 at different doses and time points (FIGURE 25 A). SMAD 
activation is followed by a rapid and robust up-regulation of the SMAD-dependent gene 
Id1 (FIGURE 25 C). Since BMP9 is capable of inducing both SMAD1,5,8 and SMAD2,3 
phosphorylation in other cell types (Sieber et al. 2009; van Caam et al. 2015) we 
checked the activation of this pathway, but no response was observed (data not 
FIGURE 50. Role of BMP9 on oval cell-mediated liver regeneration 
The increased expansion of oval cells observed in DDC-fed BMP9-KO mice is accompanied 
by a stronger inflammatory response but attenuated liver fibrosis, suggesting a more 
efficient liver regeneration.  
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shown), therefore discarding the implication of SMAD2/3 in mediating BMP9-triggered 
responses in oval cells. 
The suppressor effects of BMP9 in oval cell were demonstrated by a decrease in oval 
cell number and an increase in apoptosis (FIGURE 26). The effects of BMP9 are cell 
type specific, as both pro- and anti-proliferative effects have been described. Thus, 
BMP9 inhibits proliferation in lymphatic endothelial cells (LEC) (Yoshimatsu et al. 2013) 
and osteosarcoma cells (Li et al. 2012) while enhances proliferation in multiple types of 
ovarian cancer cells and endothelial cells (Herrera et al. 2009; Suzuki et al. 2010). As 
to the hepatic cells, we have previously described that hepatocytes and HCC cells 
respond to BMP9 with a decrease and an increase in cell proliferation, respectively 
(Herrera et al. 2013) further highlighting interesting opposite actions in normal and 
transformed cells.  
The apoptotic effect of BMP9 appears to be in dispute as well. Recently, Long et al. 
have proposed BMP9 as the preferred ligand for preventing apoptosis and enhancing 
monolayer integrity in both pulmonary arterial endothelial cells (PAECs) and blood 
outgrowth endothelial cells from subjects with pulmonary artery hypertension via   
BMPR-II (Long et al. 2015). In HepG2 cells BMP9 exerts a strong survival effect 
against serum deprivation-induced apoptosis (Herrera et al. 2013). However, several 
studies have also reported BMP9-mediated pro-apoptotic effects in different cell types, 
including prostate cancer cells (Ye et al. 2008) and INA-6 and IH-1 cells, two different 
types of human multiple myeloma cell lines (Olsen et al. 2014). 
Oval cells now join the group of BMP9 responsive hepatic cell types, showing both 
growth inhibition and induction of apoptosis. Why BMP9 effects are so heterogeneous 
is not clear at all. Extensive research is needed to clarify whether is a matter of 
activation of different receptors and signaling pathways, balance between canonical 
and non-canonical signaling, crosstalk with other growth factors and/or cytokines, 
among other potential explanations. 
Here, we have been able to demonstrate that ALK2 mediates BMP9-triggered signaling 
and suppressor effects in oval cells. Although oval cells express the stated BMP9-high 
affinity receptor ALK1, its levels are much lower than those of ALK2 (FIGURE 28). 
Crosslinking assays confirmed that ALK2 is the main receptor binding BMP9 in these 
cells but the unequivocal demonstration that ALK2 is mediating BMP9-suppressor 
effects came by in vitro knockdown approaches showing that ALK2 deletion completely 
abolishes BMP9-induced oval cell loss (FIGURE 29 D) while ALK1 deletion has no 
effect (FIGURE 33 D). This is not the only cell system where ALK2 has been shown to 
mediate BMP9 signaling. In fact, although ALK1 is the main signaling receptor for 
BMP9 in endothelial cells (David et al. 2007; Scharpfenecker et al. 2007), ALK2 has 
been shown to be critical, either alone or together with ALK1, to promote ovarian 
surface epithelial and ovarian cancer cells proliferation, BMP9-induced osteogenic 
signaling in mesenchymal stem cells or BMP9-induced growth suppression in myeloma 
cells (Herrera et al. 2009; Luo et al. 2010; Olsen et al. 2014). 
Intriguingly, our data strongly suggest that BMP9 requires binding to ALK2 but not 
Smad1 signaling to act as a suppressor factor in oval cells, since siRNA-mediated 
knockdown of Smad1 did not impair the BMP9 negative effect on oval cell number 
(FIGURE 33 F). Data in the literature support the concept that BMPs effects could rely 
not only on the SMAD canonical pathway, but also on non-canonical signaling 
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pathways. For example, BMP9-induced apoptosis in different cell types can be both 
SMAD-dependent and independent. In human colon cancer cells, Yuan et al. 
demonstrated that the anti-proliferative activity of resveratrol is due to the activation of 
the BMP9/p38 MAPK signaling pathway in a BMPR-dependent manner (Yuan et al. 
2016). Both canonical and non-canonical BMP signaling are important for dorsal 
otocyst patterning; specifically, the canonical SMAD pathway regulates Dlx5 
expression, whereas a non-canonical pathway via PKA regulates Hmx3 (Ohta et al. 
2016). In addition, BMP9-triggered p38 and ERK1/2 MAPKs have opposite effects 
during osteogenic differentiation of mesenchymal progenitor cell (MPCs) (Zhao et al. 
2012). Finally, our group has previously demonstrated that in HepG2 cells BMP9 
induces SMAD signaling but also p38 and AKT/PI3K activation, and only p38 is 
required for its survival activity (Garcia-Alvaro et al. 2015). Future studies will be 
conducted in the lab to analyze if BMP9 triggers non-canonical signaling pathways in 
oval cells and if so, its potential relevance for BMP9 suppressor action. Nevertheless, 
we cannot rule out the possibility that activation of SMAD 5 or 8 could be compensating 
for the lack of Smad1 signaling and be sufficient to cause oval cell loss upon BMP9 
treatment in Smad1-knockdown oval cells. Characterization of single and double 
knockouts for Smad1 and Smad5 suggest that they share interchangeable roles as 
transcriptional modulators of BMP target genes (Conidi et al. 2011). Nevertheless, 
differential regulatory roles for Smad 1 and 5 during embryonic hematopoiesis have 
also been proposed (McReynolds et al. 2007). Smad1 and Smad5 double knockdown 
experiments would be very useful to clarify this issue. 
Strikingly, our in vitro studies indicate that BMP9 is more than just a suppressor factor 
in oval cells. Thus, BMP9 also induces invasion in these cells (FIGURE 27), and this is 
in line with recent studies showing that BMP9 can act as a critical modulator of cell 
invasion and migration, at least in certain cell types. Once again, the scenario is not at 
all clear. Although some researchers have shown that BMP9 can inhibit the invasion 
and migration of different cancer cells in vitro and in vivo (Wang et al. 2011; Lv et al. 
2013; Ren et al. 2014; Wang et al. 2016), in the liver the expression levels 
of BMP9 have been positively correlated with invasion through a mechanism 
associated with EMT induction (Li et al. 2013). This might be relevant for different 
physio-pathological processes such as cell migration occurring during embryonic 
development or tissue regeneration. We have not yet approached the relevance of 
each of the BMP9-mediated activities in oval cells (i.e. inhibition of proliferation, 
induction of apoptosis, promotion of migration and ECM invasion) during oval cell-
associated liver regeneration in vivo. Particularly interesting is the pro-migratory/pro-
invasive activity. Although BMP9-KO mice do not seem to show any impairment in oval 
cell migration into liver parenchyma, certainly it is a process that merits a deeper 
analysis prompting us to continue this line of research.  
As to the signals mediating the pro-migratory/pro-invasive activity, experiments are 
now being conducted to confirm whether ALK2 is also the type I receptor triggering this 
response, although presumably it is what one would expect based on the expression 
data and the crosslinking results. But, differently from the suppressor activities, BMP9-
mediated oval cell migration/invasion requires Smad1 activation (FIGURE 33 F), 
evidencing the activation of specific signaling branches to trigger the multiple BMP9 
responses in oval cells. 
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Certainly, there is much work to do but altogether, our results provide novel evidence 
supporting a role for BMP9 as a master regulator of liver pathophysiology. In particular, 
our work emphasizes its implication in liver regenerative responses and its multi-target 
actions, regulating different hepatic cell populations, among which oval cells would hold 
an important position. 
2. A SIGNALING CROSSTALK BETWEEN BMP9 AND HGF/c-MET 
REGULATES OVAL CELLS FUNCTION 
One of the most interesting findings of this work is the demonstration of a functional 
crosstalk between the BMP9 and the HGF/c-Met signaling pathways. The same as any 
other signaling molecule, BMP9 may perform its biological functions by cross-talking 
with other pathways. In this work, we have studied the crosstalk at the signaling level 
and also its biological consequences. Using two different and complementary 
approaches, we have been able to show that c-Met signaling increases the canonical 
signaling pathway triggered by BMP9 by increasing phosphorylation of SMAD1,5,8 that 
resulted in an augmented Id1 up-regulation (FIGURE 31). Although this is the first 
evidence of a signaling and functional crosstalk between BMP9 and HGF/c-Met, these 
results are in line with other works describing crosstalk between HGF/c-Met and other 
BMPs. For instance, a bidirectional regulation of expression appears to exist between 
HGF and BMP2, a crucial mediator in bone formation during fracture healing. Thus, in 
human osteoblasts HGF increases BMP2 production (Tsai et al. 2012), while blocking 
c-Met signaling inhibits BMP2-induced HGF production and enhances BMP2-induced 
osteoblast differentiation (Shibasaki et al. 2015). Furthermore, HGF induces BMPR2 
expression in mouse fibroblasts and muscle-derived mesenchymal cells, thus 
contributing to fracture repair (Imai et al. 2005). BMP7 expression is also up-regulated 
by HGF in prostate cancer cells although the precise mechanism that control this 
upregulation is not known (Ye et al. 2008). Interestingly, using a sophisticated culture 
system in which primary rat hepatocytes are cultured on printed arrays of collagen 
alone or with HGF and/or BMP7, Jones et al. have demonstrated that combination of 
HGF and BMP7 reached the highest anti-apoptotic effect during exposure to ethanol 
while maintaining the epithelial phenotype (Jones et al. 2010). However, authors did 
not address whether these effects involve direct or indirect crosstalk between these 
signals or are driven by cooperative but independent pathways. 
To investigate the consequences of the BMP9/HGF signaling crosstalk in oval cells, we 
have studied the potential modulation by HGF/c-Met of BMP9-induced suppressor and 
migratory effects. On one side, we have found that cell invasion was significantly 
increased in response to the combined treatment with respect to HGF or BMP9 
treatments alone (FIGURE 34). The enhanced invasive response induced by BMP9-
HGF treatment in oval cells correlates with an increased expression of various MMPs, 
including MMP3, 9, 10, 13 (FIGURE 35), although other proteases might be also 
involved. Previous results from our group indicate that HGF/c-Met pathway acting 
through PI3K and p38MAPK induces a complex and specific migratory response in 
oval cells that involves induction and activation of MMPs (Suarez-Causado et al. 2015). 
BMP signaling also regulates matrix synthesis and degradation having being described 
collagen10a1, MMP2 and MMP9 as some of its targets, thus affecting cellular 
differentiation and migration (Bergeron et al. 2007; Li et al. 2012; van Caam et al. 
2015). Based on all this, and awaiting for further experiments to directly address the 
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relevance of these molecules in the pro-invasive response elicited by BMP9 alone or in 
combination with HGF in oval cells, our data suggest that MMPs might contribute to 
such response. 
Co-treatment with BMP9 and HGF also regulates CTGF and Laminin-a3 expression 
(FIGURE 35), other molecules with a known role in cell invasion and migration 
(Kessenbrock et al. 2010). Laminin subunit alpha-3, encoded by the LAMA3 gene, is 
one of the three subunits of laminin 5, a major component of basement membranes 
and tumor ECM (Ryan et al. 1994). It has been demonstrated that up-regulation of 
LAMA-3 promotes invasion and metastasis of several cellular types (Tani et al. 1997; 
Kinoshita et al. 2012; Liu and Korc 2012); particularly, up-regulation of LAMA3 in HCC 
patients led to propose it as a molecular target for HCC therapy (Midorikawa et al. 
2002; Zekri et al. 2008). However, laminin-a3 is not only important in carcinogenesis. 
We have previously described that laminin-a3 is upregulated by HGF in oval cells 
(Suarez-Causado et al. 2015) concomitant with induction of a migratory/invasive 
response that seems to recapitulate the epithelial morphogenic program induced by 
HGF during the liver regenerative response involving oval cells. Consistently, the 
typical regenerating ductules structures formed by oval cells in the parenchyma are 
always outlined by laminin-positive basement membranes (Dezso et al. 2012), so it is 
tempting to speculate that up-regulation of laminin by HGF and BMP9 could be an 
important part of the mechanism contributing to the oval cell-mediated regenerative 
response.  
As to the potential relevance of CTGF upregulation in oval cells, it is more difficult to 
speculate. CTGF is known to be upregulated by BMP9 during osteoblast differentiation 
of mesenchymal stem cell (Luo et al. 2004) but no further data are available regarding 
regulation by BMP9 in liver cells. On the other hand, HGF-mediated decrease in CTGF 
expression has been related to HGF inhibitory effects against TGF-β pro-fibrotic activity  
(Inoue et al. 2003; Sherriff-Tadano et al. 2006; Bogatkevich et al. 2007). However, in 
co-cultures of proximal tubular epithelial cells (PTEC) and renal tubulo-interstitial 
fibroblasts (TFB) co-treatment of HGF and TGF-β results in a bi-phasic regulation 
(early increase followed by later decrease) in CTGF that seems to be important for the 
coordinated regulation of epithelial-mesenchymal interactions (Inoue et al. 2002). 
CTGF is also a target for HGF in the liver, having an important role on cell migration, 
invasion and cell cycle progression in human HCC, pointing out once again its 
association with EMT, specifically the downregulation of E-cadherin and upregulation of 
FSP-1 (Xiu et al. 2012). Neither HGF nor BMP9 induce EMT in oval cells in vitro 
(Suarez-Causado et al., and data not shown), so a link with this process is not obvious 
in our experimental model. Nevertheless, further investigation will help us to clarify the 
role played by these molecules in the regulation of oval cell function in vitro and in vivo 
and the signaling cascades involved in the regulation of MMPs, CTGF and Laminin by 
BMP9-HGF signaling crosstalk in oval cells. 
The BMP9-HGF/c-Met signaling crosstalk in oval cells is far from simple. While HGF/c-
Met signaling amplifies BMP9-triggered SMAD activation and oval cell migration and 
invasion, which evidences a positive signaling and functional interaction between these 
two signaling pathways, HGF/c-Met signaling also blocks the inhibitory effects of BMP9 
on oval cells, evidencing a negative functional crosstalk. Besides demonstrating the 
existence of this versatile crosstalk, we show that HGF/c-Met-mediated induction of 
ALK1 is required for counteracting BMP9 suppressor actions in oval cells and that 
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Smad1 activation is required for both the HGF/c-Met mediated protective effects 
against BMP9 and the pro-migratory/invasive activity of BMP9 alone or with HGF cells 
(FIGURE 33). These results reveal a striking inverse correlation between the levels of 
SMAD1,5,8 activation and the cytostatic and apoptotic response of BMP9 but a direct 
correlation with the pro-invasive activity. Regarding the role of Smad1 in cell 
migration/invasion, results are not so surprising. In fact, previous work has revealed 
that BMPs signaling through SMADs enhances invasion and bone metastasis of breast 
cancer cells (Katsuno et al. 2008). There are also data in the literature in favour of both 
a pro-survival and a pro-apoptotic function of SMAD1,5 that might depend on the 
stimuli, dose and cell type among other factors. Sustained activation of SMADs by 
TGF-β or other BMPs has been implicated in apoptosis induction (Kiyono and Shibuya 
2003; Daly et al. 2008; Holien et al. 2012). According to this, it has been demonstrated 
that BMP9 induces apoptosis in myeloma cells in vitro by signaling through ALK2 and 
that this effect is SMAD-dependent (Olsen et al. 2014). In contrast, Ueki et al. 
demonstrated that the activation of BMP-Smad1/5/8 promotes survival of retinal 
ganglion cells after damage in vivo (Ueki and Reh 2012), which agrees with data from 
other groups in different contexts (Xu et al. 2015).  In our system, SMAD1 activation 
seems to promote oval cell survival and migration/invasion. It might be also possible 
that SMAD signaling triggers other biological activities not yet defined and that this 
functional crosstalk might be even more complex than expected, but the most 
important question here, still unanswered, is how HGF/c-Met signaling is driving 
ALK1/SMAD1 activation.  
A schematic diagram depicting the BMP9-triggered signalling and response in oval 
cells is shown (FIGURE 51). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 51. BMP9-triggered signalling and response in oval cells 
BMP9 raises as a novel regulator of oval cells biology, eliciting both suppressor and pro-
migratory/invasive activities. BMP9 requires binding to ALK2 but not SMAD1 signaling to act 
as a suppressor factor. However, Smad activation drives the pro-migratory/invasive 
response. HGF/c-Met signaling amplifies BMP9-triggered SMAD activation and oval cell 
migration and invasion while counteracting BMP9 suppressor actions via ALK1/SMAD1 
signaling.  
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Some of the obvious questions that arise are: is this a c-Met-dependent mechanism? 
Does it involve physical interaction between c-Met and ALK1 or is it just a matter of 
switching the balance from ALK2 to ALK1 receptor? Further studies are needed to 
clarify these and other questions regarding the mechanisms involved in this novel 
BMP9-HGF/c-Met crosstalk operating in oval cells. 
3. CHRONIC TREATMENT OF OVAL CELLs WITH BMP9 PROMOTES 
DIFFERENTIATION AND ENHANCES SURVIVAL 
In this last part of the thesis we have studied the effect of a chronic exposure of oval 
cells to BMP9, resembling the in vivo fibrosis situation. 
The critical role of TGF-β in organ fibrosis is well known. However, the possible 
involvement of BMPs in this process has been suggested recently. Most of the 
knowledge we have about the role of BMPs during the fibrogenetic process comes 
from kidney fibrosis studies, which have shown a protective anti-fibrotic role for BMP7 
(Weiskirchen et al. 2009). BMP7 inhibits or reverses fibrosis in experimental models of 
chronic kidney disease, mainly by antagonizing TGF-β–induced EMT (Zeisberg and 
Kalluri 2008; Meng et al. 2013; Li et al. 2015). Something similar seems to occur in the 
liver, where overexpression of BMP7 suppresses the development of liver fibrosis in 
rats, reducing the expression of α-SMA and type I collagen and hydroxyproline content 
(Kinoshita et al. 2007). Using the CCl4-induced mouse liver fibrosis model, Zeisberg et 
al. demonstrated that BMP7 significantly inhibits progression of liver fibrosis by 
inhibiting the accumulation of hepatocyte-derived fibroblasts via EMT (Zeisberg et al. 
2007). Despite these observations, the anti-fibrotic effect of BMP7 is still controversial 
and some studies even propose that BMP7 is a promoter of fibrosis in kidney and liver  
(Tacke et al. 2007; Dudas et al. 2009). Other BMP ligands have been also involved in 
organ fibrosis, although their role is again controversial. Both BMP6 and BMP2 have 
been shown to participate in renal fibrosis (Simone et al. 2012; Yano et al. 2015).  
BMP4 pro-fibrotic role has been described in liver during bile duct ligation-induced liver 
fibrosis in rats (Fan et al. 2006). On the other hand, BMP2 has the potential to 
attenuate TGF-β1-induced renal interstitial fibrosis and pressure overload-induced 
cardiac fibrosis (Yang et al. 2011; Wang et al. 2012) and BMP6 inhibits hepatic fibrosis 
in non-alcoholic fatty liver disease (Arndt et al. 2015). 
We have already mentioned in the first part of the discussion that an association 
between BMP9 and liver fibrosis has been proposed, although to date, direct evidences 
supporting this association are missing. Probably, the most stimulating data in this 
respect are those published by Li et al. proposing that BMP9 via ALK1/2 and Smad1 
activation triggers EMT in liver cancer cells and acts as a HCC promoter (Li et al. 
2013). Considering the tight connection between EMT and liver fibrosis and its 
relevance for HCC development, it urges to speculate on the role of BMP9 as a pro-
fibrotic factor during the pre-neoplastic stages of liver cancer. Our in vivo observations 
showing an improvement in fibrosis during DDC-induced liver injury in the absence of 
BMP9 (FIGURE 23) constitutes additional evidence in support of a pro-fibrotic role for 
BMP9 in the liver. This, together with the increased expression of BMP-9 and Id-1 in 
the fibrotic livers of mice that received repeated injections of CCl4 (FIGURE 37) and the 
fact that both BMP9 KO mice and ALK1-Fc mice, a different model of loss of BMP9 
signaling, display a significant decrease in the CCl4-induced fibrotic process (Breitkopf-
Heinlein et al., Gut, under revision) strongly suggest that BMP9 is a pro-fibrotic factor in 
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the liver. With the aim of further exploring this hypothesis and analyzing the oval cells 
as a target of BMP9 in the fibrotic liver, we tried to establish an in vitro context 
somehow mimicking the in vivo situation by means of chronic treatment of oval cells 
with BMP9. We reasoned that a detailed phenotypic and functional characterization of 
this population (B9T-OCs) would allow us to predict the in vivo fate of these cells in the 
context of chronic liver damage and help us to better understand their potential 
relationship with liver fibrosis development and progression. 
Strikingly, gene expression analysis of a selected set of phenotypic markers revealed 
that long exposure to BMP9 in oval cells results on one side in a decrease in Snail, the 
major master regulator and inducer of EMT (Kalluri and Weinberg 2009), together with 
an increase in E-cadherin and a decrease in N-cadherin, an epithelial and 
mesenchymal marker, respectively (FIGURE 39). These results pointed to an 
acquisition of a more epithelial, rather than mesenchymal phenotype. On the other 
side, based on the expression profile of hepatic and stem/progenitor cell markers in 
oval cells and B9T-OC, BMP9 seems to promote a step-forward in the hepatic 
differentiation process of mouse oval cells toward hepatocytes.  
Hepatocyte-lineage marker genes can be classified into different groups, representing 
stages in the sequence of molecular events of hepatocyte differentiation. Among the 
earliest markers are α-fetoprotein (AFP) and hepatocyte nuclear factor-3β (HNF-3β), 
which are expressed in endodermal cells, the precursor of all hepatocyte-lineage cells. 
Next group would include fetal hepatocyte markers such as albumin (Tilghman and 
Belayew 1982; Zaret 2002); followed by perinatal hepatocyte markers such as glucose-
6-phosphatase (G6Pase) and tyrosine aminotransferase (TAT) (Haber et al. 1995). The 
last group includes postnatal (mature) hepatocyte markers such as cytochrome P450-
3a (Cyp3a), phosphoenolpyruvate carboxykinase (Pepck) and tryptophan 2,3-
dioxygenase (TDO) (Nagao et al. 1986; Noda et al. 1994). Our analysis shows that 
BMP9 induces the expression of markers belonging to all different groups, from early to 
late stage differentiation markers. Furthermore, we believe that the following 
observations can be considered as unequivocal evidences of a differentiation process 
into hepatocytes: (i) the increase in HNF-4α, which is considered to be not only a key 
member of the complex regulatory network that defines and maintains the hepatocyte 
phenotype but an absolute requirement for hepatocyte differentiation and epithelial 
morphology (Spath and Weiss 1998; Li et al. 2000); (ii) the up-regulation of Tdo2, 
which encodes for a well-known adult liver-specific enzyme, whose induction is 
universally accepted as a proof of acquisition of a mature phenotype; and (iii) the 
notably increased capacity of B9T-OC to produce urea, a specific function of mature 
hepatocytes.  
Further evidence supporting this idea is the profound down-regulation of cd34 and Thy-
1 expression, which are hematopoietic markers typically expressed in stem/progenitor 
cells and cancer stem cells, also expressed in both fetal and adult liver progenitors 
(Petersen et al. 2003; Masson et al. 2006). A recent study in a different model of 
progenitor cells (mesenchymal stromal cells) has proposed that Thy-1 might work as 
an obstacle in the pathway of differentiation commitment, since a reduction in its 
expression enhances the osteogenic and adipogenic differentiation of these cells 
(Moraes et al. 2016). It is worth mentioning that Thy-1 is quite an interesting marker not 
exempt of controversy. Some authors have described that Thy-1 is expressed in 
hepatic myofibroblast, cells in tight contact with oval cells, rather than in oval cells 
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themselves (Dezso et al. 2007) while others came to the conclusion that Thy-1 positive 
cells are activated mesenchymal-epithelial cells distinct from resident stellate cells, 
myofibroblast and oval cells (Yovchev et al. 2009). The phenotypic heterogeneity of the 
oval cell population is well known, as it is known their mixed mesenchymal and 
epithelial phenotype and their phenotypic plasticity (Yovchev et al. 2008; Deng et al. 
2011). Despite the fact that the exact nature of the Thy-1 positive cells in the oval cell 
population is still obscure, the most consistent trait is their mesenchymal phenotype. 
Based on all this, the strong reduction in the expression of Thy-1 by chronic treatment 
with BMP9 might be reflecting not just the differentiation of oval cells into hepatocytes 
but also the switch towards a more epithelial phenotype. 
The importance of BMP signals during liver specification in embryogenesis has been 
demonstrated. Indeed, BMP2 and BMP4 have shown to be strongly expressed during 
hepatic induction in the fetus (Zaret 2002). Furthermore, although no alteration in liver 
gene induction is observed in BMP4 homozygous mutant embryos, noggin-promoted 
inhibition of BMP signaling blocks the initial induction of hepatic genes in ventral 
foregut explants (Rossi et al. 2001), which is restored by adding BMP2 or BMP4. 
Besides this, no published data is available concerning a specific role for BMP9 in 
hepatocyte differentiation. Therefore, our data in oval cells constitute the first evidence 
in that direction, demonstrating a role for BMP9 as a critical regulator of oval cell 
differentiation into hepatocytes. It is important to point out that these data are in 
agreement with additional data from our lab and others indicating that BMP9 helps 
maintain hepatocyte phenotype in culture preventing EMT and loss of metabolic 
activities. Consistent with this effect of BMP9, BMP9 KO hepatocytes show evidences 
of an altered phenotype, such as decreased expression of albumin, HNF-4a and E-
cadherin and increased expression of fibronectin, a mesenchymal marker (Breitkopf-
Heinlein et al., Gut, under revision). Based on all these observations, we propose a 
novel double function for BMP9 as a differentiation factor and promoter/stabilizer of 
epithelial phenotype in hepatocyte and hepatic progenitors. This opens up new 
perspectives in the research field of oval cells, in particular, regarding the signaling 
factors regulating the phenotype and differentiation of these cells, which until now were 
pretty much restricted to some of the classical well-known liver regulatory signals, 
namely EGFR ligands and HGF (Kitade et al. 2013). How BMP9 triggers these effects 
is totally unknown, opening new paths of research in this direction as well. 
It is somehow surprising that while BMP9 promotes a more mature and epithelial 
phenotype in oval cells, at the same time it confers clear advantages in cell 
proliferation, survival, and migration/invasion, which certainly evidence that these cells 
could have acquired a more aggressive phenotype (FIGURES from 42 to 45). These 
properties could be easily associated with an EMT process, but our data show that this 
is not the case based on the pattern of expression of Snail, E-cadherin and N-cadherin. 
With this profile, we find a pro-fibrotic role of BMP9-treated oval cells harder to sustain, 
which is not incompatible with the pro-fibrotic role proposed for BMP9, but it would 
suggest that oval cells are not a target population of its pro-fibrotic activity. On the other 
side, the ability of B9T-OC to form colonies in soft-agar or to form tumors in xenografts 
assays has not yet been tested, therefore it is not possible to assert whether or not 
long-term exposure to BMP9 is sufficient to promote malignant transformation in oval 
cells. Considering that Thy-1 has been proposed as biomarker of several tumors 
including HCC and cancer stem cells (Yang et al. 2008; Yang et al. 2008; Sukowati et 
al. 2013), loss of Thy-1 in B9T-OC may point to the opposite direction. Additional 
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studies are required to clarify this issue but we should keep in mind that the acquisition 
of a more differentiated, proliferative, migratory, invasive and resistant to apoptosis 
phenotype could be consistent with an augmentation of the regenerative potential of 
oval cells. These cellular features could certainly improve and/or accelerate the 
regenerative response facilitating the restoration of liver function upon injury.  
Another issue, still unresolved, is the mechanism promoting resistance of B9T-OC to 
TGF-β-induced apoptosis. The fact that no significant differences in kinetics or intensity 
of SMAD2,3 phosphorylation were observed in these cells in response to TGF-β 
(FIGURE 47) make us speculate the potential involvement of non-canonical pathways 
although we cannot completely discard a role for the SMAD signaling pathway in this 
cellular response. On the other hand, since we have previously found that TGF-β 
induces a mitochondria-dependent apoptotic cell death in oval cells that is dependent 
on oxidative stress (Martinez-Palacian et al. 2013), it would be very interesting to test if 
B9T-OC show a greater antioxidant capacity that protects them against the pro-
apoptotic effects of TGF-β. These hypotheses will be tested in the next months. 
Similarly, loss of suppressor effects of BMP9 in B9T-OCs is apparently not associated 
to changes in the levels of phospho-SMAD1,5,8 (FIGURE 49). This would be in 
agreement with our results showing that Smad1 is not required for the suppressor 
effect of BMP9 in oval cells (FIGURE 33). The possible involvement of non-SMAD 
pathways is currently being investigated.  
In summary, our work shows for the first time that BMP9 could push oval cells to 
differentiate into hepatocytes. BMP9-promoted differentiation is associated with 
important phenotypic and functional changes that may confer an advantage to this 
population during the liver regeneration process in response to chronic injury (FIGURE 
52). Although we think that our results do not support a pro-fibrotic role of these cells, 
this hypothesis still needs to be proved. Future studies will clarify whether BMP9 may 
or not significantly contribute, in the long term, to the pro-regenerative function of the 
oval cells.  
 
 
 
 
 
FIGURE 52. Effect of chronic treatment of oval cells with BMP9 
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GENERAL DISCUSSION 
Analysing the behaviour of oval cells in response to regulatory factors is key to expand 
our knowledge and depth of understanding of some of the most important liver 
pathophysiological processes, namely liver regeneration and hepatocarcinogenesis.  
This could be of fundamental importance to fully understand the relevance of these 
cells in liver and potentially in the future to manipulate them for therapeutic purposes 
In the present study we have demonstrated for the first time that BMP9 is an important 
regulator of oval cell biology. Acute treatment of oval cells with BMP9 is associated 
with a significant reduction of cell viability and a mild increase in apoptosis but also an 
increased cell invasive capacity. Our results have evidenced that the suppressor effect 
of BMP9 in oval cells requires its binding to ALK2, but it does not appear to require the 
activation of the canonical pathway. However, the apoptotic pathway triggered by 
BMP9 and its major mediators have not been characterized yet. Although the receptor 
mediating the pro-invasive activity of BMP9 is awaiting characterization we 
demonstrate that Smad1 activation is required for such activity highlighting the 
activation of multiple signaling pathways in oval cells to trigger different responses. The 
growth inhibitory and apoptotic effects of BMP9 in vitro are reflected in a general 
suppressor effect in vivo, where the absence of BMP9 results in a greater expansion of 
the oval cell population likely contributing to a faster and more efficient recovery from 
DDC toxicity. Based on these findings we could speculate that the suppressor effect of 
BMP9 is predominant over the pro-invasive effect, but we certainly need to expand our 
in vivo studies to clarify these and other questions. 
Furthermore, we have described a novel functional crosstalk between BMP9 and 
HGF/c-Met signaling pathway, in which HGF protects against the suppressor effect of 
BMP9 while potentiating the pro-invasive activity. This crosstalk is far from a complete 
characterization but we provide clear evidence that it involves overexpression of ALK1 
and overactivation of SMAD and we believe that may have significant implications in 
liver regeneration that deserve further attention.  
Interestingly, chronic treatment of oval cells with BMP9 results in a completely different 
outcome. Its suppressor effect is counteracted by still unknown mechanisms resulting 
in proliferative and survival advantages while cells move further in their differentiation 
process toward hepatocyte and acquire a more epithelial phenotype. These 
observations lead us to propose a role for BMP9 as a differentiation factor and 
promoter/stabilizer of epithelial phenotype in hepatic progenitors. In spite of the fact 
that the pro-fibrotic role of BMP9 in liver is becoming clear, we hypothesize that the 
long-term effects of BMP9 could contribute to increase the regenerative potential of 
oval cells rather than increase their pro-fibrotic potential, but certainly, the in vivo 
implications of such effects are still unknown. It would be very interesting to address 
whether there might be some alterations in oval cell differentiation in BMP9-KO mice. 
Isolation and characterization of BMP9-KO oval cells is on the way and we hope it 
might also help us to answer some of these questions. The consequences of chronic 
treatment with BMP9 on the fate of oval cells upon transplantation in the damaged 
liver, together with additional in vivo models where oval cells are locally exposed to 
BMP9 should also be analyzed.  
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All these studies could be helpful for a correct interpretation of the oval cells-mediated 
regenerative process and its subsequent outcome. It is clear that BMP9 could have 
high potential as a target in the therapy of several CLDs, and further exploration may 
lead to novel therapeutic approaches for these important diseases. 
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CONCLUSIONS 
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1. The absence of BMP9 results in an increased oval cell expansion in vivo in the 
DDC-induced cholestatic liver disease model, concomitant with an increased 
activation of AKT and ERK1/2 MAPKs and the HGF/c-MET pathway. 
2. The amplified oval cell reaction observed in BMP9 KO mice correlates with an 
enhanced hepatic inflammatory response, reduced expression of fibrogenic 
markers, and decreased serum levels of biochemical markers of liver damage, 
which overall evidence an ameliorated liver damage and a more efficient recovery 
from DDC toxicity. 
3. BMP9 induces the canonical signaling pathway (SMAD1,5,8) in oval cells in vitro 
through ALK2 type I receptor. 
4. BMP9 acts as a suppressor factor in oval cells by reducing proliferation and 
increasing apoptosis, effect that requires binding to ALK2 but not Smad1 activation.  
5. BMP9 also increases the invasive capacity of oval cells by a Smad1-dependent 
mechanism. 
6. A functional crosstalk between BMP9 and HGF/c-Met signaling pathway operates in 
oval cells: HGF/c-Met signaling enhances BMP9-triggered SMAD1,5,8 activation 
and protects against the suppressor effect of BMP9 while potentiating its pro-
invasive activity.  
7. BMP9 and HGF/c-Met signalling crosstalk in oval cells involves overexpression of 
ALK1 and overactivation of SMADs.  
8. Chronic treatment of oval cells with BMP9 provides proliferative, survival and 
invasive advantages while cells move further in their differentiation process toward 
hepatocyte and acquire a more epithelial phenotype. 
CONCLUDING REMARKS 
This study constitutes the first evidence supporting a role for BMP9 as an important 
regulator of oval cell biology. Although in vivo and in vitro approaches demonstrate that 
BMP9 act as a suppressor signal in oval cells, the response to BMP9 in these cells is 
far more complex than expected. Together with the inhibitory action we also reveal a 
pro-invasive activity for BMP9/Smad1 signaling. Furthermore, its effects are modulated 
by signalling crosstalk with the HGF/c-Met pathway and depend on the time of 
exposure to BMP9. Chronic treatment with BMP9 confers advantages to the cells that 
reverse the suppressor response and promote differentiation into hepatocytes. 
Altogether, our results suggest that BMP9 could significantly contribute to modulate the 
liver regenerative capacity by regulating oval cells. Full characterization of the 
mechanisms mediating these responses is needed to prove this hypothesis and may 
lead to novel therapeutic approaches in chronic liver disease. 
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ROLE OF BMP9 IN CHRONIC LIVER DISEASE: IN VIVO AND IN 
VITRO STUDIES  
INTRODUCTION 
The liver performs many complex functions involved in maintaining the homeostasis of 
the organism. A very unique aspect is its high regenerative capacity after liver damage, 
which is carried out by parenchymal cells. However, if the regenerative capacity of 
these cells is compromised, such as in chronic injury states or in presence of 
substances inhibiting adult hepatocyte proliferation (Falkowski et al. 2003; Marshall et 
al. 2005), the hepatic progenitor cells (HPCs) are activated to support or take over the 
regenerative process. 
HPCs (better known as oval cells in rodents) constitute a bipotential cell population 
from adult liver. Under chronic liver disease (CLD), they become activated, expand into 
liver parenchyma and differentiate into cholangiocytes and/or hepatocytes to 
compensate for the cellular loss and to help maintain liver homeostasis; therefore 
contributing to sustain liver regeneration during several hepatic disorders (Riehle et al. 
2011). However, recent evidence supports a pro-fibrogenic role for these cells 
(Kuramitsu et al. 2013); which together with the fact that they can also be target of 
malignant conversion and become tumor-initiating cells (Lee et al. 2009), adds to the 
confusion of which is their precise role during liver injury. Certainly, an appropriate 
regulation of these cells in the context of CLD could be a major determinant of the 
response to liver injury and its subsequent outcome. This encourages studying the 
molecular mechanisms involved in the  pro-regenerative or pro-tumorigenic potential of 
the hepatic progenitor cells, still poorly understood. 
Hepatocyte growth factor (HGF) and its tyrosine kinase receptor, c-Met, has been 
demonstrated to be critical for a successful regenerative response after acute and 
chronic liver damage regulating both hepatocytes and progenitors population (Borowiak 
et al. 2004; Huh et al. 2004; Ishikawa et al. 2012). This pro-regenerative role is the 
consequence of its powerful anti-inflammatory, anti-fibrotic and anti-apoptotic activities. 
Interestingly, absence of c-Met has profound effects in oval cells, affecting multiple 
cellular processes required for regeneration, including proliferation, survival, 
differentiation and migration (Ishikawa et al. 2012).  
 Besides the role of TGF-β as a master cytokine in CLD participating in multiple 
aspects of the fibrogenic process,  recent evidence indicates that the liver is also an 
important target of Bone Morphogenetic Proteins (BMPs), a subfamily within TGF-β 
superfamily. More particularly, an implication of BMPs in CLD has been suggested, 
although their physiopathological role and importance remains to be fully explored. 
Among the members of BMPs, BMP9 has emerged as a critical regulator of liver 
pathology. Results from our group and others have evidenced a pro-tumorigenic action 
of BMP9 in HCC cells (Herrera et al. 2013; Li et al. 2013); moreover, data obtained in 
collaboration with Dr. Breitkopf-Heilen show that BMP9 not only interferes with the liver 
regenerative response but it is directly involved in liver fibrosis, therefore acting as a 
pro-fibrogenic factor. To date nothing is known about the possible role of BMP9 on 
HPCs and its contribution to the HPC-mediated regenerative process. 
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AIMS 
1. To analyze the effect of BMP9 deletion in the expansion of oval cells in vivo after 
induction of liver damage and the overall effect on the outcome of the regenerative 
response. 
2. To characterize the signaling pathways and biological activities triggered by BMP9 
in oval cells and the potential crosstalk with the HGF/c-Met pathway using an in vitro 
model of oval cell lines. 
2.1 To analyze the effect of BMP9 on oval cell proliferation, survival and 
migration/invasion. 
2.2 To investigate the potential functional crosstalk between BMP-9 and HGF/c-
Met signaling pathways and to try to identify the mechanisms involved in this 
interaction. 
2.3  To analyze the effect of chronic exposure to BMP9 in oval cells phenotype 
and properties.  
 
RESULTS 
1. BMP9 REGULATES OVAL CELL EXPANSION IN VIVO 
 
Our results show that BMP9 plays as a negative regulatory function in the oval cell 
expansion since BMP9-KO presented a greater expansion of the oval cell population 
than WT in response to the DDC-induced cholestatic liver injury. In addition, we found 
that BMP9 and its major signaling components are downregulated during the ductular 
reaction in the DDC model, suggesting that BMP9 signaling downregulation might be 
critical to allow in vivo expansion of oval cells  
Furthermore, the increased expansion of oval cells observed in BMP9-KO mice in vivo 
is accompanied by: (i) a significant increase in the activated levels of both AKT and 
ERK1/2-MAPKs along the DDC treatment; (ii) an increased activation of the HGF/c-
MET pathway; (iii) an enhanced hepatic inflammatory response and (vi) a decreased 
expression of some fibrogenic markers. All this results in a reduced liver damage in 
BMP9-KO mice, confirmed by measuring liver function parameters, in particular alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin total levels, in 
serum of DDC fed mice. Altogether, these results suggest that the absence of BMP9 
results in a more efficient liver regeneration in response to DDC-induced damage. 
Hence, BMP9 may act as a negative regulator of the oval cell mediated liver 
regeneration. 
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2. RELEVANCE OF BMP9-MEDIATED SIGNALING IN OVAL CELL 
FUNCTION. CROSSTALK WITH THE HGF/c-Met PATHWAY 
2.1 ALK2 mediates BMP9-triggered signaling and suppressor effects in 
oval cells  
First, we showed that oval cells respond to BMP9 with an activation of the canonical 
SMAD1,5,8, pathway at different doses and time points. BMP9 inhibits oval cell 
proliferation measured by [3H] thymidine incorporation assay and induces a pro-
apoptotic effect, measured by caspase-3 activity and apoptotic index. 
BMP9 also positively regulates oval cell migration and invasion, analyzed by transwells 
migration assays, through a mechanism that remains to be further characterized.  
In an effort to further elucidate BMP9 signaling pathway in oval cells, we next studied 
the receptors involved. As other members of the BMP family, BMP9 binds to a 
heterotetrameric transmembrane receptor complex comprised by type I and type II 
serine threonine kinase receptors. ALK1 is the high affinity receptor for BMP9, but 
ALK2 has been described to mediate BMP9 signaling in some cell types (Herrera et al. 
2009; Luo et al. 2010). Our results indicate that ALK2 is the main type I receptor for 
BMP9 in oval cells: it mediates BMP9-triggered signaling and suppressor effect in oval 
cells, since shALK2 cells failed to phosphorylate SMAD1,5,8 in response to BMP9 and 
do not show evidences of BMP9 suppressor effect . 
2.2 BMP9 and HGF/c-Met signaling crosstalk in oval cells. 
Our in vivo data have revealed an over-activation of the HGF/c-Met pathway in BMP9-
KO livers as compared to WT upon DDC providing the first evidence of a potential 
functional crosstalk between BMP9 and HGF/c-Met pathways in the regulation of oval 
cells. Based on this, we then aimed to deepen in the analysis of this potential crosstalk. 
Our data indicated that HGF is able to prevent the BMP9 inhibitory effects, both in 
terms of cell loss and apoptotic effect. Moreover, oval cells that express a mutated 
inactive form of c-Met receptor lacking tyrosine kinase activity (Met-/-) show a reduction 
in the BMP9-induced phosphorylation of SMAD1,5,8 compared to Metflx/flx oval cells. 
Intriguingly, the counteracting effects of HGF on BMP9 inhibitory actions in Metflx/flx cells 
are concomitant with a potentiation of BMP9-triggered SMAD1,5,8 signaling  and we 
provide evidence that ALK1/SMAD1 signaling is actually required for HGF-mediated 
potentiation of BMP9 signaling as well as for HGF protective effects on BMP9-
suppressor action in oval cells. 
Apart from counteracting the suppressor activity of BMP9, HGF/c-Met signaling 
significantly increases the pro-invasive activity of BMP9 in oval cells, which is 
associated to an up-regulation of Mmp10, 13, Lama3 and CTGF expression, 
suggesting a role for these molecules in the regulation of cell invasion by HGF and 
BMP9. 
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3. EFFECT OF BMP9 CHRONIC TREATMENT ON OVAL CELL PHENOTYPE 
AND FUNCTION 
The role of BMP9 in liver fibrosis is currently poorly understood, although there are 
some indirect evidences that have linked BMP9 with this process (Li and Liu 2007; Bi 
and Ge 2014; Munoz-Felix et al. 2016). Unpublished work performed in collaboration 
with Dr. Breitkopf-Heinlein present the first direct evidence for the pro-fibrogenic role of 
BMP9 in liver (Breitkopf-Heinlein et al., Gut, under revision). Consistent with this, we 
found that BMP9 and Id1 mRNA levels are increased in the CCl4-induced liver fibrosis 
experimental model. Considering the association between chronic liver disease, 
fibrosis and oval cell expansion, we aimed to explore the effect of a chronic exposure 
of oval cells to BMP9, as an in vitro approach to resemble the in vivo liver fibrosis 
context. 
Based on a detailed phenotypic characterization of these cells, we have found that oval 
cells chronically treated with BMP9 (named as B9T-OC) suffer a switch towards a more 
epithelial and mature hepatic phenotype. Consistent with this, these cells showed an 
increased capacity for urea synthesis suggesting that these cells acquire hepatocyte-
like specific functions. 
B9T-OC behavior differs in different aspects from their normal counterparts. Thus, B9T-
OCs acquire growth advantage in response to the mitogenic signals present in the 
serum and have shown an intrinsic greater capacity to proliferate in the absence of 
serum. Additionally, B9T-OCs have higher invasive capacity, and are more resistant to 
TGF-β cytostatic and pro-apoptotic effects than the parental cells. Importantly, we have 
also found that BMP9 effects on oval cell viability and apoptosis are practically 
abolished in B9T-OCs. 
Further experiments are required to better elucidate the importance of these changes 
in oval cells properties in an in vivo pathophysiological context. 
DISCUSSION 
In the first part of this Thesis project, we uncover a new role for BMP9 as a negative 
regulator of oval cell expansion and oval cell-mediated liver regeneration. First of all, 
we demonstrate that the absence of BMP9 in the liver results in an amplified oval cell 
expansion from the periportal regions and an improved liver regeneration in DDC-
treated mice, which could be related to the strong activation of PI3K/AKT and ERK1/2 
signalling after DDC diet in BMP9-KO mice. We also found an up-regulation of Hgf 
levels and an increase in the levels of active phosphorylated c-Met in DDC-treated 
BMP9-KO mice that make us speculate that HGF/c-Met signaling could be responsible 
for the strong activation of PI3K/AKT and ERKs. The down-regulation of the expression 
of BMP9 and its receptors upon cholestatic injury further support a role for BMP9 as a 
negative regulator of oval cell expansion. Our data also reveal that BMP9-KO showed 
an enhanced inflammatory response concomitant with an ameliorated liver damage, as 
evidenced by decreased expression of fibrosis markers and decreased serum levels of 
biochemical markers of liver damage. These data suggest a positive role of the 
inflammatory response in oval cell-mediated liver regeneration as previously proposed 
by other authors (Evarts et al. 1992; Knight et al. 2005; Xiang et al. 2012).  
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In the second part of our study, we confirm the suppressor action of BMP9 in oval cells 
in vitro as BMP9 treatment resulted in a decrease in oval cell number and an increase 
in apoptosis. Moreover, we have been able to demonstrate that ALK2 mediates BMP9-
triggered signaling and suppressor effects in oval cells. Although oval cells express the 
BMP9-high affinity receptor ALK1, its levels are much lower than those of ALK2. Thus, 
our results are consistent with other data in the literature showing that ALK2 can be 
critical, either alone or together with ALK1, to mediate BMP9 effects in different cell 
types (Herrera et al. 2009; Olsen et al. 2014). Interestingly, the suppressor actions of 
BMP9 in oval cells are not mediated by Smad1. Certainly, BMPs effects (including 
BMP9 effects) may rely not only on the Smad canonical pathway, but also on non-
canonical signaling pathways (Garcia-Alvaro et al. 2015; Ohta et al. 2016), so further 
work is needed to clarify the intracellular mechanism driving BMP9-suppresor effect in 
oval cells. On the contrary, BMP9 might be promoting oval cell invasion through Smad1 
activation being this effect in accordance with data in literature  (Katsuno et al. 2008). 
Importantly, our data also indicate that in oval cells there is a functional crosstalk 
between the BMP9 and the HGF/c-Met signaling pathways, as previously reported for 
other BMPs (Imai et al. 2005; Ye et al. 2008; Shibasaki et al. 2015). We have found 
that HGF/c-Met signaling amplifies BMP9-triggered Smad activation and oval cell 
migration and invasion which evidence a positive signaling crosstalk, but at the same 
time HGF/c-Met signaling also blocks the inhibitory effects of BMP9 in oval cells, 
evidencing a negative functional crosstalk. Additionally, we demonstrated that ALK1 is 
required for counteracting BMP9 suppressor actions in oval cells and that Smad1 
activation is required for both the HGF/c-Met mediated protective effects against BMP9 
and the pro-migratory/invasive activity of BMP9 alone or with HGF. Many questions 
regarding the mechanisms involved in this novel BMP9-HGF/c-Met crosstalk operating 
in oval cells are still opened and further studies are needed to clarify them. 
In the last part of this study we have analysed the effects of chronic treatment with 
BMP9 in oval cells. Our results indicate that oval cell chronically exposed to BMP9 
have higher proliferative, migratory and invasive capacities and are more resistant to 
pro-apoptotic stimuli, such as serum withdrawal and treatment with BMP9 or TGF-β. 
These cells also move further in their differentiation process toward hepatocyte and 
acquire a more epithelial phenotype. These observations lead us to propose a role for 
BMP9 as a differentiation factor and promoter/stabilizer of epithelial phenotype in 
hepatic progenitors. While a pro-fibrotic role of BMP9 is becoming clear, its long term 
effect on oval cells could rather contribute to increase the regenerative potential of this 
cell population. Additional experimental approaches should be done to understand the 
in vivo implications of such effect.  
MAIN CONCLUSION 
This study constitutes the first evidence supporting a role for BMP9 as an important 
regulator of oval cell biology. Although in vivo and in vitro approaches demonstrate that 
BMP9 act as a suppressor signal in oval cells, the response to BMP9 in these cells is 
far more complex than expected. Together with the inhibitory action we also reveal a 
pro-invasive activity for BMP9/Smad1 signaling. Furthermore, its effects are modulated 
by signalling crosstalk with the HGF/c-Met pathway and depend on the time of 
exposure to BMP9. Chronic treatment with BMP9 confers advantages to the cells that 
reverse the suppressor response and promote differentiation into hepatocytes. 
Altogether, our results suggest that BMP9 could significantly contribute to modulate the 
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liver regenerative capacity by regulating oval cells. Full characterization of the 
mechanisms mediating these responses is needed to prove this hypothesis and may 
lead to novel therapeutic approaches in chronic liver disease. 
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PAPEL DE BMP9 EN LA PATOLÓGIA HEPÁTICA CRÓNICA: 
ESTUDIOS IN VIVO E IN VITRO 
INTRODUCCIÓN 
El hígado realiza numerosas funciones complejas implicadas en el mantenimiento de 
la homeostasis del organismo. Un aspecto muy característico es su elevada capacidad 
de regeneración después del daño hepático, que se lleva a cabo por las células  
parenquimáticas. Sin embargo, si se ve comprometida la capacidad de regeneración 
de estas células, como en una lesión crónica o en presencia de sustancias que inhiben 
la proliferación de los de hepatocitos (Falkowski et al. 2003; Marshall et al. 2005), las 
células progenitoras hepáticas (HPC) son activada para apoyar o asumir el proceso 
regenerativo. 
Las HPCs (que son más conocidas en ratones como células ovales) constituyen una 
población de células bipotenciales del hígado adulto. Durante la patología hepática 
crónica, se activan, se expanden en el parénquima hepático y se diferencian a 
colangiocitos y/o hepatocitos para compensar la pérdida celular y ayudar a mantener 
la homeostasis de hígado, contribuyendo así a la regeneración del hígado en 
diferentes enfermedades hepáticas (Riehle et al. 2011). Sin embargo, algunas 
evidencias recientes apoyen el papel pro-fibrogénico de estas células (Kuramitsu et al. 
2013); lo que junto al hecho de que estas células pueden ser objeto de una conversión 
maligna y transformarse en células iniciadoras de tumores (Lee et al. 2009) contribuye 
a alimentar la polémica sobre cual es el papel real que juegan durante el daño 
hepático. Ciertamente, una adecuada regulación de estas células en el contexto de la 
patología hepática crónica podría ser un determinante importante en la respuesta a la 
lesión hepática y su posterior desenlace. Todo esto anima a estudiar los mecanismos 
moleculares implicados en el potencial pro-regenerativo o pro-tumorigénico de las 
HPC, aún poco conocidos. 
El factor de crecimiento hepático (HGF) y su receptor tirosina quinasa, c-Met son 
esenciales para promover una eficaz respuesta regenerativa después del daño 
hepático agudo y crónico, actuando en los hepatocitos así como en las HPC (Borowiak 
et al. 2004; Huh et al. 2004; Ishikawa et al. 2012). Este papel pro-regenerativo es la 
consecuencia de sus actividades anti-inflamatorias, anti-fibróticas y anti-apoptóticas. 
Es interesante destacar que la ausencia de c-Met tiene profundos efectos en las 
células ovales, afectando múltiples procesos celulares necesarios para la 
regeneración, incluyendo la proliferación, supervivencia, diferenciación y migración 
(Ishikawa et al. 2012). 
Junto al papel conocido del TGF-β como citoquina clave en la patología hepática 
crónica por su participación en múltiples aspectos del proceso fibrogénico, evidencias 
recientes indican que el hígado es también una diana de la acción de las proteínas 
morfogenéticas de hueso (BMP, “Bone morphogenetic proteins”), que pertenecen a la 
superfamilia del TGF-β. Particularmente, se ha sugerido una posible implicación de las 
BMPs en la enfermedad hepática crónica, aunque su papel concreto y su importancia 
fisiopatológica aún no se han explorado completamente. Entre las BMPs, BMP9 ha 
emergido recientemente como un regulador crítico de la patología hepática. 
Específicamente, los resultados de nuestro grupo y otros han puesto de manifiesto una 
acción pro-tumorigénica de BMP9 en células HCC (Herrera et al. 2013; Li et al. 2013); 
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además, los datos obtenidos en colaboración con la Dra Breitkopf-Heinlein muestran 
que BMP9 no sólo interfiere con la respuesta regenerativa del hígado, sino que está 
directamente implicado en la fibrosis hepática, actuando por lo tanto como un factor 
pro-fibrogénico. Actualmente, no se sabe nada sobre el posible papel de BMP9 en las 
células HPC y su contribución al proceso regenerativo mediado por esta células. 
OBJETIVOS 
1. Analizar el efecto de la ausencia de BMP9 en la expansión de las células ovales in 
vivo después de la inducción de un daño hepático y su efecto global sobre el 
desenlace de la respuesta regenerativa. 
2. Caracterizar las vías de señalización y las actividades biológicas desencadenadas 
por BMP9 en células ovales y su potencial interacción con la vía HGF/c-Met, utilizando 
modelos in vitro de líneas de células ovales. 
2.1 Analizar el efecto de BMP9 sobre la proliferación, supervivencia, migración e 
invasión de células ovales. 
2.2 Investigar la posible interacción funcional entre las vías de señalización de 
BMP9 y HGF/c-Met e intentar identificar los mecanismos implicados en esta 
interacción. 
2.3 Analizar el efecto de la exposición crónica de las células ovales a BMP9 
sobre sus propiedades fenotípicas y funcionales. 
RESULTADOS 
1. BMP9 REGULA LA EXPANSION DE LAS CÉLULAS OVALES IN VIVO 
Nuestros resultados muestran que BMP9 actúa como un regulador negativo en la 
expansión de células ovales ya que los ratones BMP9-KO presentaron una mayor 
expansión de la población de células ovales respecto a los WT en respuesta a la 
lesión hepática colestásica inducida por el DDC. Además, se encontró que la 
expresión de BMP9 y otros componentes de su vía de señalización están disminuidas 
durante la reacción ductular en el modelo DDC, lo que sugiere que la regulación 
negativa de la señalización de BMP9 podría ser crítica para permitir la expansión de 
células ovales in vivo. 
Además, la mayor expansión de células ovales observada en ratones BMP9-KO in 
vivo está acompañada por: (i) un aumento significativo en los niveles de AKT y 
ERK1/2-MAPKs fosforiladas/activadas a lo largo del tratamiento DDC; (ii) una 
activación incrementada de la vía de HGF/c-MET; (iii) una respuesta inflamatoria 
hepática más acentuada y (vi) una expresión aminorada de algunos marcadores 
fibrogénicos. Todo esto da como resultado una reducción del daño hepático en los 
ratones BMP9-KO, confirmada mediante la medida de los parámetros séricos de 
función hepática, en concreto, la alanina aminotransferasa (ALT), la aspartato 
aminotransferasa (AST) y los niveles totales de bilirrubina, en el suero de ratones 
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sometidos a una dieta suplementada con DDC. Todo esto indica que la ausencia de 
BMP9 resulta en una regeneración hepática más eficiente en respuesta al daño 
inducido por DDC. Por lo tanto, nuestros datos sugieren que BMP9 puede actuar como 
un regulador negativo de la regeneración hepática mediada por células ovales. 
2. RELEVANCIA DE LA SEÑALIZACIÓN MEDIADA POR BMP9 EN LA 
FUNCIÓN DE LA CÉLULA OVAL. INTERACCIÓN CON LA VÍA HGF/c-MET. 
2.1 ALK2 media la señalización de BMP9 y sus efectos supresores en las 
células ovales 
En primer lugar, hemos demostrado que las células ovales responden a BMP9 con 
una activación de la vía canónica SMAD1,5,8 a diferentes dosis y tiempos. BMP9 
inhibe la proliferación de células ovales medida por el ensayo de incorporación de [3H]-
timidina e induce un efecto proapoptótico, medido mediante análisis de  la actividad de 
la caspasa-3 y el índice apoptótico. 
BMP9 también regula positivamente la migración de células ovales y la invasión, 
análisis realizado mediante ensayos de migración/invasión en transwells, siendo este 
efecto mediado por mecanismos que no están del todo esclarecidos. En un esfuerzo 
por elucidar la vía de señalización de BMP9 en células ovales, estudiamos los 
receptores involucrados. Como otros miembros de la familia de BMP, BMP9 se une a 
un complejo de receptor transmembrana heterotetramérico compuesto por los 
receptores de serina treonina quinasa de tipo I y tipo II. ALK1 es el receptor de alta 
afinidad para BMP9, pero también se ha descrito que ALK2 media la señalización de 
BMP9 en algunos tipos de células (Herrera et al. 2009; Luo et al. 2010). Nuestros 
resultados indican que ALK2 es el principal receptor de tipo I para BMP9 en las células 
ovales: ALK2 media la señalización desencadenada por BMP9 y su efecto supresor en 
las células ovales, ya que en las células shALK2 no se observa ni la fosforilación de 
SMAD1,5,8 ni el efecto supresor en respuesta a BMP9. 
2.2 Interacción entre la señalización de BMP9 y HGF/c-Met en las células 
ovales. 
Nuestros datos in vivo han revelado una mayor activación de la vía de HGF/c-Met en 
el hígado de ratones BMP9-KO en comparación con los WT después del tratamiento 
con DDC, sugiriendo la existencia de una interacción funcional entre BMP9 y la vía de 
HGF/c-Met en la regulación de las células ovales. En base a esto, a continuación, 
quisimos profundizar en esta interacción. 
Nuestros datos indican que el HGF es capaz de prevenir los efectos inhibidores de 
BMP9, tanto en términos de pérdida de células como de su efecto apoptótico. Por otra 
parte, células ovales que expresan una forma inactiva y mutada de c-Met (que carece 
de actividad de tirosina quinasa), células Met-/-, presentan una reducción en la 
fosforilación de SMAD1,5,8 inducida por BMP9 en comparación con las células ovales 
Metflx/flx. Curiosamente, los efectos neutralizantes del HGF sobre las acciones 
inhibitorias de BMP9 en las células Metflx/flx son concomitantes con una potenciación de 
la señalización SMAD1,5,8 disparada por BMP9, y proporcionamos evidencias de que 
la señalización vía ALK1/Smad1 es necesaria para la potenciación de la señalización 
de BMP9 mediada por HGF, así como para los efectos protectores de HGF sobre la 
acción supresora de BMP9 en las células ovales. 
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Aparte de contrarrestar la actividad supresora de BMP9, la señalización HGF/c-Met 
incrementa significativamente la actividad pro-invasiva de BMP9 en las células ovales,  
efecto que está asociado a una inducción de la expresión de MMP10, 13, Lama3 y 
CTGF, lo que sugiere que estas moléculas podrían estar implicadas en la regulación 
de la invasión por HGF y BMP9. 
3. EFFECTO DEL TRATAMIENTO CRONICO DE BMP9 SOBRE EL 
FENOTIPO Y LA FUNCION DE LAS CELULAS OVALES. 
El papel de BMP9 en la fibrosis hepática es actualmente poco conocido, aunque hay 
algunas evidencias indirectas de que BMP9 estaría relacionado con este proceso (Li 
and Liu 2007; Bi and Ge 2014; Munoz-Felix et al. 2016). El trabajo todavía no 
publicado llevado a cabo en colaboración con la Dra Breitkopf-Heinlein representa la 
primera evidencia directa del papel profibrótico de BMP9 en hígado (Breitkopf-Heinlein 
et al., Gut, en revisión). En consonancia con esto, encontramos que los niveles de 
mRNA de BMP9 e Id1 están incrementados en el modelo experimental de fibrosis 
hepática inducida por CCl4, lo que sugiere una correlación entre BMP9 y la fibrosis 
hepática. Teniendo en cuenta la asociación que existe entre la enfermedad crónica del 
hígado, la fibrosis y la expansión de células ovales, quisimos explorar el efecto de una 
exposición crónica de células ovales a BMP9, como un abordaje in vitro que 
mimetizase el contexto in vivo de la fibrosis hepática. 
Después de una caracterización fenotípica detallada de estas células, se ha 
encontrado que las células crónicamente tratadas con BMP9 (denominadas B9T-OC) 
sufren un cambio fenotípico hacia un fenotipo hepático más maduro y más epitelial. En 
consonancia con esto, estas células mostraron un aumento de la capacidad de 
síntesis de urea, lo que sugiere que estas células están adquiriendo funciones 
específicas de los hepatocitos. 
El comportamiento de las células B9T-OC difiere de las células ovales normales en 
diferentes aspectos. De hecho, las células B9T-OC adquieren una ventaja de 
crecimiento en respuesta a las señales mitogénicas presentes en el suero, así como 
una mayor capacidad intrínseca para proliferar en ausencia de suero. Además, estas 
células poseen una mayor capacidad migratoria e invasiva y son más resistentes a los 
efectos citostáticos y pro-apoptóticos del TGF-β. Asimismo, hemos encontrado que los 
efectos de BMP9 sobre la viabilidad celular y la apoptosis se pierden casi por completo 
en las B9T-OC. 
Se necesitan más experimentos para aclarar la importancia de estos cambios en las 
propiedades de las células ovales en un contexto fisiopatológico in vivo. 
DISCUSIÓN 
En la primera parte de este proyecto de tesis, hemos descubierto un nuevo papel para 
BMP9 como regulador negativo de la expansión de células ovales y de la regeneración 
hepática mediada por estas células. En primer lugar, se demuestra que la ausencia de 
BMP9 en el hígado da lugar a una expansión amplificada de las células ovales a partir 
de las regiones periportales y una mejor regeneración del hígado en los ratones 
tratados con DDC, lo que podría estar relacionado con la mayor activación de la 
señalización PI3K/Akt y ERK1/2 en respuesta a la dieta DDC en ratones BMP9-KO. 
Por otra parte, también encontramos un incremento en los niveles de expresión de 
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HGF y un aumento en los niveles de fosforilación de c-Met en los ratones BMP9-KO 
después del tratamiento, lo que nos hace especular que la señalización HGF/c-Met 
podría ser responsable de la mayor activación de PI3K/Akt y ERKs. La disminución de 
la expresión de BMP9 y sus receptores después de la lesión colestásica apoya aún 
más el papel de BMP9 como un regulador negativo de la expansión de la célula oval. 
Nuestros datos revelan también que los ratones BMP9-KO muestran una respuesta 
inflamatoria incrementada y un menor daño hepático, como se demuestra por la 
disminución de la expresión de marcadores de fibrosis y la disminución en los niveles 
séricos de marcadores bioquímicos de daño hepático. Estos datos sugieren un papel 
positivo para la respuesta inflamatoria en la regeneración hepática mediada por 
células ovales, de acuerdo con lo que ha sido previamente demostrado por otros 
autores (Evarts et al. 1992; Knight et al. 2005; Xiang et al. 2012).  
En la segunda parte de nuestro estudio, hemos confirmado la acción supresora de 
BMP9 en las células ovales in vitro, ya que el tratamiento con BMP9 resulta en una 
disminución del número de células y en un aumento de la apoptosis. Además, se ha 
demostrado que ALK2 media los efectos supresores desencadenados por la 
señalización de BMP9 en las células ovales. Aunque las células ovales expresan el 
receptor de alta afinidad ALK1, sus niveles son mucho más bajos que los de ALK2. 
Estos resultados son consistentes con otros datos encontrados en la literatura que 
demuestran que ALK2, ya sea solo o junto con ALK1, puede ser crítico para mediar los 
efectos de BMP9 en diferentes tipos celulares (Herrera et al. 2009; Olsen et al. 2014). 
Resulta interesante destacar que estas acciones supresoras de BMP9 en las células 
ovales no están mediadas por Smad1. Se sabe que los efectos de las BMPs 
(incluyendo los efectos de BMP9) pueden depender no sólo de la vía Smad canónica, 
sino también de las vías de señalización no canónica (Garcia-Alvaro et al. 2015; Ohta 
et al. 2016), por tanto, es necesario seguir trabajando para dilucidar el mecanismo 
intracelular del que dependen los efectos supresores de BMP9 en células ovales. 
Contrariamente a lo observado para las acciones supresoras, BMP9 parece promover 
la invasión de células ovales a través de la activación Smad1, de acuerdo con datos 
recogidos ya en la literatura (Katsuno et al. 2008). Nuestro trabajo también indica que 
en las células ovales opera una interacción funcional entre BMP9 y la ruta de 
señalización de HGF/c-Met, como se ha descrito anteriormente para otras BMPs (Imai 
et al. 2005; Ye et al. 2008; Shibasaki et al. 2015). Hemos encontrado que la 
señalización de HGF/c-Met amplifica la activación de Smad disparada por el BMP9, y 
también  incrementa el efecto migratorio /invasivo en las células ovales, evidenciando 
una señalización positiva; pero al mismo tiempo la señalización de HGF/c-Met también 
bloquea los efectos inhibidores de BMP9 en células ovales, lo que evidencia una 
interacción funcional negativa. Adicionalmente, hemos demostrado que se requiere 
ALK1 para contrarrestar las acciones supresoras de BMP9 en células ovales y que se 
requiere la activación de Smad1 tanto para los efectos protectores de HGF/c-Met 
frente a BMP9, como para la actividad promigratoria/invasiva de BMP9 solo o con 
HGF. Es evidente que quedan muchas preguntas por responder sobre los 
mecanismos implicados en esta nueva interacción cruzada BMP9-HGF/c-Met en 
células ovales, para lo cual son necesarios estudios adicionales. 
En la última parte de este estudio hemos analizado los efectos del tratamiento crónico 
con BMP9 en células ovales. Nuestros resultados indican que las células ovales 
crónicamente tratadas con BMP9 presentan una mayor capacidad proliferativa, 
migratoria e invasiva y son más resistentes a estímulos pro-apoptóticos, como la 
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retirada de suero y el tratamiento con BMP9 o TGF-β. Estas células están más 
adelantadas en su proceso de diferenciación hacia el hepatocito y además adquieren 
un fenotipo más epitelial. Estas observaciones nos llevan a proponer un papel para 
BMP9 como un factor de diferenciación y promotor/estabilizador del fenotipo epitelial 
en las HPC. Al mismo tiempo que el papel profibrótico de BMP9 se va consolidando, 
nuestros resultados apuntan a que el efecto de la exposición crónica de las células 
ovales a BMP9 podría por el contrario contribuir a aumentar la capacidad regenerativa 
de esta población celular. Experimentos adicionales serían necesarios para entender 
las implicaciones que estos efectos puedan tener in vivo.  
CONCLUSIÓN FINAL 
Este estudio constituye la primera evidencia que señala a BMP9 como un importante 
regulador de la biología de la célula oval. Aunque estudios in vivo e in vitro demuestran 
que BMP9 actúa como una señal supresora en las células ovales, la respuesta de 
estas células a BMP9 es mucho más compleja de lo esperado. Junto con su acción 
inhibidora, hemos encontrado que la señalización de BMP9/Smad1 dispara una 
respuesta pro-invasiva. Además, sus efectos son modulados por una interacción con 
la vía de HGF/c-Met y además dependen del tiempo de exposición a BMP9. El 
tratamiento crónico con BMP9 confiere a las células ciertas ventajas, como la 
reversión de la respuesta supresora y además promueve su diferenciación hacia 
hepatocitos. Conjuntamente, nuestros resultados sugieren que BMP9 podría contribuir 
de manera significativa a la regulación de la capacidad regenerativa del hígado, 
actuando sobre las células ovales. La caracterización completa de los mecanismos 
que median estas respuestas es necesaria para probar de manera inequívoca esta 
hipótesis y podría conducir al desarrollo de nuevas estrategias terapeúticas en la 
enfermedad hepática crónica.     
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ANNEX I 
References of products used in this thesis: 
Acetic Acid glacial (PanReac AppliChem, 141008.1611) 
Acrylamide/Bisacrylamide 30%, 37.5:1  (BIO-RAD, 1610158) 
Agarose low EEO (Agarose Standard) (PanReac AppliChem, A2114) 
Amphotericin B (Gibco, 15290-026) 
Aprotinin (from bovine lung) (Sigma, A3428) 
APS (Ammonium Persulfate) (Fisher Scientific, BP179) 
β-mercaptoethanol (2-Mercaptoethanol) (Sigma, M6250) 
BMP9 (Recombinant Human BMP-9) (R&D SYSTEMS, 3209-BP) 
Bradford reagent (BIO-RAD PROTEIN ASSAY) (BIO-RAD, 500-0006) 
Bromophenol blue (BIO-RAD, 161-0404) 
BS3 (Pierce™ Premium Grade BS3) (Thermo Scientific, PG82083) 
BSA (Albumin Fraction V) (PanReac AppliChem, A1391) 
Caspase-3 Ac-DEVD-AMC (BD Pharmingen, 556449) 
CCl4 (Carbon tetrachloride) (Sigma, 289116) 
Collagen type IV Mouse (CORNING, 354233) 
Crystal Violet (Sigma Ref C-0775)  
DDC (3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-collidine) (Cymit Quimica, 3B-D0558) 
DMEM (BioWhittaker, BE12-604F) 
DMSO (Dimethyl sulfoxide) (Sigma, D8418) 
DNA Ladder 1Kb (NIPPON Genetics EUROPE GmbH, MWD01) 
DNase (Quiagen, 79254) 
DSS (Disuccinimidyl suberate) (Thermo Scientific, 21655) 
DTT (DL-Dithiothreitol) (Sigma, D5545) 
dNTP MIX 10Mm each (BIOTOOLS, 20.031-4179) 
Dulbecco’s Phosphate Buffered Saline 10X (w/ Magnesium and w/ Calcium) 
(Dominique Dutscher, X0520) 
ECL (Pierce ECL Western Blotting Substrate) (Thermo Scientific, 32106) 
EDTA ((Ethylenedinitrilo)tetraacetic acid) (Sigma, 1233508) 
EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid) (Sigma, 
34596) 
Ethanol (absolute for analysis) (PanReac AppliChem, A1613,0500PE) 
Fast Start Universal SYBR Green Master (Rox) (Roche, 04913850001) 
FBS (Life Techologies, 10270106) 
Formalin solution, neutral buffered, 10% (Sigma, HT501128) 
GelRed TM Nucleic Acid Gel Stain (Biotium, BTIU41003) 
 178 
 
Glycerol (PanReac AppliChem, 131339.1211) 
Glycine for molecular biology (PanReac AppliChem, A1067) 
[3H]-thymidine (GE Healthcare Life Sciences, TRK300) 
Hepes (Sigma, H3375) 
HGF (Recombinant Mouse HGF) (R&D SYSTEMS, 2207-HG) 
Leupeptin (Sigma, L5793) 
Luciferase Assay System (Promega, E1500) 
Methanol (Panreac, 141091.1211) 
Mineral Oil (Sigma, M5904) 
NaCl (Panreac, 131689.1214) 
Na2CO3 (Sodium carbonate) (Sigma, S7795) 
NaF (Sodium fluoride) (Sigma, S7920) 
NaOH (Sodium hydroxide) (Panreac, 141687.1211) 
NaVO3 (Sodium orthovanadate) (Sigma, S6508) 
NP40 (Calbiochem, 492016) 
PageRuler Plus Prestained Protein Ladder (Thermo Scientific, 26619) 
Penicillin (Sigma, P3032) 
PFA (Paraformaldehyde) (Sigma, P6148) 
PMSF (Phenylmethanesulfonyl fluoride) (Sigma, P7626) 
Ponceau S solution (Sigma, P7170) 
Primer p(dT) for cDNA synthesis (ROCHE, 10814270001)  
Propidium iodide (PI) (Sigma, P4170) 
Protein A Sepharose (GE Healthcare Life Sciences, 17-0780-01) 
Proteinase K (from Tritirachium album) (Sigma, P6556) 
Puromycin dihydrochloride (from Streptomyces alboniger) (Sigma, P8833) 
Ribonuclease A (from bovine pancreas) (Sigma, R5503) 
RNasin Ribonuclease Inhibitor (Promega, N2111) 
SDS (Sodium dodecyl sulfate) (Sigma, L4509) 
Sodium deoxycholate (Sigma, D6750) 
SPINREACT kit Urea 37 (SPINREACT, UREA -37) 
Streptomycin (Sigma, S9137)  
Super Script III RT kit, is supplied with 5X first-strand buffer, and a vial of DTT 
(Invitrogen, 18080-044) 
Taq Polymerase (BIOTAQ DNA Pol.) (BIOLINE, BIO-21040) 
TEMED (N,N,N',N'-Tetrametiletilendiamina) (PanReac AppliChem, A1148) 
TGFβ1 (Human, Recombinant, CHO Cell Line) (Merck Millipore, 616455) 
Thymidine (powder, BioReagent, suitable for cell culture) (Sigma, T1895) 
Tissue-Tek (OCT COMPOUND) (Sakura® Finetek | VWR, 25608-930) 
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Trichloroacetic Acid solution 10 % (PanReac AppliChem, A3844,1000) 
Trizma base (Sigma, T1503) 
Triton X-100 (Sigma, X100) 
Trypan Blue solution (Sigma, T8154) 
Tween-20 BioChemica (PanReac AppliChem, A1389) 
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